OBO_ID (LABEL):	GO_0007596 (blood coagulation)

ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
BMJ_2012_Aug_30_345_e5605	8/2012	S7-BMJ_2012_Aug_30_345_e5605	['results no significant difference was seen between the two groups in absolute Birth weight, Birthweight centile, or ponderal index.']	N/A	N/A	[('GO_0007567', 'parturition', 78, 'birth'), ('GO_0007596', 'blood coagulation', 92, 'birthweight')]
PMC1252725	10/2005	S66-PMC1252725	['finally, mean Birth weight and Gestational age of control newborn infants Born to mothers with or without infusion treatment were compared in linear logistic regression model, while the proportion of Preterm Birth and low Birthweight were compared in unconditional logistic regression model.']	N/A	N/A	[('GO_0007567', 'parturition', 14, 'birth'), ('GO_0007565', 'female pregnancy', 31, 'gestational'), ('GO_0007567', 'parturition', 74, 'born'), ('GO_0007565', 'female pregnancy', 200, 'preterm'), ('GO_0007567', 'parturition', 208, 'birth'), ('GO_0007596', 'blood coagulation', 222, 'birthweight')]
PMC1252725	10/2005	S108-PMC1252725	['however, there was a significant reduction in mean Birth weight (3,162 ± 596 vs. 3,276 ± 511 gram) and it was reflected in a higher proportion of low Birthweight (10.4% vs. 5.7%).']	N/A	N/A	[('GO_0007567', 'parturition', 51, 'birth'), ('GO_0007596', 'blood coagulation', 150, 'birthweight')]
PMC1281283	10/2005	S104-PMC1281283	['the great majority of participants (94%) Breast-Fed their children, and half continued to Breast-Feed until at least 6 months Postpartum.']	N/A	N/A	[('GO_0007567', 'parturition', 41, 'breast'), ('GO_0007631', 'feeding behavior', 48, 'fed'), ('GO_0007596', 'blood coagulation', 90, 'breast-feed'), ('GO_0007565', 'female pregnancy', 126, 'postpartum')]
PMC1592148	7/2006	S2-PMC1592148	['internatal Care refers to a package of healthcare and ancillary services provided to a woman and her family from the Birth Of one Child to the Birth Of her next child.']	N/A	N/A	[('GO_0007567', 'parturition', 11, 'care'), ('GO_0007596', 'blood coagulation', 117, 'birth of ... child'), ('GO_0007567', 'parturition', 143, 'birth of')]
PMC1592148	7/2006	S24-PMC1592148	['internatal Care refers to a package of healthcare and ancillary services provided to a woman and her family from the Birth Of one Child to the Birth Of her next child.']	N/A	N/A	[('GO_0007567', 'parturition', 11, 'care'), ('GO_0007596', 'blood coagulation', 117, 'birth of ... child'), ('GO_0007567', 'parturition', 143, 'birth of')]
PMC1852384	1/2007	S40-PMC1852384	['prophylaxis against Deep Vein Thrombosis consisted of 5,000 units of unfractionated Heparin administered subcutaneously every 8\xa0h and pneumatic compression stockings until Ambulatory.']	N/A	N/A	[('UBERON_0001639', 'hepatic portal vein', 20, 'deep vein'), ('GO_0007596', 'blood coagulation', 30, 'thrombosis'), ('CHEBI_28304', 'heparin', 84, 'heparin'), ('GO_0040011', 'locomotion', 172, 'ambulatory')]
PMC1852384	1/2007	S52-PMC1852384	['complications were classified as systemic (prolonged intubation, deep Venous Thrombosis, Pulmonary embolism, and myocardial infarction/fatal arrhythmia) or technical (incisional hernia, intestinal obstruction, leak/perforation, dehiscence, Gi bleeding, Anastomotic stricture, and anastomotic ulcer).']	N/A	N/A	[('UBERON_0001638', 'vein', 70, 'venous'), ('GO_0007596', 'blood coagulation', 77, 'thrombosis'), ('UBERON_0002048', 'lung', 89, 'pulmonary'), ('UBERON_2001302', 'vagal ganglion 1', 240, 'GI'), ('UBERON_2000691', 'supraorbital bone', 253, 'anastomotic')]
PMC1937008	7/2007	S121-PMC1937008	['as with women who smoke, obese women have lower intention to Breastfeed [37,69].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 61, 'breastfeed')]
PMC2098747	10/2007	S15-PMC2098747	['each of these women denied a personal or family history of Thrombosis.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 59, 'thrombosis')]
PMC2100429	9/2007	S61-PMC2100429	['the groups of variables were: (1) maternal pre-Pregnant size (height, Skinfold thicknesses, Head circumference, mid-upper-Arm circumference [muac] and waist and hip circumferences); (2) maternal Macronutrient intakes (energy, protein, Carbohydrate and fat intakes at 18 and 28\xa0weeks); (3) maternal Micronutrient-rich Foods in Pregnancy (frequency of Intake of dairy products, glv, fruit and non-vegetarian items [meat, fish and Eggs] at 18 and 28\xa0weeks of Gestation); (4) maternal Micronutrient status (Vitamin B12, Folate, thcy and Mma concentrations at 18 and 28\xa0weeks); (5) newborn size (Birthweight, length, skinfold thicknesses, muac, Head and Abdominal circumferences); and (6) 6\xa0year body composition (height and dexa measurements of lean mass, and total, Truncal and Limb fat).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 47, 'pregnant'), ('UBERON_0009007', 'superficial inguinal lymph node', 70, 'skinfold'), ('UBERON_0000033', 'head', 92, 'head'), ('UBERON_0001460', 'arm', 122, 'arm'), ('CHEBI_33937', 'macronutrient', 195, 'macronutrient'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 235, 'carbohydrate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 298, 'micronutrient'), ('CHEBI_33290', 'food', 317, 'foods'), ('GO_0007565', 'female pregnancy', 326, 'pregnancy'), ('GO_0007631', 'feeding behavior', 350, 'intake'), ('CL_0000025', 'egg cell', 428, 'eggs'), ('GO_0007565', 'female pregnancy', 456, 'gestation'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 481, 'micronutrient'), ('CHEBI_33279', 'vitamin D5', 503, 'vitamin B12'), ('CHEBI_30863', '5-azaorotic acid', 516, 'folate'), ('CHEBI_34840', 'methyl methacrylate', 533, 'MMA'), ('GO_0007596', 'blood coagulation', 591, 'birthweight'), ('UBERON_0000033', 'head', 640, 'head'), ('UBERON_0000916', 'abdomen', 649, 'abdominal'), ('UBERON_0002061', 'truncus arteriosus', 763, 'truncal'), ('UBERON_0002101', 'limb', 775, 'limb')]
PMC2231404	10/2007	S35-PMC2231404	['Pregnant women (<36 wk Gestation) were eligible for the overall study if they were healthy, non-smoking, between the ages of 16 to 40 years and intended to exclusively Breastfeed for greater than 4 months Postpartum.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 23, 'gestation'), ('GO_0007596', 'blood coagulation', 168, 'breastfeed'), ('GO_0007565', 'female pregnancy', 205, 'postpartum')]
PMC2359644	3/2008	S0-PMC2359644	["longitudinal study on Birthweight and the incidence of Endometrial cancer\n\nabstract\nfrom 1976 to 2004, we followed 71\u2009751 participants of the nurses' health study and identified 676 invasive Endometrial cancer cases."]	N/A	N/A	[('GO_0007596', 'blood coagulation', 22, 'birthweight'), ('UBERON_0001983', 'crypt of Lieberkuhn', 55, 'endometrial'), ('UBERON_0001983', 'crypt of Lieberkuhn', 191, 'endometrial')]
PMC2359644	3/2008	S11-PMC2359644	['for the current analysis, we excluded women with missing Birthweight data, prevalent cases of Endometrial or other cancers, and women with hysterectomy at baseline.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 57, 'birthweight'), ('UBERON_0001983', 'crypt of Lieberkuhn', 94, 'endometrial')]
PMC2359644	3/2008	S13-PMC2359644	['in 1992, we asked participants to report their own Birthweight with the following options: <2.500, 2500–<3182, 3182–<3863, 3863–<4545, ⩾4545\u2009g. on each biennial questionnaire, participants were asked whether they had been newly diagnosed with Endometrial cancer during the previous 2 years.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 51, 'birthweight'), ('UBERON_0001983', 'crypt of Lieberkuhn', 243, 'endometrial')]
PMC2359644	3/2008	S25-PMC2359644	['the association between Birthweight and incidence of Endometrial cancer was analysed using a cox proportional hazards model.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 24, 'birthweight'), ('UBERON_0001983', 'crypt of Lieberkuhn', 53, 'endometrial')]
PMC2359644	3/2008	S37-PMC2359644	['Birthweight was not associated with Endometrial cancer (hr (95% ci)=1.14 (0.83–1.57), 1.10 (0.85–1.42), 1.14 (0.89, 1.46) for a Birthweight of <2500, 2500–<3182, 3182–<3863\u2009 g , respectively, as compared to ⩾3863\u2009 g , p for trend=0.52) in the age-adjusted analysis (table 2).']	N/A	N/A	[('GO_0007608', 'sensory perception of smell', 0, 'Birthweight'), ('UBERON_0001983', 'crypt of Lieberkuhn', 36, 'endometrial'), ('GO_0007596', 'blood coagulation', 128, 'birthweight')]
PMC2359644	3/2008	S45-PMC2359644	['based on 73, no significant association was found between Birthweight and Endometrial cancer (hr=0.65 (95% ci 0.34–1.24) comparing the incidence in women with Birthweight <2500\u2009 g to that in women >3000\u2009 g ) (lof et al , 2007).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 58, 'birthweight'), ('UBERON_0001983', 'crypt of Lieberkuhn', 74, 'endometrial'), ('GO_0007596', 'blood coagulation', 159, 'birthweight')]
PMC2671035	5/2009	S127-PMC2671035	['caption (table-wrap): table 2\n\npathway analysis (mappfinder)Regulation by Antenatal nutritionregulation by Postnatal nutritionupregulated in u-c versus c-cupregulated in u-c versus u-upathway z score ppermutedpathway z score ppermutedcholesterol Biosynthesis3.90.003krebs-tca cycle6.4<0.001pentose phosphate pathway4.40.001electron transport chain3.60.004glycolysis and Gluconeogenesis3.60.003proteasome degradation2.50.026fatty Acid β-Oxidation bigcat2.90.012prostaglandin Synthesis regulation2.90.009fatty Acid Synthesis bigcat2.90.02triacylglycerol Synthesis bigcat2.70.017downregulated in u-c versus c-Cdownregulated in u-c versus u-upathway z score ppermutedpathway z score ppermutedribosomal proteins10.8<0.001mrna processing3.30.001translation factors5.2<0.001mrna processing4.4<0.001\nresults of mappfinder pathway analysis comparing patterns of Gene Expression in c-c versus u-c and u-c versus u-u.']	N/A	N/A	[('GO_0065007', 'biological regulation', 60, 'Regulation'), ('GO_0007567', 'parturition', 74, 'antenatal'), ('GO_0007567', 'parturition', 107, 'postnatal'), ('GO_0007596', 'blood coagulation', 246, 'biosynthesis3'), ('GO_0006094', 'gluconeogenesis', 370, 'gluconeogenesis3'), ('CHEBI_37527', 'acid', 429, 'acid'), ('GO_0006196', 'AMP catabolic process', 435, '-oxidation'), ('GO_0009057', 'macromolecule catabolic process', 474, 'synthesis'), ('CHEBI_37527', 'acid', 508, 'acid'), ('GO_0009851', 'auxin biosynthetic process', 508, 'acid synthesis'), ('GO_0009057', 'macromolecule catabolic process', 552, 'synthesis'), ('GO_0006231', 'dTMP biosynthetic process', 606, 'CDownregulated'), ('GO_0010467', 'gene expression', 853, 'gene expression'), ('SO_0000704', 'gene', 853, 'gene')]
PMC2704503	6/2007	S53-PMC2704503	['specifically, there was no evidence of meningitis, inflammatory Optic neuropathy nor Venous Sinus Thrombosis.']	N/A	N/A	[('UBERON_0000970', 'eye', 64, 'optic'), ('UBERON_0006615', 'venous sinus', 85, 'venous sinus'), ('GO_0007596', 'blood coagulation', 98, 'thrombosis')]
PMC2759448	6/2009	S8-PMC2759448	['the low incidence of premature Births and low Birthweight among these mothers continued to advance their Cognitive growth through 24\xa0months of age.']	N/A	N/A	[('GO_0007567', 'parturition', 31, 'births'), ('GO_0007596', 'blood coagulation', 46, 'birthweight'), ('GO_0050890', 'cognition', 105, 'cognitive')]
PMC2759448	6/2009	S62-PMC2759448	['measurement\n\nchild health, physical growth, and cognitive outcomes\nBirth certificates provided data on Prematurity (more than 21\xa0days pre-term) and Birthweight status (normal, greater than 2,500\xa0g; moderately low, 1,500–2,500; very low, less than 1,500).']	N/A	N/A	[('GO_0007567', 'parturition', 67, 'Birth'), ('GO_0007565', 'female pregnancy', 103, 'prematurity'), ('GO_0007596', 'blood coagulation', 148, 'birthweight')]
PMC2759448	6/2009	S130-PMC2759448	['toddlers who were of moderate or very low Birthweight continued to lag behind other toddlers in their 24-month weight.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 42, 'birthweight')]
PMC2776230	10/2009	S34-PMC2776230	['the resulting stimulation of th1 cytokines can suppress Th2 Responses [21].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 56, 'Th2 responses')]
PMC2874518	6/2010	S34-PMC2874518	['assessment of Pregnancy outcomes\ninformation was obtained from the hospital maternity records on Antenatal Pregnancy complications and Delivery details (Gestational age at Delivery, Birthweight and sex of the baby).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 14, 'pregnancy'), ('GO_0007567', 'parturition', 97, 'antenatal'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('GO_0007567', 'parturition', 135, 'delivery'), ('GO_0007565', 'female pregnancy', 153, 'gestational'), ('GO_0007567', 'parturition', 172, 'delivery'), ('GO_0007596', 'blood coagulation', 182, 'birthweight')]
PMC2874518	6/2010	S35-PMC2874518	['we analysed Birthweight as the primary outcome measure in two forms: as a continuous variable in grams and as expressed on customised centile charts that took into account maternal height, weight, ethnicity and parity, and neonatal Birthweight and sex.18we examined Preterm Birth, defined as Delivery at <37 weeks of Gestation, as a secondary outcome measure.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 12, 'birthweight'), ('GO_0007596', 'blood coagulation', 232, 'birthweight'), ('GO_0007565', 'female pregnancy', 266, 'preterm birth'), ('GO_0007567', 'parturition', 292, 'delivery'), ('GO_0007565', 'female pregnancy', 317, 'gestation')]
PMC2874518	6/2010	S40-PMC2874518	['we performed unconditional logistic regression for small-for-Gestational-age and preterm births, and general linear modelling for birthweight and customised birth centile using stata version 10.19maternal age, height, weight, ethnicity and parity at booking and neonatal Gestation at Delivery and baby’s sex were taken into account in the definition for customised Birth centile, and were adjusted for in the model for Birthweight.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 61, 'gestational'), ('GO_0007565', 'female pregnancy', 271, 'gestation'), ('GO_0007567', 'parturition', 284, 'delivery'), ('GO_0007567', 'parturition', 365, 'birth'), ('GO_0007596', 'blood coagulation', 419, 'birthweight')]
PMC2874518	6/2010	S65-PMC2874518	['the mean Birthweight was 3439 g (95% ci 3397, 3461).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 9, 'birthweight')]
PMC2874518	6/2010	S85-PMC2874518	['sensitivity analyses\nin addition, we adjusted for the clinical diagnosis of iugr detected by ultrasound scan during Pregnancy and documented in the maternity notes, in the relationship between taking a multivitamin–Mineral supplement preparation and both Birthweight and Preterm Birth.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('CHEBI_46662', 'mineral', 215, 'mineral'), ('GO_0007596', 'blood coagulation', 255, 'birthweight'), ('GO_0007565', 'female pregnancy', 271, 'preterm'), ('GO_0007567', 'parturition', 279, 'birth')]
PMC2874518	6/2010	S116-PMC2874518	['25found that more low Birthweight babies were Born to women who took these Antioxidants than to controls.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 22, 'birthweight'), ('GO_0007567', 'parturition', 46, 'born'), ('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 75, 'antioxidants')]
PMC2991548	10/2010	S42-PMC2991548	['mothers who were not approached in Pregnancy, were approached and enrolled in the first months after Birth Of their Child when newborns visit the routine child health centers [2].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0007596', 'blood coagulation', 101, 'birth of ... child')]
PMC2999828	3/2009	S20-PMC2999828	['after Degranulation, Mast Cells lose Membrane area, become activated, and start a de novo Synthesis Of Prostaglandins and Leukotrienes from Membrane arachidonic acid [4,5].']	N/A	N/A	[('GO_0043694', 'monoterpene catabolic process', 6, 'degranulation'), ('CL_0000097', 'mast cell', 21, 'mast cells'), ('GO_0016020', 'membrane', 37, 'membrane'), ('GO_0035196', 'production of miRNAs involved in gene silencing by miRNA', 90, 'synthesis of prostaglandins'), ('CHEBI_26333', 'prostaglandin', 103, 'prostaglandins'), ('GO_0007596', 'blood coagulation', 122, 'leukotrienes'), ('GO_0016020', 'membrane', 140, 'membrane')]
PMC3031146	1/2011	S196-PMC3031146	['the bead chips were then subjected to a single-Base Extension reaction using the hybridized dna as a template incorporating fluorescently labeled nucleotides of two different colors, each corresponding to the cytosine (methylated) or uracil (unmethylated) identity of the bisulfite-converted nucleotide at a specific Cpg Site.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 47, 'base extension'), ('SO_0000409', 'binding_site', 317, 'CpG site')]
PMC3052301	3/2011	S110-PMC3052301	['thus, following the body Weight development until one year of age (d21, d180, d360), the reduced body mass in the c-hp group was highly significant ( p<0.0001) whereby the difference became less prominent with Aging.10.1371/journal.pone.0017443.g005\n\ncaption (fig): figure 5\nbody weight and fat content at day 360.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 25, 'weight'), ('GO_0007568', 'aging', 210, 'aging')]
PMC3107945	5/2011	S2-PMC3107945	['results\nin the daughters of short mothers (<median height), systolic Blood pressure (sbp) rose as Placental breadth increased (β = 0.69 mmhg/cm, p = 0.05) and as the ratio of Placental surface area to Birthweight increased (p = 0.0003).']	N/A	N/A	[('UBERON_0000178', 'blood', 69, 'blood'), ('UBERON_0001987', 'placenta', 98, 'placental'), ('UBERON_0001987', 'placenta', 175, 'placental'), ('GO_0007596', 'blood coagulation', 201, 'birthweight')]
PMC3107945	5/2011	S72-PMC3107945	['we calculated the difference between the length and breadth of the surface and the ratio of Placental area to Birthweight.']	N/A	N/A	[('UBERON_0001987', 'placenta', 92, 'placental'), ('GO_0007596', 'blood coagulation', 110, 'birthweight')]
PMC3107945	5/2011	S84-PMC3107945	['among boys, neither systolic nor diastolic pressure was related to Birthweight, Head circumference, Birth length or the length of Gestation.table 2shows the trends in Blood pressure with Placental size.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 67, 'birthweight'), ('UBERON_0000033', 'head', 80, 'head'), ('GO_0007567', 'parturition', 100, 'birth'), ('GO_0007565', 'female pregnancy', 130, 'gestation'), ('UBERON_0000178', 'blood', 167, 'blood'), ('UBERON_0001987', 'placenta', 187, 'placental')]
PMC3107945	5/2011	S93-PMC3107945	['among girls, systolic and diastolic pressure fell as Birthweight increased (systolic pressure fell by 4.2 mmhg per kg increase in Birthweight, 95% ci 1.4–6.9, p = 0.003; diastolic pressure fell by 2.6 mmhg per kg increase, 95% ci 0.3–4.9, p = 0.03, after adjusting for current bmi).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 53, 'birthweight'), ('GO_0007596', 'blood coagulation', 130, 'birthweight')]
PMC3107945	5/2011	S96-PMC3107945	['systolic Blood pressure rose as the ratio of area to Birthweight increased.']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('GO_0007596', 'blood coagulation', 53, 'birthweight')]
PMC3107945	5/2011	S99-PMC3107945	['among girls whose mothers’ height was below the median, systolic pressure rose as Placental breadth increased (β = 0.69 mmhg/cm) and as the ratio of Placental area to Birthweight increased.']	N/A	N/A	[('UBERON_0001987', 'placenta', 82, 'placental'), ('UBERON_0001987', 'placenta', 149, 'placental'), ('GO_0007596', 'blood coagulation', 167, 'birthweight')]
PMC3120183	7/2011	S45-PMC3120183	['toward the end of Pregnancy, intervention women were referred to a Lactation consultant who discussed the benefits of breastfeeding, offered a Breast pump, and encouraged the women to exclusively Breastfeed for 6 months (19).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 18, 'pregnancy'), ('GO_0007595', 'lactation', 67, 'lactation'), ('UBERON_0000310', 'breast', 143, 'breast'), ('GO_0007596', 'blood coagulation', 196, 'breastfeed')]
PMC3120183	7/2011	S69-PMC3120183	['the use of diabetes Medications, number of Perinatal clinic visits during Pregnancy, and infant Birthweight were obtained from the medical records.']	N/A	N/A	[('CHEBI_25441', 'mycothiols', 20, 'medications'), ('GO_0036268', 'swimming', 43, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 43, 'perinatal'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007596', 'blood coagulation', 96, 'birthweight')]
PMC3130670	6/2011	S241-PMC3130670	['the questionnaire collects information on socioeconomic factors including Food security, demography, maternity history, Antenatal, Delivery and Postnatal Care, newborn care and health care seeking, Maternal Eating Practices during Pregnancy and Postpartum, infant feeding practices and awareness of and exposure to the interventions under test.']	N/A	N/A	[('CHEBI_33290', 'food', 74, 'food'), ('GO_0043653', 'mitochondrial fragmentation involved in apoptotic process', 120, 'antenatal ...'), ('GO_0007567', 'parturition', 131, 'delivery'), ('GO_0007596', 'blood coagulation', 144, 'postnatal care'), ('GO_0007437', 'adult salivary gland morphogenesis', 198, 'maternal eating practices'), ('GO_0007565', 'female pregnancy', 231, 'pregnancy'), ('GO_0007565', 'female pregnancy', 245, 'postpartum')]
PMC3134395	6/2011	S39-PMC3134395	['Fetal Thyroidogenesis occurs by approximately the twelfth week of Gestation.']	N/A	N/A	[('GO_0008618', '7-methylguanosine metabolic process', 0, 'Fetal'), ('GO_0007596', 'blood coagulation', 6, 'thyroidogenesis'), ('GO_0007565', 'female pregnancy', 66, 'gestation')]
PMC3168906	11/2011	S7-PMC3168906	['there was no significant reduction in the rate of Preterm Birth and low Birthweight in Pregnant women with late onset pre-eclampsia after Folic Acid supplementation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 50, 'preterm birth'), ('GO_0007596', 'blood coagulation', 72, 'birthweight'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('CHEBI_30751', 'formic acid', 138, 'folic acid')]
PMC3180355	8/2011	S42-PMC3180355	['two case vignettes were presented in the survey - 1) a breastfeeding woman requires 300 mg/day of Propylthiouracil (Ptu) and has no preference for a Feeding method; and 2) a woman on the same dose wishes to Breastfeed.']	N/A	N/A	[('CHEBI_8474', 'propane-2-thiol', 98, 'propylthiouracil'), ('CHEBI_16199', 'urea', 116, 'PTU'), ('GO_0007631', 'feeding behavior', 149, 'feeding'), ('GO_0007596', 'blood coagulation', 207, 'breastfeed')]
PMC3180355	8/2011	S50-PMC3180355	['1 in 4 endocrinologists who were found to be against breastfeeding during ptu treatment reported that they would change their advice to being in favour of breastfeeding if the woman wanted to Breastfeed.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 192, 'breastfeed')]
PMC3180355	8/2011	S188-PMC3180355	['48% (395/820) of women continued to Breastfeed at 6 months and 19% (153/820) were breastfeeding at the time of completion of the questionnaire.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 36, 'breastfeed')]
PMC3180355	8/2011	S199-PMC3180355	['62% (24/39) of physicians advised women to Breastfeed, 33% (13/29) advised not to Breastfeed and 5% (2/29) gave equivocal advice.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 43, 'breastfeed'), ('GO_0007596', 'blood coagulation', 82, 'breastfeed')]
PMC3198285	11/2011	S34-PMC3198285	['the enrolled subjects were centrally randomized to study diet by computer-generated random numbers, stratified by bmi (bmi <30 vs. ≥30 kg/m2) and Weeks Of Gestation (<28 or ≥28 weeks).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 146, 'weeks of'), ('GO_0007565', 'female pregnancy', 155, 'gestation')]
PMC3248362	11/2011	S43-PMC3248362	["Postpartum procedures for cases with Preeclampsia and control subjects\nafter Delivery, study staff collected data from the mother's and infant's hospital chart and by interview on infant Birthweight, sex, Placental weight, Gestational age and Pregnancy course since the 24-26 week study visit."]	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Postpartum'), ('GO_0007128', 'meiotic prophase I', 37, 'preeclampsia'), ('GO_0007567', 'parturition', 77, 'delivery'), ('GO_0007596', 'blood coagulation', 187, 'birthweight'), ('UBERON_0001987', 'placenta', 205, 'placental'), ('GO_0007565', 'female pregnancy', 223, 'gestational'), ('GO_0007565', 'female pregnancy', 243, 'pregnancy')]
PMC3248362	11/2011	S44-PMC3248362	['infant Birthweight and Placental weight were recorded as the weights obtained in the Delivery room.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 7, 'birthweight'), ('UBERON_0001987', 'placenta', 23, 'placental'), ('GO_0007567', 'parturition', 85, 'delivery')]
PMC3248362	11/2011	S60-PMC3248362	['sga and lga Births were defined as having Birthweight below the 10thpercentile and above the 90thpercentile, respectively, using the same canadian population-based standards used to obtain the bwga z-scores.']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'births'), ('GO_0007596', 'blood coagulation', 42, 'birthweight')]
PMC3250923	10/2011	S250-PMC3250923	['reasons women gave for Terminating Pregnancies included poverty, existing illness, and having young children (table2).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 23, 'terminating'), ('GO_0007565', 'female pregnancy', 35, 'pregnancies')]
PMC3262346	12/2011	S0-PMC3262346	['the wandering Spleen: an unusual case of Thrombocytopenia\n\nabstract\nThrombocytopenia is a common laboratory finding in current medical practices.']	N/A	N/A	[('UBERON_0002106', 'spleen', 14, 'spleen'), ('GO_0007596', 'blood coagulation', 41, 'thrombocytopenia'), ('GO_0015976', 'carbon utilization', 68, 'Thrombocytopenia')]
PMC3262346	12/2011	S28-PMC3262346	['the diagnosis of Thrombocytopenia due to peripheral sequestration in a wandering Spleen was made.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 17, 'thrombocytopenia'), ('UBERON_0002106', 'spleen', 81, 'spleen')]
PMC3340401	4/2012	S9-PMC3340401	['those who developed kwashiorkor had 333 g (95% confidence interval 217 to 449, p<0.001) higher mean Birthweight than those who developed marasmus.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 100, 'birthweight')]
PMC3350070	1/2011	S77-PMC3350070	['this female child was Born at term with a Birthweight of 4536 grams (>98th percentile).']	N/A	N/A	[('GO_0007567', 'parturition', 22, 'born'), ('GO_0007596', 'blood coagulation', 42, 'birthweight')]
PMC3354911	12/2011	S116-PMC3354911	['the time to Thrombolysis (ttt) dropped significantly (median difference of 54 minutes, p<0.05) after the intervention program.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 12, 'Thrombolysis')]
PMC3354911	12/2011	S117-PMC3354911	['additionally, when ttt was stratified into different groups, 52.1% of stemi patients received Thrombolysis within the first 2 hours of the onset of symptoms in the post-intervention group as compared with 45.3% in the pre-intervention group.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 94, 'thrombolysis')]
PMC3355057	5/2012	S63-PMC3355057	["116 in control arm; 116 in intervention armnutritional regime for Gestational diabetesgestational weight gain; Gestational diabetes; caesarean section; Pregnancy outcomestatistically significant reduction in Gestational weight gain, no statistically significant reduction in prevalence of Gestational diabetes, caesarean section or Birthweightguelinckx et al ., 2010 [26]100% caucasian/belgiumobese (bmi > 30 kg/m2) women enrolled at 15 weeks' Gestation.195 randomised85 analysed65 in control arm; 65 in passive arm, 65 in intervention armthree arms: group sessions with a dietician; written brochures; and standard caredietary and physical activity guidance provided by dietician and in written brochuresnutritional habits; Gestational weight gain; Gestational diabetes; caesarean section; Birthweightimproved nutritional habits; no statistically significant reduction in Gestational weight gain, prevalence of Gestational diabetes, caesarean section or Birthweight.phelan et al ., 2011 [34]67% white/usapregnant women bmi between 19.8 and 40 kg/m2recruited between 10 and 16 weeks' Gestation401 randomised.201 in non-intervention arm; 200 in intervention armexercise and nutrition information (oral and newsletter) personalised graphs and behavioural counsellinggestational weight gain; Gestational diabetes; caesarean section; Pregnancy outcomesignificant reduction in Gestational weight gain; no statistically significant reduction in prevalence of Gestational diabetes, caesarean section or Birthweightquinlivan et al ., 2011 [59]73% white, 19% asian/australiapregnant women: overweight (bmi 25 to 29.9 kg/m2) and obese (bmi ≥ 30 kg/m2)132 randomised.65 in non-intervention arm; 67 in intervention armattended a study- specific Antenatal clinic providing continuity of care, weighing on arrival, brief dietary intervention by Food technologist and psychological assessment and intervention if indicatedgestational weight gain; Gestational diabetes; Birthweightstatistically significant reduction in Gestational weight gain and prevalence of Gestational weight gain."]	N/A	N/A	[('GO_0007565', 'female pregnancy', 66, 'gestational'), ('GO_0007565', 'female pregnancy', 111, 'gestational'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('GO_0007565', 'female pregnancy', 208, 'gestational'), ('GO_0007565', 'female pregnancy', 289, 'gestational'), ('GO_0035095', 'behavioral response to nicotine', 332, 'birthweightGuelinckx'), ('GO_0007565', 'female pregnancy', 444, 'gestation'), ('GO_0007565', 'female pregnancy', 725, 'gestational'), ('GO_0007565', 'female pregnancy', 750, 'gestational'), ('GO_0001657', 'ureteric bud development', 791, 'birthweightImproved'), ('GO_0007565', 'female pregnancy', 873, 'gestational'), ('GO_0007565', 'female pregnancy', 912, 'gestational'), ('GO_0007596', 'blood coagulation', 955, 'birthweight'), ('GO_0007565', 'female pregnancy', 1084, 'gestation401'), ('GO_0007565', 'female pregnancy', 1289, 'gestational'), ('GO_0007565', 'female pregnancy', 1330, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1372, 'gestational'), ('GO_0007565', 'female pregnancy', 1453, 'gestational'), ('GO_0007596', 'blood coagulation', 1496, 'birthweightQuinlivan'), ('GO_0007567', 'parturition', 1733, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 1733, 'antenatal'), ('CHEBI_33290', 'food', 1831, 'food'), ('GO_0007565', 'female pregnancy', 1932, 'gestational'), ('GO_0048148', 'behavioral response to cocaine', 1954, 'birthweightStatistically'), ('GO_0007565', 'female pregnancy', 2004, 'gestational'), ('GO_0007565', 'female pregnancy', 2046, 'gestational')]
PMC3355057	5/2012	S64-PMC3355057	['no statistically significant reduction in Birthweight.luoto et al ., 2011 [43]predominantly white/finlandpregnant women at risk of Gestational diabetes.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 42, 'birthweight'), ('GO_0007565', 'female pregnancy', 131, 'gestational')]
PMC3355057	5/2012	S65-PMC3355057	['all bmi ranges399 cluster randomised.219 in non-intervention arm; 180 in intervention armattended a study-specific individual Antenatal Lifestyle counselling clinic including group exercisegestational diabetes; Gestational weight gain; Birthweightstatistically significant reduction in Birthweight and macrosomia but no statistically significant difference in Gestational diabetesnascimento et al ., 2011 [44]predominantly white/brazilpregnant women of all bmi categories82 randomised.42 in non-intervention arm; 40 in intervention armattended a group-based exercise under supervision and received a home exercise counsellinggestational weight gain; raised Blood pressure; Perinatal outcomeno statistically significant difference in Gestational weight gain in terms of Gestational weight gain, raised Blood pressure or Perinatal outcome\nbmi: body mass index; sd: standard deviation\n\ncaption (table-wrap): table 3\n\nsummary of the studies that met the criteria of the systematic review on lifestyle interventions in overweight and obese Pregnant women: non-randomised trialsauthor (year)ethnic group/countryparticipants/settingsample sizeinterventionoutcome measure(s)conclusiongray-donald et al.']	N/A	N/A	[('GO_0007567', 'parturition', 126, 'antenatal'), ('GO_0006266', 'DNA ligation', 136, 'lifestyle'), ('GO_0007565', 'female pregnancy', 211, 'gestational'), ('GO_0048148', 'behavioral response to cocaine', 236, 'birthweightStatistically'), ('GO_0007596', 'blood coagulation', 286, 'birthweight'), ('GO_0007565', 'female pregnancy', 360, 'gestational'), ('UBERON_0000178', 'blood', 657, 'blood'), ('GO_0036268', 'swimming', 673, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 673, 'perinatal'), ('GO_0007565', 'female pregnancy', 733, 'gestational'), ('GO_0007565', 'female pregnancy', 769, 'gestational'), ('UBERON_0000178', 'blood', 801, 'blood'), ('GO_0036268', 'swimming', 819, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 819, 'perinatal'), ('GO_0007565', 'female pregnancy', 1035, 'pregnant')]
PMC3355057	5/2012	S66-PMC3355057	['(2000) [38]native americans/canadarecruited before the 26thweek of Pregnancy, non-parallel recruitment of control and intervention arms.mean bmi = 29.6 kg/m2(sd = 6.45) in non-intervention arm and mean bmi = 30.8 kg/m2(sd = 6.85) in intervention arm at baseline.219107 in non-intervention arm; 112 in intervention armdietary and weight counsellingexercise groups providedgestational weight gain; Gestational diabetes;caesarean section;Birthweight;Postpartum weight retentionno statistically significant difference in Gestational weight gain, prevalence of Gestational diabetes, caesarean section or large for Gestational age babyolson et al.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('GO_0007565', 'female pregnancy', 396, 'gestational'), ('GO_0007596', 'blood coagulation', 435, 'birthweight'), ('GO_0007565', 'female pregnancy', 447, 'postpartum'), ('GO_0007565', 'female pregnancy', 517, 'gestational'), ('GO_0007565', 'female pregnancy', 556, 'gestational'), ('GO_0007565', 'female pregnancy', 609, 'gestational')]
PMC3355057	5/2012	S74-PMC3355057	["historical non-intervention group.5428 in non-parallel control arm; 28 in intervention arm)one-to-one counselling; six structured seminars on healthy living (healthy eating and walking)Gestational weight gain; Gestational diabetes; caesarean sectionstatistically significant reduction in Gestational weight gain; no difference in prevalence of Gestational diabetesmottola et al ., (2010) [35]not stated/canadaoverweight (bmi ≥ 25 to 29.9 kg/m2) and obese (bmi ≥ 30 kg/m2) Pregnant women recruited before 16 weeks' Gestation; historical non-intervention group.65 matched non-parallel control of 260individualised nutrition plan; exercise consisted of walking (three to four times per week, used pedometers)Gestational weight gain; caesarean section; Birthweight; Peripartum weight retentionpossible reduction in Gestational weight gain; no difference in prevalence of caesarean section or large for Gestational age baby; minimal effect on Peripartum weight retention\nbmi: body mass index; sd: standard deviation."]	N/A	N/A	[('GO_0007565', 'female pregnancy', 185, 'Gestational'), ('GO_0007565', 'female pregnancy', 210, 'gestational'), ('GO_0007565', 'female pregnancy', 288, 'gestational'), ('GO_0007565', 'female pregnancy', 344, 'gestational'), ('GO_0007565', 'female pregnancy', 472, 'pregnant'), ('GO_0007565', 'female pregnancy', 514, 'gestation'), ('GO_0007565', 'female pregnancy', 705, 'Gestational'), ('GO_0007596', 'blood coagulation', 749, 'birthweight'), ('UBERON_0002222', 'perichondrium', 762, 'peripartum'), ('GO_0007565', 'female pregnancy', 811, 'gestational'), ('GO_0007565', 'female pregnancy', 898, 'gestational'), ('UBERON_0002222', 'perichondrium', 938, 'peripartum')]
PMC3355057	5/2012	S120-PMC3355057	['caption (fig): figure 6\n\nforest plot of randomised trials investigating the effect of lifestyle advice versus standard care on Birthweight .']	N/A	N/A	[('GO_0007596', 'blood coagulation', 127, 'birthweight')]
PMC3355895	1/2011	S133-PMC3355895	['after adjusting for age, gender, and Adult weight Individuals in the lowest third for Birthweight had a higher Spine bmd if they were of the bb genotype ( p \u2009=\u20090.01).']	N/A	N/A	[('UBERON_0007023', 'adult organism', 37, 'adult'), ('NCBITaxon_1', 'root', 50, 'individuals'), ('GO_0007596', 'blood coagulation', 86, 'birthweight'), ('UBERON_0001013', 'adipose tissue', 111, 'spine')]
PMC3366611	4/2012	S229-PMC3366611	['nutrition information re: improving healthful Food Intake via radio broadcasts, booklets, supermarket tours and cooking demosimprove dietary i/t, optimize gwg, glycemia, Birthweight & ppwrno sign difference in gwg, Glycemic levels, or ppwrno difference in bwolson 2004 [220]a,b,c prospective cohort & historical controlbmi 19.8–29.0usa.']	N/A	N/A	[('CHEBI_33290', 'food', 46, 'food'), ('GO_0007631', 'feeding behavior', 46, 'food intake'), ('GO_0007596', 'blood coagulation', 170, 'birthweight'), ('GO_0006096', 'glycolytic process', 215, 'glycemic')]
PMC3387724	7/2012	S25-PMC3387724	['retrospective studies investigating offspring exposed to famine during the siege of leningrad did not show any relationship between Birthweight and Adult Metabolic sequelae (stanner and yudkin,2001).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 132, 'birthweight'), ('UBERON_0007023', 'adult organism', 148, 'adult'), ('GO_0008152', 'metabolic process', 154, 'metabolic')]
PMC3387724	7/2012	S61-PMC3387724	['when dams are Fed 30% of ad libitum Intake throughout Pregnancy, i.e., a severe level of un, offspring Birthweights and Placental weights were 25–30% lower than offspring of control Fed mothers.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 14, 'fed'), ('GO_0007631', 'feeding behavior', 36, 'intake'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('GO_0007596', 'blood coagulation', 103, 'birthweights'), ('UBERON_0001987', 'placenta', 120, 'placental'), ('GO_0007631', 'feeding behavior', 182, 'fed')]
PMC3387724	7/2012	S179-PMC3387724	['maternal Dex reduced Birthweight and delayed the onset of puberty in offspring and elicited hyperleptinemia and increased fat mass in offspring by 6\u2009months of age.']	N/A	N/A	[('CHEBI_4450', 'desmopressin', 9, 'DEX'), ('GO_0007596', 'blood coagulation', 21, 'birthweight')]
PMC3420688	5/2012	S2-PMC3420688	['a spectrum of disorders occurs in pnh ranging from hemolytic anemia and Thrombosis to myelodysplasia, aplastic anemia and, Myeloid leukemias.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 72, 'thrombosis'), ('CL_0000763', 'myeloid cell', 123, 'myeloid')]
PMC3420688	5/2012	S15-PMC3420688	['Complement-Mediated Intravascular Hemolysis and Thromboses are classical manifestations of pnh [3].']	N/A	N/A	[('GO_0061588', 'calcium activated phospholipid scrambling', 0, 'Complement-mediated'), ('GO_0005622', 'intracellular anatomical structure', 20, 'intravascular'), ('GO_0071839', 'apoptotic process in bone marrow cell', 20, 'intravascular hemolysis'), ('GO_0007596', 'blood coagulation', 48, 'thromboses')]
PMC3420688	5/2012	S66-PMC3420688	['Abdominal imaging showed resolution of the Hepatic Vein Thromboses.']	N/A	N/A	[('UBERON_0000916', 'abdomen', 0, 'Abdominal'), ('UBERON_0001143', 'hepatic vein', 43, 'hepatic vein'), ('GO_0007596', 'blood coagulation', 56, 'thromboses')]
PMC3420688	5/2012	S91-PMC3420688	['eculizumab, a humanized monoclonal Antibody against C5, acts as a terminal Complement Inhibitor and is effective in targeting classical manifestations of pnh including Complement-Mediated Hemolysis and Thromboses [12].']	N/A	N/A	[('GO_0042571', 'immunoglobulin complex, circulating', 35, 'antibody'), ('PR_000004904', 'complement C5', 52, 'C5'), ('CHEBI_75293', 'methyltrioctylammonium', 75, 'complement'), ('CHEBI_35222', 'inhibitor', 86, 'inhibitor'), ('GO_0000911', 'cytokinesis by cell plate formation', 168, 'complement-mediated hemolysis'), ('GO_0007596', 'blood coagulation', 202, 'thromboses')]
PMC3475131	6/2012	S101-PMC3475131	['pena-rosas 2009 [32] (a high quality review) found no significant difference in small for Gestational age, Birthweight, Perinatal death, or admission to special care unit, among infants whose mothers received Iron and Folic Acid supplementation or not.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 90, 'gestational'), ('GO_0007596', 'blood coagulation', 107, 'birthweight'), ('GO_0036268', 'swimming', 120, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 120, 'perinatal'), ('CHEBI_24870', 'ion', 209, 'iron'), ('CHEBI_30751', 'formic acid', 218, 'folic acid')]
PMC3475131	6/2012	S157-PMC3475131	['the Erythropoietin group demonstrated a significant increase in Platelet count, but no increased Thrombotic events.']	N/A	N/A	[('CHEBI_24009', 'eumelanin', 4, 'erythropoietin'), ('CL_0000233', 'platelet', 64, 'platelet'), ('GO_0007596', 'blood coagulation', 97, 'thrombotic')]
PMC3520859	11/2012	S3-PMC3520859	['dietary Intake, physical activity levels, Gestational weight gain knowledge, smoking cessation, and intention to Breastfeed were assessed at service-entry and 12 weeks later.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('GO_0007565', 'female pregnancy', 42, 'gestational'), ('GO_0007596', 'blood coagulation', 113, 'breastfeed')]
PMC3520859	11/2012	S54-PMC3520859	['intention to Breastfeed (secondary) and pre-Pregnancy bmi was also collected.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 13, 'breastfeed'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy')]
PMC3520859	11/2012	S138-PMC3520859	['no significant between-group difference was observed in women’s intention to Breastfeed (itt or pp) (table3); these score were high at both time points for both groups, with a score range being 0 (low) to 16 (high) [38].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 77, 'breastfeed')]
PMC3520859	11/2012	S151-PMC3520859	['this population already had a high intention to Breastfeed.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 48, 'breastfeed')]
PMC3521768	12/2012	S4-PMC3521768	['about 575 subjects were successfully followed until Delivery and Birthweight was measured within 72 hours after Delivery.']	N/A	N/A	[('GO_0007567', 'parturition', 52, 'delivery'), ('GO_0007596', 'blood coagulation', 65, 'birthweight'), ('GO_0007567', 'parturition', 112, 'delivery')]
PMC3521768	12/2012	S5-PMC3521768	['the association between the exposures and Birthweight was examined using log-binomial and liner regression analyses.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 42, 'birthweight')]
PMC3521768	12/2012	S7-PMC3521768	['results\nthe mean Birthweight (± standard deviation) was 2896 g (±423).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 17, 'birthweight')]
PMC3521768	12/2012	S70-PMC3521768	['the occurrence of Births in the cohort were promptly identified and reported by prearranged local community health promoters and Birthweight was measured within 72 hours of Birth by trained health extension workers.']	N/A	N/A	[('GO_0007567', 'parturition', 18, 'births'), ('GO_0007596', 'blood coagulation', 129, 'birthweight'), ('GO_0007567', 'parturition', 173, 'birth')]
PMC3521768	12/2012	S84-PMC3521768	['independent t-test and one-way analysis of variance (anova) were used to compare Birthweight across categories of independent variables.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 81, 'birthweight')]
PMC3521768	12/2012	S97-PMC3521768	['linear regression analysis was also used to control confounders and to assess the association between Birthweight and various covariates.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 102, 'birthweight')]
PMC3521768	12/2012	S111-PMC3521768	['the exclusion was on the bases of loss to follow-up (34), Birthweight measurement taken after 72 hours of Birth (22), fetal loss (9), multiple Birth (6) and early neonatal death (4).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 58, 'birthweight'), ('GO_0007567', 'parturition', 106, 'birth'), ('GO_0007567', 'parturition', 143, 'birth')]
PMC3521768	12/2012	S117-PMC3521768	['prevalence and general determinants of lbw\nthe mean Birthweight (± standard deviation) was 2896 g (±423).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 52, 'birthweight')]
PMC3521768	12/2012	S122-PMC3521768	['the mean Birthweight increased from 2829 g in the poorest to 2951 g in the richest wealth quintiles.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 9, 'birthweight')]
PMC3521768	12/2012	S132-PMC3521768	['the Birthweight of babies Born to thin women (2697 g±361) was significantly inferior compared to their counterparts (2971 g±361) (t\u200a=\u200a7.255, p\u200a=\u200a0.000) .']	N/A	N/A	[('GO_0007596', 'blood coagulation', 4, 'birthweight'), ('GO_0007567', 'parturition', 26, 'born')]
PMC3521768	12/2012	S137-PMC3521768	['using independent t-test analysis, statistically significant 82 g (95% ci: 9–150 g) and 76 g (95% ci: 6–145 g) decrease on Birthweight was observed in babies Born to women who had Prenatal Vitamin A and zinc deficiencies, respectively.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 123, 'birthweight'), ('GO_0007567', 'parturition', 158, 'born'), ('GO_0007565', 'female pregnancy', 180, 'prenatal'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin A')]
PMC3521768	12/2012	S145-PMC3521768	['linear modeling of predictors of Birthweight\nin the bivariate linear regression model altitude of the kebeles, number of anc visits, Diastolic Blood pressure during Pregnancy were not associated to Birthweight (p>0.05) .']	N/A	N/A	[('GO_0007596', 'blood coagulation', 33, 'birthweight'), ('GO_0007586', 'digestion', 133, 'diastolic'), ('UBERON_0000178', 'blood', 143, 'blood'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy'), ('GO_0007596', 'blood coagulation', 198, 'birthweight')]
PMC3521768	12/2012	S206-PMC3521768	['conclusion\nthe prevalence of low Birthweight was 16.5%.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 33, 'birthweight')]
PMC3532199	11/2012	S637-PMC3532199	['the propensities for Giving Birth will apply to the outcomes measured among study Births (cleft recurrence and severity, Birthweight, Gestational age, etc.)']	N/A	N/A	[('GO_0007567', 'parturition', 21, 'giving birth'), ('GO_0007567', 'parturition', 82, 'births'), ('GO_0007596', 'blood coagulation', 121, 'birthweight'), ('GO_0007565', 'female pregnancy', 134, 'gestational')]
PMC3533960	10/2012	S100-PMC3533960	['caption (table-wrap): table 2\n\ndata collection and measurementsmeasurementspre-pregnancypregnancybirthpost-Partum \xa0\xa0 6-12 weeks23-28 weeks30-36 weeks \xa0\xa0 maternal \xa0\xa0\xa0\xa0\xa0\xa0demographics, ses status√\xa0\xa0\xa0\xa0\xa0obgyn history√\xa0\xa0\xa0\xa0\xa0Food frequency questionnaire√\xa0\xa0\xa0\xa0\xa0helminthic infections√\xa0\xa0\xa0\xa0\xa0mental health√√√√\xa0√morbidity\xa0√√√\xa0√periodontitis screening\xa0√√√\xa0\xa0workload\xa0√√√\xa0\xa0Blood pressure√√√√\xa0\xa0anthropometry√√√√\xa0√hematological measures\xa0\xa0\xa0\xa0\xa0\xa0Hemoglobin√√√√\xa0√Serum ferritin√√√\xa0\xa0√Transferrin Receptor√√√\xa0\xa0√infection indicators (crp, agp)√√√\xa0\xa0√other biological indicators\xa0\xa0\xa0\xa0\xa0\xa0Vitamin A√√√\xa0\xa0√Blood Glucose\xa0√√\xa0\xa0\xa0Urine protein\xa0√√√\xa0\xa0 Fetal Development (ultrasound) \xa0√√√\xa0\xa0 Birth information \xa0\xa0\xa0\xa0√\xa0 child measurement \xa0\xa0\xa0\xa0\xa0\xa0Gestational age\xa0\xa0\xa0\xa0√\xa0anthropometry\xa0\xa0\xa0\xa0√√hematological measures\xa0\xa0\xa0\xa0\xa0\xa0hemoglobin\xa0\xa0\xa0\xa0\xa0√Serum ferritin\xa0\xa0\xa0\xa0√\xa0Transferrin Receptor\xa0\xa0\xa0\xa0√\xa0infant Feeding practices\xa0\xa0\xa0\xa0\xa0√ supplement information \xa0\xa0\xa0\xa0\xa0\xa0supplement consumption√√√√\xa0\xa0side effects√√√√\xa0\xa0\n\nmeasurement of key outcomes\nBirth size : infant anthropometry is measured as early as possible within seven days after Birth and at one and three months Postpartum using standard procedures [34,35].']	N/A	N/A	[('GO_0007567', 'parturition', 107, 'partum'), ('UBERON_0001013', 'adipose tissue', 107, 'partum'), ('CHEBI_33290', 'food', 217, 'Food'), ('GO_0007596', 'blood coagulation', 355, 'Blood'), ('UBERON_0000178', 'blood', 355, 'Blood'), ('CHEBI_5679', 'herniarin', 422, 'Hemoglobin'), ('UBERON_0001977', 'blood serum', 438, 'Serum'), ('PR_000001703', 'mas-related G-protein coupled receptor X2', 458, 'Transferrin receptor'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 554, 'Vitamin A'), ('CHEBI_33290', 'food', 569, 'Blood'), ('UBERON_0000178', 'blood', 569, 'Blood'), ('CHEBI_17234', 'glucose', 575, 'Glucose'), ('UBERON_0001088', 'urine', 588, 'Urine'), ('GO_0060132', 'prolactin secreting cell development', 608, 'Fetal development'), ('GO_0007567', 'parturition', 646, 'Birth'), ('GO_0007565', 'female pregnancy', 695, 'Gestational'), ('UBERON_0001977', 'blood serum', 779, 'Serum'), ('PR_000001703', 'mas-related G-protein coupled receptor X2', 799, 'Transferrin receptor'), ('GO_0007631', 'feeding behavior', 832, 'feeding'), ('GO_0007567', 'parturition', 961, 'Birth'), ('GO_0007567', 'parturition', 1052, 'birth'), ('GO_0007565', 'female pregnancy', 1086, 'postpartum')]
PMC3543392	12/2012	S217-PMC3543392	['abbreviations\nala: Linolenic Acid; ara: Arachidonic Acid; bp: Blood pressure; cad: Coronary Artery disease; cefa: Cholesterol Ester Fatty Acid; cvd: Cardiovascular diseases; Dha: Docosahexaenoic Acid; disc: dietary interventio dietary intervention study in children; dbp: diastolic bp; espghan: european society of pediatric Gastroenterology hepatology and nutrition; Epa: Eicosapentaenoic Acid; foad: fetal origins of Adult disease; Hdl-C: High-density Lipoprotein Cholesterol; Hmg-Coa: Hydroxymethylglutaril Coenzyme A; Igf-1: Insulin Growth Factor 1; ir: Insulin resistance; La: Linoleic Acid; lbw: low Birthweight; lcpufa: Long Chain polyunsaturated Fatty Acids; ldl-c: low-density lipoprotein Cholesterol; mufa: monounsaturated Fatty Acid; ms: Metabolic syndrome; pufa: polyunsaturated Fatty Acids; sbp: systolic bp; strip: special turku Coronary risk factor intervention project; tc: total Cholesterol; t2dm: type 2 diabetes mellitus; tg: Triglycerides; who: world health organization.']	N/A	N/A	[('CHEBI_16494', 'lipoic acid', 19, 'Linolenic acid'), ('CHEBI_15843', 'arachidonic acid', 40, 'Arachidonic acid'), ('UBERON_0000178', 'blood', 62, 'Blood'), ('UBERON_0001621', 'coronary artery', 83, 'Coronary artery'), ('CHEBI_82381', '5-Aminoacenaphthene', 114, 'Cholesterol ester fatty acid'), ('UBERON_0004535', 'cardiovascular system', 149, 'Cardiovascular'), ('CHEBI_17874', 'dihydrozeatin', 174, 'DHA'), ('CHEBI_78869', 'octacosapentaenoic acid', 179, 'Docosahexaenoic acid'), ('UBERON_0010898', 'gastralium', 325, 'gastroenterology'), ('CHEBI_34733', 'EPN', 368, 'EPA'), ('CHEBI_31001', 'octacosanoic acid', 373, 'Eicosapentaenoic acid'), ('UBERON_0007023', 'adult organism', 419, 'adult'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 434, 'HDL-C'), ('PR_000008466', 'hepatitis B virus X-interacting protein', 441, 'High'), ('PR_000009893', 'acyl-CoA:lysophosphatidylglycerol acyltransferase 1', 454, 'lipoprotein'), ('CHEBI_16113', 'cholesterol', 466, 'cholesterol'), ('CHEBI_17883', 'hydrogen chloride', 479, 'HMG'), ('CHEBI_15346', 'coenzyme A', 483, 'CoA'), ('CHEBI_15729', 'L-ornithine', 488, 'Hydroxymethylglutaril coenzyme A'), ('PR_000008929', 'interferon-related developmental regulator 1', 522, 'IGF-1'), ('PR_000008929', 'interferon-related developmental regulator 1', 529, 'Insulin growth factor 1'), ('PR_000045358', 'insulin family protein', 558, 'Insulin'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 578, 'LA'), ('CHEBI_16494', 'lipoic acid', 582, 'Linoleic acid'), ('GO_0007596', 'blood coagulation', 606, 'birthweight'), ('CHEBI_6541', 'losartan', 627, 'Long chain'), ('CHEBI_35366', 'fatty acid', 654, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 698, 'cholesterol'), ('CHEBI_35366', 'fatty acid', 733, 'fatty acid'), ('GO_0008152', 'metabolic process', 749, 'Metabolic'), ('CHEBI_35366', 'fatty acid', 791, 'fatty acids'), ('UBERON_0005985', 'coronary vessel', 843, 'coronary'), ('CHEBI_16113', 'cholesterol', 896, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 945, 'Triglycerides')]
PMC3544621	11/2012	S112-PMC3544621	['[34]11 (1987-1999)Calcium supplementationmaternal: ↑b/p with or without proteinuria, ↑b/p with significant proteinuria, infant: Preterm Delivery, Birthweight, admission to nicu, Stillbirth or Deathpre-eclampsia ↓(rr 0.68, 95% ci 0.57-0.81)yes\xa0\xa0\xa0\xa0fewer babies Born <2500g (rr 0.83 95% ci 0.71-0.98)\xa0hofmeyr et al.']	N/A	N/A	[('CHEBI_31341', 'calcium dihydroxide', 18, 'Calcium'), ('GO_0007565', 'female pregnancy', 128, 'preterm'), ('GO_0007567', 'parturition', 136, 'delivery'), ('GO_0007596', 'blood coagulation', 146, 'birthweight'), ('GO_0001966', 'thigmotaxis', 178, 'stillbirth'), ('GO_0008209', 'androgen metabolic process', 192, 'deathPre'), ('GO_0007567', 'parturition', 259, 'born')]
PMC3547777	12/2012	S8-PMC3547777	['during fgd all primigravidae (n\u2009=\u200917) intended to Breastfeed and all multigravidae (n\u2009=\u200933) had previously Breastfed; expected or previous duration of Feeding was for more than one year or longer.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 50, 'breastfeed'), ('GO_0007567', 'parturition', 107, 'breastfed'), ('GO_0007631', 'feeding behavior', 151, 'feeding')]
PMC3547777	12/2012	S10-PMC3547777	['women stated their intention to Breastfeed with certainty.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 32, 'breastfeed')]
PMC3547777	12/2012	S65-PMC3547777	['this chart specifies the time of the first Breastfeed and every Breastfeed in the first 4 hours.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 43, 'breastfeed'), ('GO_0007596', 'blood coagulation', 64, 'breastfeed')]
PMC3547777	12/2012	S102-PMC3547777	['when the baby was not Breastfed within four hours of Birth the midwifery notes were searched to find the time of the first Breastfeed.']	N/A	N/A	[('GO_0007567', 'parturition', 22, 'breastfed'), ('GO_0007567', 'parturition', 53, 'birth'), ('GO_0007596', 'blood coagulation', 123, 'breastfeed')]
PMC3547777	12/2012	S184-PMC3547777	['when asked, 100% (50/50) of women expressed their intention to Breastfeed or their experience of breastfeeding with certainty.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 63, 'breastfeed')]
PMC3547777	12/2012	S187-PMC3547777	['another women in her group spontaneously assured her that she could Breastfeed for longer if she wished.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 68, 'breastfeed')]
PMC3547777	12/2012	S193-PMC3547777	['a longer duration of breastfeeding was expressed as an expected commitment to the Wellbeing of the baby:\n"“i feel pity for the baby if breastfeeding [is] stopped before one year as the baby is too small” (khee lar say, first Pregnancy, aged 23 years, plans to Breastfeed for more than 2 years) and:"\n"“i will Breastfeed for more than one year- until my baby is big enough for other Food, after 14 months my baby is big enough for other Food” (mu chai, first Pregnancy, aged 21 years, plans to Breastfeed for more than one year),"\n"“i Breastfed for one year, seven months, the baby stopped because she didn’t like [to Breastfeed] and [wanted] to eat other Food.”(lwe lahr paw, mother of one, aged 26 years, Breastfed her baby for more than one year), or a similar commitment to the health of the baby:"\n"“this is my only[first]baby so i want the baby to be very healthy”(ma kyi aye, first Pregnancy, aged 20 years, plans to Breastfeed for more than 3 years)."']	N/A	N/A	[('GO_0001905', 'activation of membrane attack complex', 82, 'wellbeing'), ('GO_0007565', 'female pregnancy', 225, 'pregnancy'), ('GO_0007596', 'blood coagulation', 260, 'breastfeed'), ('GO_0007596', 'blood coagulation', 309, 'breastfeed'), ('CHEBI_33290', 'food', 382, 'food'), ('CHEBI_33290', 'food', 436, 'food'), ('GO_0007565', 'female pregnancy', 458, 'pregnancy'), ('GO_0007596', 'blood coagulation', 493, 'breastfeed'), ('GO_0007567', 'parturition', 534, 'breastfed'), ('GO_0007596', 'blood coagulation', 617, 'breastfeed'), ('CHEBI_33290', 'food', 655, 'food'), ('GO_0007567', 'parturition', 706, 'breastfed'), ('GO_0007565', 'female pregnancy', 888, 'pregnancy'), ('GO_0007596', 'blood coagulation', 923, 'breastfeed')]
PMC3547777	12/2012	S197-PMC3547777	['[she later added] “if i Breastfeed [my daughter] she will Grow up to Breastfeed.”"\n\nbottle Feeding is for other People\nwithin all except one of the focus groups the topic of bottle Feeding was spontaneously introduced.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 24, 'breastfeed'), ('GO_0040007', 'growth', 58, 'grow'), ('GO_0007596', 'blood coagulation', 69, 'breastfeed'), ('GO_0007631', 'feeding behavior', 91, 'feeding'), ('NCBITaxon_10088', 'Mus <genus>', 112, 'people'), ('GO_0007631', 'feeding behavior', 181, 'feeding')]
PMC3547777	12/2012	S211-PMC3547777	['one midwife drew on her personal experiences to illustrate her views:\n"“nobody told [showed] me about breastfeeding –i just knew i would Breastfeed when i had my baby.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 137, 'breastfeed')]
PMC3547777	12/2012	S212-PMC3547777	['our women are strong and we always Breastfeed our babies so that they will be strong and healthy too” (chit su, aged 40)."']	N/A	N/A	[('GO_0007596', 'blood coagulation', 35, 'breastfeed')]
PMC3547777	12/2012	S218-PMC3547777	['if wrapped, the baby will be warm and sleep a long time.if you want to pick her up, you know and Breastfeed, it is easier [to do this] if the baby is wrapped.” (chit su, aged 40),"\n"“swaddling is for the baby to get the feeling of being held like you would give a proper hug to someone you care for.” (mu may, aged 45)."']	N/A	N/A	[('GO_0007596', 'blood coagulation', 97, 'breastfeed')]
PMC3547777	12/2012	S232-PMC3547777	['primigravidae anticipated they would Breastfeed for more than one year or longer.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 37, 'breastfeed')]
PMC3547777	12/2012	S268-PMC3547777	['women and midwives have expressed certainty and confidence in women’s ability to Breastfeed and an acceptance of breastfeeding as an integral part of being a mother.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 81, 'breastfeed')]
PMC3558353	12/2012	S76-PMC3558353	['each participant gave written informed consent for the release of hospital Perinatal data related to the Birth Of their Child, completion of a participant maternal baseline survey, and for individual follow-up.']	N/A	N/A	[('GO_0036268', 'swimming', 75, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 75, 'perinatal'), ('GO_0007596', 'blood coagulation', 105, 'birth of ... child')]
PMC3561108	9/2012	S8-PMC3561108	['factors facilitating gdm self-management included: Thinking about the baby and psychological support from partners and families.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 51, 'thinking')]
PMC3664621	5/2013	S7-PMC3664621	['the expectant mothers also received a written information leaflet to motivate them to Breastfeed their offspring for at least 6 months.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 86, 'breastfeed')]
PMC3710985	7/2013	S83-PMC3710985	['thirty-eight per cent of mothers taking sgas did not Breastfeed, which is approximately eight times greater than in controls (p<0.001).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 53, 'breastfeed')]
PMC3734354	7/2013	S169-PMC3734354	['mothers were asked if they Planned to Breastfeed or not.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'planned'), ('GO_0007596', 'blood coagulation', 38, 'breastfeed')]
PMC3734354	7/2013	S245-PMC3734354	['Behavioral development was assessed at both time points using the bsid and Feeding information was collected from 3-day Feeding records obtained monthly.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 0, 'Behavioral'), ('GO_0007631', 'feeding behavior', 75, 'feeding'), ('GO_0007631', 'feeding behavior', 120, 'feeding')]
PMC3743734	9/2013	S22-PMC3743734	['it is common for women in the gambia, who Breastfeed each child for ∼2 y, to become Pregnant again while still breastfeeding or shortly afterward.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 42, 'breastfeed'), ('GO_0007565', 'female pregnancy', 84, 'pregnant')]
PMC3756974	8/2013	S15-PMC3756974	['Catechin eliminates Free Radicals and decreases Cholesterol level preventing cancer development, high Blood pressure, Arterial sclerosis, Thrombosis, Heart attacks and Brain strokes and Aging arrestment [5].']	N/A	N/A	[('CHEBI_3461', 'Casuarictin', 0, 'Catechin'), ('CHEBI_26519', 'radical', 20, 'free radicals'), ('CHEBI_16113', 'cholesterol', 48, 'cholesterol'), ('UBERON_0000178', 'blood', 102, 'blood'), ('UBERON_0001637', 'artery', 118, 'arterial'), ('GO_0007596', 'blood coagulation', 138, 'thrombosis'), ('UBERON_0000948', 'heart', 150, 'heart'), ('UBERON_0000955', 'brain', 168, 'brain'), ('GO_0007568', 'aging', 186, 'aging')]
PMC3763666	7/2012	S110-PMC3763666	['[22]132 high-risk infants for atopy lactobacillus rhamnosus gg (1 × 1010cfu daily)r, db, pcfrom 2–4 weeks Prenatally to 24 weeks Postnatallyat 2 years ad frequency halved in Probiotic group vs .']	N/A	N/A	[('GO_0019230', 'proprioception', 106, 'prenatally'), ('GO_0007596', 'blood coagulation', 129, 'postnatallyAt'), ('CHEBI_73033', 'pterocarpan', 174, 'probiotic')]
PMC3763666	7/2012	S124-PMC3763666	['[31]112 high-risk infants for atopy bifidobacterium bifidum (1.6 × 109cfu), bifidobacterium lactis (1.6 × 109cfu), lactobacillus acidophilus (1.6 × 109cfu) dailyr, db, pcto mothers from 8 weeks Prenatally and to mothers/infants for 6 months Postnatallyat 6 and 12 months the prevalence of ad in Probiotics group was reduced than in placebo group.']	N/A	N/A	[('GO_0019230', 'proprioception', 194, 'prenatally'), ('GO_0007596', 'blood coagulation', 241, 'postnatallyAt'), ('CHEBI_26346', 'prostaglandins J', 295, 'probiotics')]
PMC3783381	9/2013	S203-PMC3783381	['in these rural areas, usually most families Breastfeed as a cultural practice consistent with religious belief.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 44, 'breastfeed')]
PMC3850328	3/2013	S7-PMC3850328	['in addition, Biological changes during throughout their Lives such as Menstruation, Menopause, Sexual and Reproductive aspects, as well as care-giving to children and elderly members of the family leads them to use more health services.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 13, 'biological'), ('UBERON_0000104', 'life cycle', 56, 'lives'), ('GO_0042703', 'menstruation', 70, 'menstruation'), ('GO_0042697', 'menopause', 84, 'menopause'), ('GO_0019331', 'anaerobic respiration, using ammonium as electron donor', 95, 'sexual'), ('GO_0000003', 'reproduction', 106, 'reproductive')]
PMC3853358	10/2013	S97-PMC3853358	['table\xa02also shows the Birthweight, Gestational age, and gender distributions.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 22, 'birthweight'), ('GO_0007565', 'female pregnancy', 35, 'gestational')]
PMC3864158	12/2013	S5-PMC3864158	['there was also no differential effect of Prenatal interventions on Birthweight or birthlength.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 41, 'prenatal'), ('GO_0007596', 'blood coagulation', 67, 'birthweight')]
PMC3864158	12/2013	S105-PMC3864158	['calculations of the original sample size were made on the basis of finding a difference in Birthweight.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 91, 'birthweight')]
PMC3864158	12/2013	S114-PMC3864158	['Birthweight, length) and child growth up to 54 months of age and body composition (fm, ffm) at 54 months of follow-up.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 0, 'birthweight')]
PMC3864158	12/2013	S133-PMC3864158	['at enrolment, 27% of women were malnourished (bmi <18.5 kg/m2), 30% of infants were lbw (Birthweight <2,500 g), and 8% of children were pre-term (Born <37 weeks of Gestation).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 89, 'birthweight'), ('GO_0007567', 'parturition', 146, 'born'), ('GO_0007565', 'female pregnancy', 164, 'gestation')]
PMC3864158	12/2013	S134-PMC3864158	['the mean Birthweight of 3,267 singletons was 2,694 g and at 54 months of follow-up, the mean weight was 13.8 kg, and the mean height was 99.8 cm, with no significant differences among groups.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 9, 'birthweight')]
PMC3877972	12/2013	S205-PMC3877972	['regarding the prognosis of lbw, with the development of Perinatology, the survival rate of lbw infants has substantially increased.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 56, 'perinatology'), ('UBERON_0022351', 'parietal serous membrane', 56, 'perinatology')]
PMC3880212	12/2013	S68-PMC3880212	['data collection\nduring the telephone survey, we collected information on demographics; mother’s residential history one year before and after Birth Of the Child; maternal water usage; mother’s medical history during Pregnancy; family history of Birth defects; maternal smoking, Alcohol use, and occupation; and father’s lifestyle habits and occupational history.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 142, 'birth of ... child'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('GO_0007567', 'parturition', 245, 'birth'), ('CHEBI_30879', 'alcohol', 278, 'alcohol')]
PMC3882256	1/2014	S61-PMC3882256	['Gestational age at Delivery and Birthweight were obtained from the obstetric records.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('GO_0007567', 'parturition', 19, 'delivery'), ('GO_0007596', 'blood coagulation', 32, 'birthweight')]
PMC3893866	12/2013	S89-PMC3893866	['multiple linear regression analysis was used to determine the association of Birthweight, wfl z-score at Birth, and wfl z-score at 4–6 months with ahei-p, amed, gi, and gl.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 77, 'birthweight'), ('GO_0007567', 'parturition', 105, 'birth')]
PMC3893866	12/2013	S90-PMC3893866	['models for Birthweight and Birth wfl z-score were fully adjusted for the above-mentioned covariates with additional adjustment for Gestational age.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 11, 'birthweight'), ('GO_0007567', 'parturition', 27, 'birth'), ('GO_0007565', 'female pregnancy', 131, 'gestational')]
PMC3893866	12/2013	S118-PMC3893866	['discussion\nin a nationally distributed sample of 893 us mothers of healthy singletons Delivered after 35 weeks of Gestation, maternal dietary patterns and Carbohydrate quality during third trimester were not associated with offspring outcomes consisting of Birthweight, size-for-Gestational age (small or large), and infant growth in the first 4–6 months of Life.']	N/A	N/A	[('GO_0007567', 'parturition', 86, 'delivered'), ('GO_0007565', 'female pregnancy', 114, 'gestation'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 155, 'carbohydrate'), ('GO_0007596', 'blood coagulation', 257, 'birthweight'), ('GO_0007565', 'female pregnancy', 279, 'gestational'), ('UBERON_0000104', 'life cycle', 358, 'life')]
PMC3914197	7/2012	S22-PMC3914197	['the other newborn was a female with a Birthweight of 2180 grams.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 38, 'birthweight')]
PMC3933411	12/2013	S76-PMC3933411	['less than half the participants (42.0%) declared they received advice on diet during Pregnancy and 83.5% stated they were advised to Breastfeed (table\xa01).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('GO_0007596', 'blood coagulation', 133, 'breastfeed')]
PMC3937977	2/2014	S34-PMC3937977	['for health centre Deliveries, Birthweight, length, Head circumference and Knee-Heel lengths were measured immediately following Delivery.']	N/A	N/A	[('GO_0007567', 'parturition', 18, 'deliveries'), ('GO_0007596', 'blood coagulation', 30, 'birthweight'), ('UBERON_0000033', 'head', 51, 'head'), ('UBERON_0001485', 'knee joint', 74, 'knee-heel'), ('GO_0007567', 'parturition', 128, 'delivery')]
PMC3937977	2/2014	S78-PMC3937977	['caption (table-wrap): table 1\n\nnumber of infants with ti measurements available at each time point, and the status and cause of death of these infants, by time pointnumber of infantsbirth8 weeks24 weekstotal number of ti observations116816271595status\u2003\u2003\u2003\u2003alive114016011572\u2003\u2003\u2003\u2003death in infancy1472\u2003\u2003\u2003\u2003death in childhood141921cause of deatha\u2003\u2003\u2003\u2003infection1283\u2003\u2003\u2003\u2003asphyxia1\u2003\u2003\u2003\u2003Preterm, lbw\u2003\u2003\u2003\u2003malformation1\u2003\u2003\u2003\u2003other131719\u2003\u2003\u2003\u2003unknown111\nlbw, low Birthweight.']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 373, 'Preterm'), ('GO_0007596', 'blood coagulation', 441, 'birthweight')]
PMC3973835	3/2014	S76-PMC3973835	['a list of adequate Prenatal physical exercise programmes, brochures including recommendations for a balanced diet in Pregnancy as well as a chart for adequate weight gain according to baseline bmi category to self-monitor Weight development are handed out.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'prenatal'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy'), ('GO_0007596', 'blood coagulation', 222, 'weight')]
PMC3999948	4/2014	S158-PMC3999948	['the options discussed included (1) child adiposity or bmi outcome downstream, (2) macrosomia (Birthweight > 90th percentile), (3) meeting the iom gwg guidelines, and (4) infant Birth weight.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 94, 'birthweight'), ('GO_0007567', 'parturition', 177, 'birth')]
PMC4018969	5/2014	S206-PMC4018969	['**Gestational diabetes; pre-eclampsia; Thrombosis; proportion staying within iom guidance on weight gain in Pregnancy [20]; form of pain relief; Birth delivery mode; Gestation at Delivery; induction of labour; Shoulder dystocia, 3rd/4thdegree Perineal tear; Postpartum bleeding or Thrombosis; apgar scores.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 2, 'gestational'), ('GO_0007596', 'blood coagulation', 39, 'thrombosis'), ('GO_0007565', 'female pregnancy', 108, 'pregnancy'), ('GO_0007567', 'parturition', 145, 'birth'), ('GO_0007565', 'female pregnancy', 166, 'gestation'), ('GO_0007567', 'parturition', 179, 'delivery'), ('UBERON_0001467', 'shoulder', 210, 'shoulder'), ('UBERON_0001977', 'blood serum', 243, 'perineal'), ('GO_0007565', 'female pregnancy', 258, 'postpartum'), ('GO_0007596', 'blood coagulation', 281, 'thrombosis')]
PMC4034700	5/2014	S150-PMC4034700	['in addition, No exerts many vasoprotective and anti-atherosclerotic properties, including protection from Thrombosis, reduction of adhesion Molecule Expression and Leukocyte adhesion.']	N/A	N/A	[('CHEBI_16382', 'iodide', 13, 'NO'), ('GO_0007596', 'blood coagulation', 106, 'thrombosis'), ('CHEBI_36357', 'polyatomic entity', 140, 'molecule'), ('GO_0010467', 'gene expression', 149, 'expression'), ('CL_0000738', 'leukocyte', 164, 'leukocyte')]
PMC4047075	6/2014	S76-PMC4047075	['in the majority of instances (10/12 for daughter Milk yield, 7/12 for daughter Milk fat and 9/12 for daughter milk protein), the daughter responses were greater when the dams’ herd test trait was included in the model (the average across all dam traits, breeds and Lactations in daughters was −29.0 litres milk volume, 0.66 kg milk fat and −0.13 kg milk protein) compared with when the grand-dams’ herd test trait was included (−14.9 litres milk volume, 0.27 kg milk fat and −0.15 kg milk protein).10.1371/journal.pone.0098928.t004\n\ncaption (table-wrap): table 4\nregression coefficients of grand-dam traits on daughter Milking performance.breedprenatalenvironment indicatortraitlactationregression coefficientvolume (litres)fat (kg)protein (kg)jerseygrand-dam milk volume (litres)1−13.7±3.3**0.09±0.03**0.10±0.02**26.3±0.9**0.14±0.04**0.15±0.03**grand-dam fat %1−20.0±3.1**0.17±0.14ns−0.43±0.10**2−52.0±3.6**0.09±0.19ns−0.64±0.14nsgrand-dam protein %14.8±0.6**−0.03±0.14ns−0.16±0.11ns2−17.1±4.1**−0.19±0.18ns−0.27±0.14nsholsteinfriesiangrand-dam Milk volume (litres)12.52±0.36**−0.03±0.01**0.03±0.01**23.66±0.49**−0.01±0.02ns0.06±0.02**grand-dam fat %1−26.7±2.6**0.99±0.10**−0.25±0.79ns2−40.0±3.6**1.00±0.14**−0.50±0.11**grand-dam protein %1−10.2±2.9**0.51±0.12**0.14±0.09ns2−16.2±3.8**0.51±0.15**0.02±0.11ns\nstandard errors are given for each estimate.']	N/A	N/A	[('UBERON_0001913', 'milk', 49, 'milk'), ('UBERON_0001913', 'milk', 79, 'milk'), ('GO_0007596', 'blood coagulation', 265, 'lactations'), ('GO_0007601', 'visual perception', 619, 'milking'), ('UBERON_0001913', 'milk', 1046, 'milk')]
PMC4048511	5/2014	S48-PMC4048511	['regarding Birth To Child with defects, 42 (10.5%) had positive and 358 (89.5%) had negative history.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 10, 'birth to child')]
PMC4054662	7/2014	S20-PMC4054662	['other characteristics of the condition include higher circulating levels of soluble adhesion Molecules produced by the activated Endothelium(14,15), and of the potent inflammatory Mediator peroxynitrite that causes vasoconstriction, Platelet Aggregation and Thrombus Formation(16–18).']	N/A	N/A	[('CHEBI_36357', 'polyatomic entity', 93, 'molecules'), ('UBERON_0001986', 'endothelium', 129, 'endothelium'), ('CHEBI_35222', 'inhibitor', 180, 'mediator'), ('CL_0000233', 'platelet', 233, 'platelet'), ('GO_0070527', 'platelet aggregation', 233, 'platelet aggregation'), ('GO_0007596', 'blood coagulation', 258, 'thrombus formation'), ('UBERON_0010210', 'blood clot', 258, 'thrombus')]
PMC4113768	7/2014	S3254-PMC4113768	['Birthweight was recorded and centiles were calculated using customised Birthweight charts incorporating Gestational age at Birth, sex and maternal ethnicity.']	N/A	N/A	[('GO_0007608', 'sensory perception of smell', 0, 'Birthweight'), ('GO_0007596', 'blood coagulation', 71, 'birthweight'), ('GO_0007565', 'female pregnancy', 104, 'gestational'), ('GO_0007567', 'parturition', 123, 'birth')]
PMC4113771	7/2014	S23-PMC4113771	['no effect of the low gi diet was noted on Birthweight or macrosomia [8,9].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 42, 'birthweight')]
PMC4120194	7/2014	S654-PMC4120194	['obsessions are defined as recurrent, persistent, and intrusive Thoughts, images, or urges that cause marked anxiety, and compulsions are defined as repetitive behaviors or mental acts that the patient feels compelled to perform to reduce the obsession-related anxiety [26].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 63, 'thoughts')]
PMC4122175	8/2014	S116-PMC4122175	['knowing this, we tracked maternal and paternal Expression of the maternally Imprinted Gene that encodes the Thyroid Metabolizing Enzyme Deiodinase 3 (Dio3) in several Brain Regions of the sb f1 Rat offspring (sittig et al.,2011b).']	N/A	N/A	[('GO_0010467', 'gene expression', 47, 'expression'), ('GO_0071514', 'genetic imprinting', 76, 'imprinted'), ('SO_0000704', 'gene', 86, 'gene'), ('GO_0007596', 'blood coagulation', 108, 'thyroid metabolizing'), ('PR_000016293', 'protein-glutamine gamma-glutamyltransferase 2', 108, 'thyroid metabolizing enzyme deiodinase 3'), ('UBERON_0002046', 'thyroid gland', 108, 'thyroid'), ('PR_000006480', 'type I iodothyronine deiodinase', 150, 'Dio3'), ('UBERON_0002616', 'regional part of brain', 167, 'brain regions'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 194, 'rat')]
PMC4143835	8/2014	S101-PMC4143835	['we did not observe a statistically significant difference between occupational groups for Pregnancy complications ( p = 0.36), low Birth Weight Delivery ( p = 0.29) or Preterm Delivery ( p = 0.88) (table 5).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('GO_0007596', 'blood coagulation', 131, 'birth weight'), ('GO_0007567', 'parturition', 144, 'delivery'), ('GO_0007565', 'female pregnancy', 168, 'preterm'), ('GO_0007567', 'parturition', 176, 'delivery')]
PMC4143835	8/2014	S104-PMC4143835	['more than half of the women in both groups reported they Breastfed their infants and continued to Breastfeed to almost six months of age of their infants.']	N/A	N/A	[('GO_0007567', 'parturition', 57, 'breastfed'), ('GO_0007596', 'blood coagulation', 98, 'breastfeed')]
PMC4161853	8/2014	S195-PMC4161853	['as a consequence, in the case of a Bloodstream Invasion Of bacteria at the same time as p. falciparum infection, bacteria will find the Mz almost inhabited and the rp Macrophages busy and skewed to irbc and urbc Phagocytosis.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 35, 'bloodstream'), ('UBERON_0001969', 'blood plasma', 35, 'bloodstream'), ('GO_0007267', 'cell-cell signaling', 47, 'invasion of'), ('UBERON_2005031', 'dorsal longitudinal vein', 136, 'MZ'), ('CL_0000235', 'macrophage', 167, 'macrophages'), ('GO_0006909', 'phagocytosis', 212, 'phagocytosis')]
PMC4169551	9/2014	S203-PMC4169551	['the balance between Th1 and Th2 Responses in the newborn is skewed towards a th2 profile, resulting in high susceptibility to Intracellular pathogen infection[46].']	N/A	N/A	[('GO_0050909', 'sensory perception of taste', 20, 'Th1'), ('GO_0007596', 'blood coagulation', 28, 'Th2 responses'), ('GO_0005622', 'intracellular anatomical structure', 126, 'intracellular')]
PMC4176103	10/2013	S103-PMC4176103	['sample size\nthe primary outcome of the rolo study was difference in infant Birthweight between the intervention and control groups.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 75, 'birthweight')]
PMC4176103	10/2013	S162-PMC4176103	['there were no significant differences in the primary outcome (mean infant Birthweight) between the two groups (4050\xa0g vs. 4000\xa0g in the intervention vs. control groups, p\u2009=\u20090.224).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 74, 'birthweight')]
PMC4190350	9/2014	S28-PMC4190350	['supplements were taken from enrolment until 3\xa0months post-Partum and primary outcome was infant Birthweight.']	N/A	N/A	[('GO_0007567', 'parturition', 58, 'partum'), ('GO_0007596', 'blood coagulation', 96, 'birthweight')]
PMC4193257	7/1992	S148-PMC4193257	['in addition, many european countries provide cash benefits to replace income forgone because of the Birth Of A Child, and protect the job of the mother while she is on maternity leave (kahn and kammerman, 1988;miller, 1988).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 100, 'birth of a child')]
PMC4202003	10/2014	S185-PMC4202003	['caption (table-wrap): table\xa02\n\nanalysis plan detailing the outcomes and the covariates that will be considered for adjustment in the statistical modelsprimary outcomesecondary outcomesbirth weightbooking statusmeasures of stagemeasures of size:other Birth outcomesmaternal smoking during this Pregnancygestation at bookingbooking before 25\u2005weeksgestational age at Deliveryterm at Birthweight-for-dateshead circumference,mode of Deliverystillbirth5\u2005min apgar scoreneonatal deathcovariatescrown to Heel length i.']	N/A	N/A	[('GO_0007567', 'parturition', 250, 'birth'), ('GO_0006117', 'acetaldehyde metabolic process', 293, 'pregnancyGestation'), ('GO_0008209', 'androgen metabolic process', 364, 'deliveryTerm'), ('GO_0007596', 'blood coagulation', 380, 'birthWeight'), ('GO_0007569', 'cell aging', 428, 'deliveryStillbirth5'), ('UBERON_0015875', 'heel', 496, 'heel')]
PMC4268639	11/2014	S35-PMC4268639	['six sessions over one and a half months surrounding Labor and Postpartum Management contained a lamaze-based training in addition to information about Waterbirth and Doula attended Births, but contained no formal nutritional recommendations.']	N/A	N/A	[('GO_0007612', 'learning', 52, 'labor'), ('GO_0007547', 'germ-line processes downstream of sex determination signal', 62, 'postpartum management'), ('GO_0007596', 'blood coagulation', 151, 'waterbirth'), ('UBERON_0000997', 'mammalian vulva', 166, 'doula'), ('GO_0007567', 'parturition', 181, 'births')]
PMC4275595	9/2014	S114-PMC4275595	['women were expected to contribute to society through Reproduction, both Bearing and Rearing Children, in the role of housewife and mother.']	N/A	N/A	[('GO_0000003', 'reproduction', 53, 'reproduction'), ('GO_0007596', 'blood coagulation', 72, 'bearing ...'), ('GO_0000302', 'response to reactive oxygen species', 84, 'rearing children')]
PMC4289552	12/2014	S32-PMC4289552	['when Pregnant women were screened for initial recruitment, they were excluded if they exhibited any of the following conditions: any factor that could interfere with maternal calcium Metabolism, intention not to Breastfeed, Preeclampsia, Kidney or Cardiac diseases, Gestational diabetes, history of Urinary infections, family or personal history of Kidney stone formation, seizure disorder requiring daily medications, or ingestion of Corticosteroids.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'pregnant'), ('GO_0008152', 'metabolic process', 183, 'metabolism'), ('GO_0007596', 'blood coagulation', 212, 'breastfeed'), ('GO_0007128', 'meiotic prophase I', 224, 'preeclampsia'), ('UBERON_0002113', 'kidney', 238, 'kidney'), ('UBERON_0000948', 'heart', 248, 'cardiac'), ('GO_0007565', 'female pregnancy', 266, 'gestational'), ('UBERON_0001088', 'urine', 299, 'urinary'), ('UBERON_0002113', 'kidney', 349, 'kidney'), ('CHEBI_50850', 'etabonate ester', 435, 'corticosteroids')]
PMC4377862	2/2015	S48-PMC4377862	['the inclusion criteria were: aged > 18 years, pre-Pregnancy bmi 25–35 kg/m2, intention to Breastfeed, singleton Pregnancy, english-speaking, and <26 weeks Gestation at the initial screening.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('GO_0007596', 'blood coagulation', 90, 'breastfeed'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy'), ('GO_0007565', 'female pregnancy', 155, 'gestation')]
PMC4380381	3/2015	S4-PMC4380381	['physiologic changes induced by Pregnancy increase the risk of Cerebral Venous Thrombosis, dissection, and Pituitary apoplexy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnancy'), ('GO_0022412', 'cellular process involved in reproduction in multicellular organism', 62, 'cerebral'), ('UBERON_0008998', 'vasculature of brain', 62, 'cerebral venous'), ('GO_0007601', 'visual perception', 71, 'venous'), ('GO_0007596', 'blood coagulation', 78, 'thrombosis'), ('UBERON_0002109', 'pair of nares', 106, 'pituitary')]
PMC4380381	3/2015	S29-PMC4380381	['laboratory studies revealed a Leukocytosis of 13.6 × 109white Blood Cells/l and normal electrolytes.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 30, 'leukocytosis'), ('CL_0000081', 'blood cell', 62, 'blood cells'), ('UBERON_0000178', 'blood', 62, 'blood')]
PMC4383437	3/2015	S52-PMC4383437	['medical and obstetric history variables relevant to the tested outcomes were combined into an obstetric/fetal risk factor variable, which included history of Kidney disease; hypertension; anemia; Heart disease; seizures; diabetes; hiv; Rh negative status; asthma; Sexually Transmitted infections; abnormal Blood Clotting; Thyroid disorders; Vaginal, Cervical, or Urinary Tract infections; Endocrine disorders; abnormal Pregnancy weight gain (<4\u2009kg or >18\u2009kg); Preeclampsia; or abnormal bleeding during Pregnancy.']	N/A	N/A	[('UBERON_0002113', 'kidney', 158, 'kidney'), ('UBERON_0000948', 'heart', 196, 'heart'), ('PR_000013773', 'retinoblastoma-associated protein', 236, 'Rh'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 264, 'sexually transmitted'), ('GO_0007596', 'blood coagulation', 306, 'blood clotting'), ('UBERON_0000178', 'blood', 306, 'blood'), ('UBERON_0002046', 'thyroid gland', 322, 'thyroid'), ('UBERON_0001987', 'placenta', 341, 'vaginal'), ('UBERON_0005434', 'cervical region', 350, 'cervical'), ('UBERON_0001553', 'medial tarsal artery', 363, 'urinary tract'), ('GO_0006397', 'mRNA processing', 389, 'endocrine'), ('UBERON_0002049', 'vasculature', 389, 'endocrine'), ('GO_0007565', 'female pregnancy', 419, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 460, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 502, 'pregnancy')]
PMC4397922	4/2015	S140-PMC4397922	['she no longer reported Sleep disturbance, suicidal Thoughts, or anxiety.']	N/A	N/A	[('GO_0030431', 'sleep', 23, 'sleep'), ('GO_0007596', 'blood coagulation', 51, 'thoughts')]
PMC4402995	2/2014	S11-PMC4402995	['introduction\nthe Birth Of the first Child is a unique event for most of the parents.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 17, 'birth of ... child')]
PMC4404558	4/2015	S42-PMC4404558	['to monitor fetal growth, women were scheduled for ultrasound scans every six weeks and followed up until Birth when Birthweight (bw) was measured to the nearest 10\xa0g (cupid digital scale, charder medical, taiwan).']	N/A	N/A	[('GO_0007567', 'parturition', 105, 'birth'), ('GO_0007596', 'blood coagulation', 116, 'birthweight')]
PMC4404558	4/2015	S53-PMC4404558	['suboptimal fetal growth was suspected upon detection of an efw or bw below the 10thcentile (sga) of the hadlock standard (10thcentiles of ultrasound-estimated and Birthweight-derived standards are similar at term) [19,22], and/or observation of low fetal weight gain, defined as a change in weight z-score (∆z) below the 25thcentile of the overall distribution of ∆z, using weight measurements obtained >14\xa0days apart.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 163, 'birthweight')]
PMC4409764	4/2015	S154-PMC4409764	['if there was no chair i would ask for one and say “i want to Breastfeed my baby”, so they would.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 61, 'breastfeed')]
PMC4409764	4/2015	S170-PMC4409764	['this is a particular challenge for women who feel a sense of shyness or need a private space to relax to Breastfeed.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 105, 'breastfeed')]
PMC4419394	4/2015	S40-PMC4419394	['caption (table-wrap): table 1\n\nmaternal and infant characteristics of the cohort by racenon-blackblackn%n%pvalue sample size6675.92124.1adequate Prenatal care\u2003no1319.7628.60.38\u2003yes5380.31571.4parity\u2003multiparous4365.21676.20.43\u2003nulliparous2334.9523.8prenatal Vitamin use\u2003no1015.2628.60.20\u2003yes5684.91571.4smoker\u2003no5887.91885.70.72\u2003yes812.1314.3infant gender\u2003female2842.41152.40.46\u2003male3857.61047.6 mean\u2009±\u2009sdmean\u2009±\u2009sd maternal age (years)29.2\u2009±\u20096.625.6\u2009±\u20094.60.02gestational age (weeks)38.0\u2009±\u20092.438.4\u2009±\u20091.70.49abw (grams)3294.2\u2009±\u2009455.03064.5\u2009±\u2009483.30.04 Igf1 methylation0.26\u2009±\u20090.050.29\u2009±\u20090.060.03\nabbr : abw\u2009=\u2009Gestational age-adjusted Birthweight; sd\u2009=\u2009standard deviation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 145, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 258, 'vitamin'), ('GO_0007600', 'sensory perception', 550, 'IGF1'), ('PR_000008954', 'insulin-like growth factor-binding protein-like 1', 550, 'IGF1'), ('GO_0007565', 'female pregnancy', 606, 'gestational'), ('GO_0007596', 'blood coagulation', 631, 'birthweight')]
PMC4421033	4/2015	S47-PMC4421033	['conceptualization and measurement of key variables\nFetal growth was represented by size-for-Gestational-age (small for Gestational age (sga), appropriate-for-Gestational-age (aga), and lga; resp., Birthweight <10th, 10th–90th, and >90th percentile for Gestational age) based on published canadian standards [16].']	N/A	N/A	[('GO_0008618', '7-methylguanosine metabolic process', 51, 'Fetal'), ('GO_0007565', 'female pregnancy', 92, 'gestational'), ('GO_0007565', 'female pregnancy', 119, 'gestational'), ('GO_0007565', 'female pregnancy', 158, 'gestational'), ('GO_0007596', 'blood coagulation', 197, 'birthweight'), ('GO_0007565', 'female pregnancy', 252, 'gestational')]
PMC4446740	4/2015	S71-PMC4446740	['childhood growth indices included Birthweight and bmi z -score.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 34, 'birthweight')]
PMC4446740	4/2015	S78-PMC4446740	['analyses were conducted using: (i) unadjusted data; (ii) data adjusted for maternal energy intake and child Birthweight; and (iii) data adjusted for maternal energy intake, Birthweight and child bmi z -score.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 108, 'birthweight'), ('GO_0007596', 'blood coagulation', 173, 'birthweight')]
PMC4446740	4/2015	S105-PMC4446740	['% e, percentage of energy.1analysis models: (a) adjusted for maternal energy intake and child Birthweight; (b) adjusted for maternal energy intake, child Birthweight and child bmi z -score.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 94, 'birthweight'), ('GO_0007596', 'blood coagulation', 154, 'birthweight')]
PMC4464209	6/2015	S93-PMC4464209	['Birth Plan and emergency preparedness (table3): a sub-sample of women (n=77,871) was assessed for four elements related to preparation of a Birth plan.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 0, 'Birth plan'), ('UBERON_0000029', 'lymph node', 6, 'plan'), ('GO_0007567', 'parturition', 140, 'birth')]
PMC4500842	2/2015	S57-PMC4500842	['in a social Learning environment, participants explore new ways of Thinking, practice health skills, and acquire positive attitudes about health via modeling with one another [30,31].']	N/A	N/A	[('GO_0007612', 'learning', 12, 'learning'), ('GO_0007596', 'blood coagulation', 67, 'thinking')]
PMC4569192	9/2015	S63-PMC4569192	['overall the mean Birthweight at Delivery was 4016 ± 502g.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 17, 'birthweight'), ('GO_0007567', 'parturition', 32, 'delivery')]
PMC4569192	9/2015	S74-PMC4569192	['following adjustment for maternal Early Pregnancy bmi, Birthweight, smoking and original study group assignment on multiple regression analysis three significant differences between male and female offspring were apparent.']	N/A	N/A	[('GO_0051318', 'G1 phase', 34, 'early'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('GO_0007596', 'blood coagulation', 55, 'birthweight')]
PMC4569192	9/2015	S83-PMC4569192	['adjusted p-value adjusted for maternal bmi, infant Birthweight, smoking status and original study group assignment with multiple regression analysis.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 51, 'birthweight')]
PMC4588865	8/2015	S92-PMC4588865	['where Birthweight was the outcome, age was defined as Gestational age at Birth.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 6, 'birthweight'), ('GO_0007565', 'female pregnancy', 54, 'gestational'), ('GO_0007567', 'parturition', 73, 'birth')]
PMC4600246	10/2015	S51-PMC4600246	['thirty six patients, 19 on warfarin for more than 10\u2005years and 17 controls from five different Thrombosis services in the netherlands, were studied.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 95, 'thrombosis')]
PMC4618150	10/2015	S158-PMC4618150	['the infrastructure for delivering information to participants to assist them in making an informed choice exists within Antenatal and Postnatal Care in the uk national health service (nhs).']	N/A	N/A	[('GO_0007567', 'parturition', 120, 'antenatal'), ('GO_0007596', 'blood coagulation', 134, 'postnatal care')]
PMC4641416	11/2015	S55-PMC4641416	['the rolo study was a randomised controlled trial of a low gi dietary intervention versus usual care among 800 non-diabetic, secundigravida women with a history of macrosomia, with the primary objective of reducing Birthweight.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 214, 'birthweight')]
PMC4641416	11/2015	S58-PMC4641416	['the low gi dietary intervention in this study had no impact on Birthweight or other neonatal outcomes, including various neonatal anthropometric measures except for Thigh circumference [46].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 63, 'birthweight'), ('UBERON_0000376', 'hindlimb stylopod', 165, 'thigh')]
PMC4641416	11/2015	S65-PMC4641416	['Cord Bloods were collected at Delivery and neonatal anthropometric measurements were taken during the first 72\xa0h of Life including; Birthweight, length, Occipital Frontal Head circumference (Ofc), Chest, Abdominal, Thigh and mid upper Arm circumferences.']	N/A	N/A	[('UBERON_0000948', 'heart', 0, 'Cord'), ('UBERON_0000178', 'blood', 5, 'bloods'), ('GO_0007567', 'parturition', 30, 'delivery'), ('UBERON_0000104', 'life cycle', 116, 'life'), ('GO_0007596', 'blood coagulation', 132, 'birthweight'), ('UBERON_2001420', 'anal fin pterygiophore', 153, 'occipital frontal head'), ('UBERON_0004145', 'outflow tract', 191, 'OFC'), ('UBERON_0001443', 'chest', 197, 'chest'), ('UBERON_0000916', 'abdomen', 204, 'abdominal'), ('UBERON_0000376', 'hindlimb stylopod', 215, 'thigh'), ('UBERON_0001460', 'arm', 235, 'arm')]
PMC4641416	11/2015	S111-PMC4641416	['the first involved a cohort with an average birthweight of 3.77kg [43] conducted in china in 2004 and the second [44] a cohort with an average Birthweight of 2.95kg in lithuania.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 143, 'birthweight')]
PMC4661500	11/2014	S177-PMC4661500	['further items included slight Cognitive dysfunction being unable to concentrate, Memory loss, and “jumpy” Thoughts.']	N/A	N/A	[('GO_0050890', 'cognition', 30, 'cognitive'), ('GO_0007613', 'memory', 81, 'memory'), ('GO_0007596', 'blood coagulation', 106, 'thoughts')]
PMC4661586	4/2015	S21-PMC4661586	['these processes include Thinking, knowing, Remembering, judging, and problem-solving.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 24, 'thinking'), ('GO_0070514', 'SRF-myogenin-E12 complex', 43, 'remembering')]
PMC4661586	4/2015	S80-PMC4661586	['one year after Termination Of Pregnancy 18 children were alive and 5 children were described as being abnormal.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 15, 'termination of'), ('GO_0007565', 'female pregnancy', 30, 'pregnancy')]
PMC4667490	12/2015	S10-PMC4667490	['the 372 babies Born to 365 super-obese women with outcomes known had significantly higher rates of Birthweight ≥4500\xa0g (aor 19.94, 95 % ci: 6.81–58.36), hospital transfer (aor 3.81, 95 % ci: 1.93–7.55) and admission to Neonatal Intensive Care unit (nicu) (aor 1.83, 95 % ci: 1.27–2.65) compared to babies of the comparison group, but not Prematurity (10.5\xa0% versus 9.2\xa0%) or Perinatal mortality (11.0 (95\xa0% ci: 4.3–28.0) versus 6.6 (95\xa0% ci: 2.6- 16.8) per 1 000 singleton Births).']	N/A	N/A	[('GO_0007567', 'parturition', 15, 'born'), ('GO_0007596', 'blood coagulation', 99, 'birthweight'), ('UBERON_0001982', 'capillary', 219, 'Neonatal'), ('UBERON_0002483', 'trabecular bone tissue', 228, 'Intensive Care'), ('GO_0007565', 'female pregnancy', 338, 'prematurity'), ('GO_0036268', 'swimming', 375, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 375, 'perinatal'), ('GO_0007567', 'parturition', 473, 'births')]
PMC4667490	12/2015	S45-PMC4667490	['), labour characteristics (onset of labour and method of Delivery), maternal outcomes (admission to icu or hdu) and Perinatal outcomes (Birthweight ≥4 500\xa0g, admission to nicu, and need for transfer).']	N/A	N/A	[('GO_0007567', 'parturition', 57, 'delivery'), ('GO_0036268', 'swimming', 116, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 116, 'perinatal'), ('GO_0007596', 'blood coagulation', 136, 'birthweight')]
PMC4667490	12/2015	S79-PMC4667490	['of the 36 singletons with a Birthweight ≥4 500\xa0g, 16.6\xa0% of their mothers had pre-existing diabetes.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 28, 'birthweight')]
PMC4676908	12/2015	S18-PMC4676908	['there was no effect on Pregnancy-related deaths (average or 0.69, 95% ci 0.45 to 1.08; participants = 114,930; studies = 10; heterogeneity: tau² = 0.00; i² = 0%; low quality evidence ), Perinatal mortality (average or 0.98, 95% ci 0.90 to 1.07; studies = 15; heterogeneity: tau² = 0.01; i² = 58%; moderate quality evidence ) or low Birthweight (average or 0.94, 95% ci 0.82 to 1.06; studies = five; heterogeneity: tau² = 0.00; i² = 5%; high quality evidence ).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('UBERON_0012101', 'perinatal stage', 186, 'perinatal'), ('GO_0007596', 'blood coagulation', 332, 'birthweight')]
PMC4676908	12/2015	S52-PMC4676908	['interventions did not improve rates of Maternal death ( low quality ), Baby Deaths ( moderate quality ) or low Birthweight ( high quality ).']	N/A	N/A	[('GO_0007618', 'mating', 39, 'maternal'), ('GO_0007567', 'parturition', 71, 'baby deaths'), ('GO_0007596', 'blood coagulation', 111, 'birthweight')]
PMC4676908	12/2015	S174-PMC4676908	['the proportion of low-Birthweight infants Born.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 22, 'birthweight'), ('GO_0007567', 'parturition', 42, 'born')]
PMC4676908	12/2015	S235-PMC4676908	['the proportion of low-Birthweight infants Born.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 22, 'birthweight'), ('GO_0007567', 'parturition', 42, 'born')]
PMC4676908	12/2015	S555-PMC4676908	['outcomes not reported in the included studies: low Birthweight; Preterm labour; intermittent prophylactic treatment for malaria; proportion of women who received anc from professional health workers; Pregnant women with a written Birth and emergency plan by 37 weeks; Pregnant women screened for syphilis; Pregnant women screened for asymptomatic bacteriuria; Pregnant women screened for hiv; Pregnant women receiving a complete Antiretroviral course for prevention of hiv transmission; and maternal near miss defined as: "a woman who nearly died but survived a complication that occurred during Pregnancy, Childbirth or within 42 days of Termination Of Pregnancy" (pattinson2009).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 51, 'birthweight'), ('GO_0007565', 'female pregnancy', 64, 'preterm'), ('GO_0007565', 'female pregnancy', 200, 'pregnant'), ('GO_0007567', 'parturition', 230, 'birth'), ('GO_0007565', 'female pregnancy', 268, 'pregnant'), ('GO_0007565', 'female pregnancy', 306, 'pregnant'), ('GO_0007565', 'female pregnancy', 360, 'pregnant'), ('GO_0007565', 'female pregnancy', 393, 'pregnant'), ('CHEBI_65417', '(+)-aplysinillin', 429, 'antiretroviral'), ('GO_0007565', 'female pregnancy', 596, 'pregnancy'), ('GO_0007623', 'circadian rhythm', 607, 'childbirth'), ('GO_0012501', 'programmed cell death', 639, 'termination of pregnancy')]
PMC4680925	12/2015	S254-PMC4680925	['adherence to harmful traditional Newborn Care practices and neglecting to exclusively Breastfeed were identified as other matters to which mobile midwife attended.']	N/A	N/A	[('GO_0001967', 'suckling behavior', 33, 'newborn care'), ('UBERON_0000025', 'tube', 33, 'newborn'), ('GO_0007596', 'blood coagulation', 86, 'breastfeed')]
PMC4682386	12/2015	S31-PMC4682386	['[15] briefly, 415 Pregnant women living in trondheim, norway, and who intended to Breastfeed were randomised to receive equivalently tasting study Milk containing probiotic bacteria or sterile cultured Milk as a placebo from 36 weeks Gestation until 3 months Postnatal.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('GO_0007596', 'blood coagulation', 82, 'breastfeed'), ('UBERON_0001913', 'milk', 147, 'milk'), ('UBERON_0001913', 'milk', 202, 'milk'), ('GO_0007565', 'female pregnancy', 234, 'gestation'), ('GO_0007567', 'parturition', 259, 'postnatal')]
PMC4682386	12/2015	S99-PMC4682386	['the most highly enriched Biological Processes and molecular functions included Chromatin and chromosome organisation, transcription and Negative Regulation Of Gene Expression and Biosynthetic Processes (s3 file).']	N/A	N/A	[('GO_0008150', 'biological_process', 25, 'biological processes'), ('GO_0000785', 'chromatin', 79, 'chromatin'), ('GO_0007567', 'parturition', 136, 'negative'), ('GO_0010468', 'regulation of gene expression', 145, 'regulation of gene expression'), ('SO_0000704', 'gene', 159, 'gene'), ('GO_0007596', 'blood coagulation', 179, 'biosynthetic processes')]
PMC4683742	12/2015	S120-PMC4683742	['other approaches directed at community health workers (chws) and tbas assign them mnh responsibilities related to community-based Antenatal, Delivery and Postnatal Care.']	N/A	N/A	[('GO_0043653', 'mitochondrial fragmentation involved in apoptotic process', 130, 'antenatal ...'), ('GO_0007567', 'parturition', 141, 'delivery'), ('GO_0007596', 'blood coagulation', 154, 'postnatal care')]
PMC4700169	12/2015	S46-PMC4700169	['laboratory data revealed Leucocytosis of 16.8 and Sodium of 163\u2009meq/l.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 25, 'leucocytosis'), ('CHEBI_52632', 'potassium-39 atom', 50, 'sodium')]
PMC4728621	1/2016	S17-PMC4728621	[', velocity of infant weight gain) regardless of Birthweight [35,36,37,38].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 48, 'birthweight')]
PMC4728621	1/2016	S28-PMC4728621	['in brief; the primary outcome was Birthweight which was not reduced and the secondary outcomes were Gestational weight gain and Glucose intolerance which were both reduced in the intervention group.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 34, 'birthweight'), ('GO_0007565', 'female pregnancy', 100, 'gestational'), ('CHEBI_17234', 'glucose', 128, 'glucose')]
PMC4728621	1/2016	S129-PMC4728621	['z-score values were adjusted for Birthweight, education, intervention group, breastfeeding and definite underreporting (goldberg ratio ≤ 0.9).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 33, 'birthweight')]
PMC4728621	1/2016	S130-PMC4728621	['non-z-score values were adjusted for Birthweight, education, infant age at measurement, infant gender, intervention group, breastfeeding and definite underreporting (goldberg ratio ≤ 0.9).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 37, 'birthweight')]
PMC4730270	12/2015	S55-PMC4730270	['c, e and Taurine)2 weeks before until 4 weeks after Birthprevented hypertension.']	N/A	N/A	[('CHEBI_15891', 'taurine', 9, 'taurine'), ('GO_0007596', 'blood coagulation', 52, 'birthPrevented')]
PMC4730270	12/2015	S58-PMC4730270	['↓ Renal Gene Expression of Ass and Asl at 2 weekscitrulline2 weeks before until 6 weeks after Birth↓ hypertension in females and until 20 weeks in males ↑ Renal No at 2 weeksuntil 50 weeks of age[35]diabetes (stz) during Pregnancy and lactationsprague-dawley ratshypertension, Renal injurycitrullineduring Pregnancy and Lactation↓ bp ↓ Renal injuryuntil 12 weeks of age[36]dexamethasone during Pregnancysprague-dawley ratshypertensioncitrullineduring Pregnancy and Lactation↓ bpuntil 12 weeks of age[37]l-Name during Pregnancysprague-dawley ratshypertensioncitrullineduring Pregnancy and Lactation↓ bp ↓ admauntil 12 weeks of age[38,39]Genetic hypertension, Renal injuryfhh ratshypertension progressive Renal injurymolsidomine (No Donor)2 weeks before until 4 weeks after Birthprevented hypertension.']	N/A	N/A	[('UBERON_0002113', 'kidney', 2, 'Renal'), ('GO_0010467', 'gene expression', 8, 'gene expression'), ('SO_0000704', 'gene', 8, 'gene'), ('PR_000004376', 'ATPase GET3', 27, 'ASS'), ('PR_000004376', 'ATPase GET3', 35, 'ASL'), ('GO_0007567', 'parturition', 94, 'birth'), ('GO_0007567', 'parturition', 99, '↓'), ('UBERON_0002113', 'kidney', 155, 'Renal'), ('CHEBI_16382', 'iodide', 161, 'NO'), ('GO_0007565', 'female pregnancy', 221, 'pregnancy'), ('UBERON_0002113', 'kidney', 277, 'renal'), ('GO_0007565', 'female pregnancy', 306, 'pregnancy'), ('GO_0007595', 'lactation', 320, 'lactation'), ('GO_0007567', 'parturition', 329, '↓'), ('UBERON_0002113', 'kidney', 336, 'Renal'), ('GO_0012501', 'programmed cell death', 394, 'pregnancySprague'), ('GO_0007565', 'female pregnancy', 451, 'pregnancy'), ('GO_0007595', 'lactation', 465, 'lactation'), ('GO_0007567', 'parturition', 474, '↓'), ('CHEBI_13389', 'NAD', 505, 'NAME'), ('GO_0012501', 'programmed cell death', 517, 'pregnancySprague'), ('GO_0007565', 'female pregnancy', 574, 'pregnancy'), ('GO_0007595', 'lactation', 588, 'lactation'), ('GO_0007567', 'parturition', 597, '↓'), ('SO_0000704', 'gene', 636, 'Genetic'), ('UBERON_0002113', 'kidney', 658, 'renal'), ('UBERON_0002113', 'kidney', 703, 'renal'), ('CHEBI_7570', 'nigerose', 728, 'NO donor'), ('GO_0007596', 'blood coagulation', 772, 'birthPrevented')]
PMC4730270	12/2015	S62-PMC4730270	['↓ oxidative stress.until 12 weeks of age[47]Genetic hypertensionshr and wky ratshypertensionpyrrolidine Di-Thio-Carbamate (Nf-Κb inhibitor)2 weeks before until 4 weeks after Birth↓ bp ↑ natriuresis at 4 weeks ↓ oxidative stress markersuntil 28 weeks of age[48]Genetic hypertensionfhh ratshypertension progressive Renal injurypyrrolidine Di-Thio-Carbamate (Nf-Κb Inhibitor)2 weeks before until 4 weeks after Birthprevented hypertension ↓ glomerulosclerosisuntil 36 and 42 weeks of age[49]\n\n4.']	N/A	N/A	[('SO_0000704', 'gene', 44, 'Genetic'), ('CHEBI_35694', 'cyclobutane-1,1-dicarboxylate(1-)', 104, 'di-thio-carbamate'), ('GO_0071159', 'NF-kappaB complex', 123, 'NF-κB'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 123, 'NF-κB'), ('GO_0007567', 'parturition', 174, 'birth'), ('GO_0007567', 'parturition', 179, '↓'), ('SO_0000704', 'gene', 260, 'Genetic'), ('UBERON_0002113', 'kidney', 313, 'renal'), ('CHEBI_35694', 'cyclobutane-1,1-dicarboxylate(1-)', 337, 'di-thio-carbamate'), ('GO_0071159', 'NF-kappaB complex', 356, 'NF-κB'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 356, 'NF-κB'), ('CHEBI_35222', 'inhibitor', 362, 'inhibitor'), ('GO_0007596', 'blood coagulation', 407, 'birthPrevented')]
PMC4752592	2/2016	S20-PMC4752592	['iron deficiency is the most common cause of anaemia during Pregnancy and daily use of iron supplements during Pregnancy significantly reduces the prevalence of maternal anaemia and risk of low Birthweight (5,6).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007596', 'blood coagulation', 193, 'birthweight')]
PMC4752592	2/2016	S36-PMC4752592	["for each interviewed ever-married woman of Reproductive age in both surveys, a complete Birth history was recorded, and for the most recent Birth during the last 5 years prior to the survey additional information about the woman's Antenatal Care (anc), Delivery, and Postnatal Care services were recorded."]	N/A	N/A	[('GO_0000003', 'reproduction', 43, 'reproductive'), ('GO_0007567', 'parturition', 88, 'birth'), ('GO_0007567', 'parturition', 140, 'birth'), ('GO_0007608', 'sensory perception of smell', 231, 'antenatal care'), ('GO_0007567', 'parturition', 253, 'delivery'), ('GO_0007596', 'blood coagulation', 267, 'postnatal care')]
PMC4752592	2/2016	S37-PMC4752592	['the Birth history recorded all Live Births of a woman in chronological order, the date of the Birth Of each Child, whether singleton or multiple Births, the sex of the child, the survival status of the child on the day of the interview, and, if deceased, the date of death.']	N/A	N/A	[('GO_0007567', 'parturition', 4, 'birth'), ('GO_0008610', 'lipid biosynthetic process', 31, 'live births'), ('GO_0007596', 'blood coagulation', 94, 'birth of ... child'), ('GO_0007567', 'parturition', 145, 'births')]
PMC4752899	11/2015	S131-PMC4752899	['treatment did not have a significant impact on the primary outcome, Birthweight, or the rate of low Birth weight newborns.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 68, 'birthweight'), ('GO_0007567', 'parturition', 100, 'birth')]
PMC4774132	3/2016	S129-PMC4774132	['several tbas said they instruct women to Breastfeed immediately after Birth, and help them to establish breastfeeding over the ensuing days.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 41, 'breastfeed'), ('GO_0007567', 'parturition', 70, 'birth')]
PMC4796349	3/2015	S53-PMC4796349	['cohen’s perceived stress scale was used to assess general perceived stress in the past month, including Thoughts and feelings about stressful events, Control, overcoming, and Coping with stress.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 104, 'thoughts'), ('GO_0065007', 'biological regulation', 150, 'control'), ('GO_0065007', 'biological regulation', 175, 'coping')]
PMC4798618	3/2016	S40-PMC4798618	['significant exclusion criteria included Cavity-distorting Intramural fibroids, stage iii or iv endometriosis, Hydrosalpinx, history of previous poor response, recurrent Miscarriage, Adrenal or Thyroid disease, and Thromboembolic disease or disorder.']	N/A	N/A	[('UBERON_0005985', 'coronary vessel', 40, 'cavity'), ('UBERON_3000715', 'heterocoelous', 58, 'intramural'), ('UBERON_0011601', 'gingiva of upper jaw', 110, 'hydrosalpinx'), ('GO_0046660', 'female sex differentiation', 169, 'miscarriage'), ('UBERON_0002369', 'adrenal gland', 182, 'adrenal'), ('UBERON_0002046', 'thyroid gland', 193, 'thyroid'), ('GO_0007596', 'blood coagulation', 214, 'thromboembolic')]
PMC4811107	3/2016	S43-PMC4811107	["Prenatal medical chart review\nthe maternal Prenatal chart was reviewed for key information used in the analyses including maternal height, parity, Delivery type, Gestational age at delivery, and the child's Birthweight."]	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('GO_0007567', 'parturition', 147, 'delivery'), ('GO_0007565', 'female pregnancy', 162, 'gestational'), ('GO_0007596', 'blood coagulation', 207, 'birthweight')]
PMC4811107	3/2016	S58-PMC4811107	['factors compared between the groups include child race, winter Birth, Delivery type, firstborn status, maternal atopic status, Birthweight, Gestational age, and maternal Prenatal level of 25(Oh)D.\n\n3.']	N/A	N/A	[('GO_0007567', 'parturition', 63, 'birth'), ('GO_0007567', 'parturition', 70, 'delivery'), ('GO_0007596', 'blood coagulation', 127, 'birthweight'), ('GO_0007565', 'female pregnancy', 140, 'gestational'), ('GO_0007565', 'female pregnancy', 170, 'prenatal'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D')]
PMC4811107	3/2016	S67-PMC4811107	['no statistically significant differences were found between those who were and were not Born in the winter and were of Preterm or low Birthweight, or by Delivery mode or by maternal atopic status.']	N/A	N/A	[('GO_0007567', 'parturition', 88, 'born'), ('GO_0007565', 'female pregnancy', 119, 'preterm'), ('GO_0007596', 'blood coagulation', 134, 'birthweight'), ('GO_0007567', 'parturition', 153, 'delivery')]
PMC4811441	3/2016	S73-PMC4811441	['preexisting medical conditions relevant to this study were Heart disease, Coagulations disorders including previous Thrombosis, Autoimmune disease (diabetes, multiple sclerosis, systemic lupus erythematosus and reumatoid arthritis) and Kidney disease.']	N/A	N/A	[('UBERON_0000948', 'heart', 59, 'heart'), ('GO_0050817', 'coagulation', 74, 'coagulations'), ('GO_0007596', 'blood coagulation', 116, 'thrombosis'), ('UBERON_0001442', 'skeleton of manus', 128, 'autoimmune'), ('UBERON_0002113', 'kidney', 236, 'kidney')]
PMC4835505	4/2016	S105-PMC4835505	['fresh Milk samples were collected using hand Expression at the conclusion of a morning Breastfeed (between 09.00 and 12.00 h).']	N/A	N/A	[('UBERON_0001913', 'milk', 6, 'milk'), ('GO_0010467', 'gene expression', 45, 'expression'), ('GO_0007596', 'blood coagulation', 87, 'breastfeed')]
PMC4846845	4/2016	S200-PMC4846845	['Prenatal stress\nmaternal stress during Pregnancy is an overwhelmingly common event, with 70.2% of women reporting the occurrence a stressful Life event in the year preceding the Birth Of their Child including Pregnancy-specific stress, intimate partner violence, and natural disasters [161].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('UBERON_0000104', 'life cycle', 141, 'life'), ('GO_0007596', 'blood coagulation', 178, 'birth of ... child'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]
PMC4856298	5/2016	S141-PMC4856298	['gap between two successive Pregnancies (0.11–0.36); when to call a baby as “low Birth weight” (0.12–0.35); age up to which to exclusively Breastfeed (0.14–0.39); age to initiate complementary Feeding (0.03–0.28).jalloh-vos et al.a2014 study design: nrct (step-wedge approach) / research methods: mixed methods.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnancies'), ('GO_0007567', 'parturition', 80, 'birth'), ('GO_0007596', 'blood coagulation', 138, 'breastfeed'), ('GO_0007631', 'feeding behavior', 192, 'feeding')]
PMC4874157	5/2016	S71-PMC4874157	['following Delivery, the mother’s condition was Neurologically assessed, and the woman was asked to continue without treatment in order to Breastfeed.']	N/A	N/A	[('GO_0007567', 'parturition', 10, 'delivery'), ('UBERON_0001016', 'nervous system', 47, 'neurologically'), ('GO_0007596', 'blood coagulation', 138, 'breastfeed')]
PMC4878056	5/2016	S17-PMC4878056	['overall, the intervention effectively increased the use of acs among women who Delivered Infants with a Birthweight below the 5thpercentile.']	N/A	N/A	[('GO_0007567', 'parturition', 79, 'delivered'), ('GO_0007566', 'embryo implantation', 89, 'infants'), ('GO_0007596', 'blood coagulation', 104, 'birthweight')]
PMC4878056	5/2016	S32-PMC4878056	['additionally, use of Antenatal Corticosteroids, neonatal and Perinatal mortality, and suspected maternal infection were measured for all Births, irrespective of Birthweight.']	N/A	N/A	[('GO_0007567', 'parturition', 21, 'antenatal'), ('CHEBI_50850', 'etabonate ester', 31, 'corticosteroids'), ('GO_0036268', 'swimming', 61, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 61, 'perinatal'), ('GO_0007567', 'parturition', 137, 'births'), ('GO_0007596', 'blood coagulation', 161, 'birthweight')]
PMC4878056	5/2016	S84-PMC4878056	['among infants who were ≥25thpercentile for Birthweight and died up to 28\xa0days, the acs exposure was 11\xa0% and 2\xa0% in the intervention and control groups, respectively.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 43, 'birthweight')]
PMC4891833	6/2016	S155-PMC4891833	['a child questionnaire administered to all primary caregivers includes a retrospective report on Delivery and Birth Of the Child, breastfeeding history and status, timing\xa0of\xa0introduction of complementary Feeding, a module on Appetite and responsive Feeding, and a 24\xa0h Food Recall.']	N/A	N/A	[('GO_0008283', 'cell proliferation', 96, 'delivery ...'), ('GO_0007596', 'blood coagulation', 109, 'birth of ... child'), ('GO_0007631', 'feeding behavior', 203, 'feeding'), ('GO_0000239', 'pachytene', 224, 'appetite'), ('GO_0007631', 'feeding behavior', 248, 'feeding'), ('CHEBI_33290', 'food', 268, 'food'), ('GO_0007631', 'feeding behavior', 268, 'food recall')]
PMC4896250	4/2016	S939-PMC4896250	['results: the pbs and Vector control groups displayed typical Th2 Responses upon Met E 1 challenge.']	N/A	N/A	[('SO_0000440', 'vector_replicon', 21, 'vector'), ('GO_0007596', 'blood coagulation', 61, 'Th2 responses'), ('PR_000010123', 'microtubule-associated protein 1S', 80, 'Met e 1')]
PMC4896250	4/2016	S942-PMC4896250	['Met E 1-specific Ige and th2-linked cytokines in these Mice remained at basal levels, with the mem49-encoding dna vaccine providing more robust protection against Th2 Responses.']	N/A	N/A	[('PR_000010123', 'microtubule-associated protein 1S', 0, 'Met e 1'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 17, 'IgE'), ('NCBITaxon_10088', 'Mus <genus>', 55, 'mice'), ('GO_0007596', 'blood coagulation', 163, 'Th2 responses')]
PMC4896250	4/2016	S4079-PMC4896250	['the most commonly sensitized Allergen was house dust Mite ( dermatophagoides pteronyssinus 16.5%, dermatophagoides farina 15.5%), followed by early blossoming Tree pollen Mix (8.9%) and late Blossoming tree pollen Mix (7.9%).']	N/A	N/A	[('CHEBI_50904', 'allergen', 29, 'allergen'), ('CHEBI_46662', 'mineral', 53, 'mite'), ('NCBITaxon_1', 'root', 159, 'tree'), ('CHEBI_60004', 'mixture', 171, 'mix'), ('GO_0007596', 'blood coagulation', 191, 'blossoming'), ('CHEBI_60004', 'mixture', 214, 'mix')]
PMC4896250	4/2016	S7751-PMC4896250	['the mentioned patients were provided with: the data of aero-polinometer- "burkard trap", annual calendar for distribution of Aeroallergens reflecting concentrations of Blossoming Plant-trees and atmospheric aerosols in the air in imereti region at a given period of time.']	N/A	N/A	[('CHEBI_33656', 'antiaromatic compound', 125, 'aeroallergens'), ('GO_0007596', 'blood coagulation', 168, 'blossoming'), ('NCBITaxon_33208', 'Metazoa', 179, 'plant')]
PMC4896250	4/2016	S8461-PMC4896250	['case\na baby girl, 7 days old, was referred to neonatology unit from other hospital due to Thrombocytopenia with mark increased in ast and alt.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 90, 'thrombocytopenia')]
PMC4910255	6/2016	S90-PMC4910255	['[28]cluster3811 women in 104 clusters96\xa0days until Birthiron 60\xa0mg, Folic Acid 400\xa0μgunimmap20.9birthweight in mmn, 3198\xa0g; Birthweight in control, 3174\xa0gsga in mmn, 16.9\xa0%; sga in control, 18.9\xa0%Gestation in mmn, 39.8\xa0weeks; Gestation in control, 39.8\xa0weekspmr in mmn group, 50.9; pmr in control group, 36.9nmr in mmn group, 12.4; nmr in control group, 10.7guinea bissaukaestel et al.']	N/A	N/A	[('GO_0007567', 'parturition', 51, 'birthIron'), ('CHEBI_30751', 'formic acid', 68, 'folic acid'), ('GO_0007596', 'blood coagulation', 124, 'birthweight'), ('GO_0006266', 'DNA ligation', 196, 'Gestation'), ('GO_0007565', 'female pregnancy', 226, 'gestation')]
PMC4910255	6/2016	S96-PMC4910255	['[31]cluster14,036 women under Pregnancy surveillance; 2007 Pregnancies recruited in 169 clusters80\xa0days until 12\xa0weeks after Birthiron 60\xa0mg, Folic Acid 400\xa0μg, vit a 1000\xa0μgvit a, Thiamine, riboflavin, vit b3, vit b6, Folic Acid, vit b12, vit c, vit d, vit e, vit k, copper, iron as Ferrous Fumerate, magnesium and zinc; Albendazole was offered in 2nd and 3rd trimesters19.3birthweight in mmn, 2659\xa0g; Birthweight in control, 2652\xa0gsga in mmn, 53.8\xa0%; sga in control, 51.7\xa0%pmr in mmn group, 87.1; pmr in control group, 62.4nmr in mmn group, 54.0; nmr in control group, 36.3\nadata from margetts et al.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 30, 'pregnancy'), ('GO_0007565', 'female pregnancy', 59, 'pregnancies'), ('GO_0007567', 'parturition', 125, 'birthIron'), ('CHEBI_30751', 'formic acid', 142, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 181, 'thiamine'), ('CHEBI_30751', 'formic acid', 219, 'folic acid'), ('CHEBI_83697', 'N(5)-alkyl-L-glutamine residue', 284, 'ferrous fumerate'), ('CHEBI_16664', 'albendazole', 322, 'albendazole'), ('GO_0007596', 'blood coagulation', 403, 'birthweight')]
PMC4910255	6/2016	S208-PMC4910255	['follow-up reports\nthe trials were powered on the primary outcomes of Gestational age and Birthweight (and mortality, in the case of the\xa0bangladesh jivita indonesia trials) [29].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 69, 'gestational'), ('GO_0007596', 'blood coagulation', 89, 'birthweight')]
PMC4919374	6/2016	S41-PMC4919374	['the exception to this is the preference for non-hormonal contraception for women with known increased clotting risk or prior history of Venous Thrombosis or patent Foramen Ovale.']	N/A	N/A	[('UBERON_0001638', 'vein', 136, 'venous'), ('GO_0007596', 'blood coagulation', 143, 'thrombosis'), ('UBERON_0006699', 'foramen cecum of tongue', 164, 'foramen ovale')]
PMC4933715	7/2016	S214-PMC4933715	['none of the children had Thrombosis or other Antiphospholipid symptomatology (abisror et al.,2013).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 25, 'thrombosis'), ('CHEBI_16240', 'hydrogen peroxide', 45, 'antiphospholipid')]
PMC4944244	7/2016	S83-PMC4944244	['caption (table-wrap): table 3\n\ncombination of descriptive and simple logistic regression analysis to show the relationship between risk factors and hypovitaminosis d ( n \u2009=\u2009396)variableserum 25(Oh)D <50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)Serum 25(Oh)D ≥50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)crude or (95 % ci) p valueage(year)c27.91\u2009±\u20093.9529.47\u2009±\u20095.070.91(0.84, 0.99)0.026ethnic groupscmalay296 (96.40)11 (3.60)22.42(9.63, 52.21)<0.001chinese24 (54.50)20 (45.5)1.00indian32 (91.40)3 (8.60)8.89(2.36, 33.40)0.001others6 (60.00)4 (40.00)1.25(0.31, 5.06)0.754education levelcprimary11 (68.80)5 (31.20)1.00secondary136 (91.30)13 (8.70)4.75(1.43, 15.80)0.011tertiary211 (91.30)20 (8.70)4.80(1.52, 15.18)0.008working statusworking275 (91.40)26 (8.60)1.000.252not working83 (87.40)12 (12.60)0.65(0.32, 1.35)household income per monthc3500 (2800,5000)3750 (2500,5250)1.00(1.00, 1.00)0.060household Membersc3 (2,4)3 (2,5)0.90(0.75, 1.07)0.225weeks of Pregnancy at first Antenatal visitc10.0 (8.0,12.0)11.5 (8.0,12.0)0.89(0.77,1.02)0.100parityc0 (0,1)1 (0,1)0.79(0.61, 1.03)0.083last child Birth≤ 2\xa0years111 (89.50)13 (10.50)0.86(0.43,1.75)0.686>2 yearsa247 (90.80)25 (9.20)1.00breastfeedingyes36 (87.80)5 (12.20)0.74(0.27,2.01)0.552nob322 (90.70)33 (9.30)1.00bmi before Pregnant (kg/m2)22.76 (20.00,26.25)22.15 (19.75,26.58)1.02(0.96,1.09)0.499weight at first Antenatal visit (Kg)57.85 (49.30,68.54)57.03 (51.49,65.61)1.01(0.98,1.03)0.569fitzpatrick classificationcskin type i-ii83 (80.60)20 (19.40)1.00skin type iii163 (94.20)10 (5.80)3.93(1.76,8.77)0.001skin type iv-vi112 (93.30)8 (6.70)3.37(1.42,8.03)0.006melanin indices (using mexameter)(0-999.000)306.17 (254.17,373.67)242.83 (181.08, 354.00)1.01(1.00,1.01)0.006sun protection score(0-8)c5 (4,5)3.5 (1,5)1.77(1.42,2.21)<0.001total of respondents exposed to sunlight (10\xa0am-2\xa0pm)yes201 (90.10)22 (9.90)1.00no157 (90.80)16 (9.20)1.07(0.55,2.11)0.836the length of time exposed to sunlight (minutes in week)35 (0,150)55 (0,210)1.00(1.00,1.00)0.570intake of Vitamin D from Food (iu/day)c197.51 (122.70,332.05)263.81 (142.90,460.55)1.00(1.00,1.00)0.042intake of Vitamin D from Food and supplements (iu/day)215.080 (132.93,361.98)302.135 (147.89,515.74)1.00(1.00,1.00)0.064the level of Vitamin D in Foods and supplements (iu/day)<200\xa0iu/day165 (92.70)13 (7.30)1.64(0.82,3.32)0.165≥200\xa0iu/day193 (88.50)25 (11.50)1.00\nor odds ratio, ci confidence interval\np values have been derived from wald tests\narespondents with last child Birth more than 2\xa0years and respondents who did not have previous child (primid)\nbrespondents who did not Breastfeed during Pregnancy and those who did not have children.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 191, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 194, 'OH ... D'), ('UBERON_0001977', 'blood serum', 238, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 247, 'OH ... D'), ('PR_000010433', 'makorin-3', 890, 'membersc3'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('GO_0007567', 'parturition', 961, 'antenatal'), ('GO_0007567', 'parturition', 1080, 'birth'), ('GO_0007565', 'female pregnancy', 1261, 'pregnant'), ('GO_0007567', 'parturition', 1351, 'antenatal'), ('UBERON_0001465', 'knee', 1368, 'kg'), ('CHEBI_27300', 'vitamin D', 2001, 'vitamin D'), ('CHEBI_33290', 'food', 2016, 'food'), ('CHEBI_27300', 'vitamin D', 2104, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 2112, 'D'), ('CHEBI_33290', 'food', 2119, 'food'), ('CHEBI_27300', 'vitamin D', 2227, 'vitamin D'), ('CHEBI_33290', 'food', 2240, 'foods'), ('GO_0007567', 'parturition', 2468, 'birth'), ('GO_0007596', 'blood coagulation', 2574, 'breastfeed'), ('GO_0007565', 'female pregnancy', 2592, 'pregnancy')]
PMC4956033	7/2016	S41-PMC4956033	['sga was defined as Birthweight <10thpercentile for ga using the intergrowth-21th[11].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 19, 'birthweight')]
PMC4956033	7/2016	S52-PMC4956033	['this approach was used to compare differences in growth and nutritional parameters longitudinally during infancy, comparing infants Born in distinct Birthweight categories while adjusting for within-subject correlation.']	N/A	N/A	[('GO_0007567', 'parturition', 132, 'born'), ('GO_0007596', 'blood coagulation', 149, 'birthweight')]
PMC4956033	7/2016	S71-PMC4956033	['between one and six-months-old, there were significantly more non-lbw infants (93.2%) who were exclusively Breastfed than lbw infants (84.0%).10.1371/journal.pone.0159461.t001\n\ncaption (table-wrap): table 1\nbasic descriptive data by Birthweight and size for Gestational agea.covariatebirthweightsize for Gestational agelow birthweightb(n = 50)non-low birthweight (n = 307) p valuecsmall-for-Gestational aged(n = 82)non-small-for-Gestational age (n = 275) p valuebirth data\xa0\xa0\xa0\xa0female, %44.0 (30.2–57.8)47.2 (41.6–52.8)0.6740.2 (29.6–50.8)48.7 (42.8–54.6)0.17\xa0\xa0\xa0\xa0length, cm44.9 (44.0–45.8)47.2 (46.8–47.5)<0.00146.0 (45.4–46.7)47.1 (46.7–47.5)<0.001\xa0\xa0\xa0\xa0weight-for-length0.049 (0.047–0.051)0.063 (0.062–0.064)<0.0010.053 (0.052–0.055)0.063 (0.062–0.064)<0.001\xa0\xa0\xa0\xa0weight, kg2.19 (2.09–2.28)2.96 (2.93–3.00)<0.0012.45 (2.38–2.51)2.98 (2.93–3.02)<0.001\xa0\xa0\xa0\xa0Gestational age, wk37.5 (36.8–38.2)38.7 (38.6–38.8)<0.00139.0 (38.7–39.3)38.4 (38.2–38.6)<0.001\xa0\xa0\xa0\xa0small-for-Gestational age, %80.0 (68.9–91.1)20.0 (15.5–24.5)<0.001\xa0\xa0\xa0\xa0low Birthweight, %48.8 (38.0–59.6)3.6 (1.4–5.8)<0.001feeding\xa0\xa0\xa0\xa0exclusively breastfeeding, %\xa0\xa0\xa0\xa0\xa0\xa0Birth to 1month90.0 (81.7–98.3)94.5 (91.9–97.1)0.2190.2 (83.8–96.6)94.9 (92.3–97.5)0.12\xa0\xa0\xa0\xa0\xa0\xa01 to 6 months84.0 (73.8–94.2)93.2 (90.4–96.0)0.04586.6 (79.2–94.0)93.5 (90.6–96.4)0.046\xa0\xa0\xa0\xa0\xa0\xa06 to 12 months82.0 (71.4–92.6)90.6 (87.3–93.9)0.0785.4 (77.8–93.0)90.6 (87.2–94.0)0.18first-trimester maternal data\xa0\xa0\xa0\xa0age, y25.3 (23.2–27.4)26.2 (25.5–26.9)0.1926.0 (24.5–27.6)26.1 (25.3–26.8)0.76\xa0\xa0\xa0\xa0parity, no3.1 (2.5–3.8)3.7 (3.4–3.9)0.0273.4 (3.0–3.9)3.7 (3.4–3.9)0.31\xa0\xa0\xa0\xa0height, cm146.6 (145.2–148.0)147.6 (147.0–148.2)0.26146.1 (144.9–147.3)147.9 (147.2–148.5)0.011\xa0\xa0\xa0\xa0body mass index, kg/m221.7 (20.8–22.5)21.9 (21.6–22.3)0.5621.9 (21.3–22.5)21.9 (21.5–22.2)0.77\xa0\xa0\xa0\xa0weight, kg46.6 (44.7–48.5)47.7 (46.9–48.5)0.2846.7 (45.3–48.0)47.8 (46.9–48.7)0.34\xa0\xa0\xa0\xa0education (≥ high school)66.0 (52.9, 79.1)56.4 (50.9, 62.0)0.2057.3 (46.6–68.0)57.8 (52.0–63.6)0.94\navalues are means or proportions (95% confidence intervals), n = 357.\nbdefined as Birthweight <2.5kg.']	N/A	N/A	[('GO_0007567', 'parturition', 107, 'breastfed'), ('GO_0007596', 'blood coagulation', 233, 'birthweight'), ('GO_0007565', 'female pregnancy', 258, 'gestational'), ('GO_0007565', 'female pregnancy', 304, 'gestational'), ('GO_0007565', 'female pregnancy', 391, 'gestational'), ('GO_0007565', 'female pregnancy', 429, 'gestational'), ('GO_0007565', 'female pregnancy', 850, 'Gestational'), ('GO_0007565', 'female pregnancy', 959, 'gestational'), ('GO_0007596', 'blood coagulation', 1023, 'birthweight'), ('GO_0007567', 'parturition', 1117, 'Birth'), ('GO_0007596', 'blood coagulation', 2044, 'birthweight')]
PMC4956033	7/2016	S83-PMC4956033	['low Birthweight was defined as Birthweight <2.5kg.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 4, 'birthweight'), ('GO_0007596', 'blood coagulation', 31, 'birthweight')]
PMC4956033	7/2016	S84-PMC4956033	['small-for-Gestational age was defined as Birthweight <10thpercentile for Gestational age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'gestational'), ('GO_0007596', 'blood coagulation', 41, 'birthweight'), ('GO_0007565', 'female pregnancy', 73, 'gestational')]
PMC4956033	7/2016	S85-PMC4956033	['* p<0.05, ** p<0.01, *** p<0.001 different from low birthweight or small-for-Gestational age group.10.1371/journal.pone.0159461.g003\n\ncaption (fig): fig 3\n\nlength-for-age (laz), weight-for-length (wlz) and weight-for-age (waz) z scores from Birth to 12 months of age by Birthweight (a, laz; b, wlz; c, waz) and size for Gestational age (d, laz; e, wlz; f, waz).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 77, 'gestational'), ('GO_0007567', 'parturition', 241, 'birth'), ('GO_0007596', 'blood coagulation', 270, 'birthweight'), ('GO_0007565', 'female pregnancy', 320, 'gestational')]
PMC4956033	7/2016	S89-PMC4956033	['low Birthweight was defined as Birthweight <2.5kg.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 4, 'birthweight'), ('GO_0007596', 'blood coagulation', 31, 'birthweight')]
PMC4956033	7/2016	S90-PMC4956033	['small-for-Gestational age was defined as Birthweight <10thpercentile for Gestational age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'gestational'), ('GO_0007596', 'blood coagulation', 41, 'birthweight'), ('GO_0007565', 'female pregnancy', 73, 'gestational')]
PMC4956033	7/2016	S95-PMC4956033	['finally, neither lbw nor sga infants experienced higher linear growth velocities (fig 4a and 4d), such that infants in these disadvantaged Birth categories had persistently higher prevalence of stunting and lower mean hlz throughout infancy (figs2and3a and 3b).10.1371/journal.pone.0159461.g004\n\ncaption (fig): fig 4\n\nlength, weight-for-length and weight gains from Birth to 12 months of age by Birthweight (a, length gain; b, weight-for-length gain; c, weight gain) and size for Gestational age (d, length gain; e, weight-for-length gain; f, weight gain).']	N/A	N/A	[('GO_0007567', 'parturition', 139, 'birth'), ('GO_0007567', 'parturition', 366, 'birth'), ('GO_0007596', 'blood coagulation', 395, 'birthweight'), ('GO_0007565', 'female pregnancy', 480, 'gestational')]
PMC4956033	7/2016	S99-PMC4956033	['low Birthweight was defined as Birthweight <2.5kg.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 4, 'birthweight'), ('GO_0007596', 'blood coagulation', 31, 'birthweight')]
PMC4956033	7/2016	S100-PMC4956033	['small-for-Gestational age was defined as Birthweight <10thpercentile for Gestational age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'gestational'), ('GO_0007596', 'blood coagulation', 41, 'birthweight'), ('GO_0007565', 'female pregnancy', 73, 'gestational')]
PMC4956033	7/2016	S108-PMC4956033	['edefined as Birthweight <2.5kg.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 12, 'birthweight')]
PMC4956033	7/2016	S109-PMC4956033	['fdefined as Birthweight <10thpercentile for Gestational age.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 12, 'birthweight'), ('GO_0007565', 'female pregnancy', 44, 'gestational')]
PMC4956033	7/2016	S116-PMC4956033	['there were no significant interactions between either Birthweight category and other predictors.10.1371/journal.pone.0159461.t003\n\ncaption (table-wrap): table 3\nmultivariable generalized estimating equations models predicting stunting, wasting and underweight during infancya.covariatereferencestuntingbwastingcunderweightdor (95% ci) p valueor (95% ci) p valueor (95% ci) p value low Birthweight (lbw) model \xa0\xa0\xa0\xa0sex (male)female2.06 (1.24, 3.42)0.0052.21 (1.41, 3.45)<0.001\xa0\xa0\xa0\xa0Gestational age, wke0.72 (0.63, 0.83)<0.0010.74 (0.65, 0.85)<0.001\xa0\xa0\xa0\xa0lbwfnon-lbw2.64 (1.53, 4.53)<0.0012.33 (1.47, 3.70)<0.0013.76 (2.21, 6.40)<0.001\xa0\xa0\xa0\xa0Feeding (breastfeeding or bottle formula)exclusively Breastfeeding2.46 (1.44, 4.20)0.001\xa0\xa0\xa0\xa0maternal age (≥30 y old)<30 years old1.73 (1.18, 2.52)0.0051.88 (1.23, 2.86)0.003\xa0\xa0\xa0\xa0maternal height, cm0.95 (0.91, 0.99)0.007\xa0\xa0\xa0\xa0maternal education (<high school)≥high school1.56 (1.08, 2.27)0.0191.52 (1.01, 2.31)0.047 small for Gestational age (sga) model \xa0\xa0\xa0\xa0sex (male)female1.81 (1.13, 2.89)0.0142.01 (1.33, 3.04)0.001\xa0\xa0\xa0\xa0sgagnon-sga2.60 (1.62, 4.19)<0.0011.75 (1.16, 2.64)0.0072.82 (1.81, 4.37)<0.001\xa0\xa0\xa0\xa0Feeding (breastfeeding or bottle formula)exclusively Breastfeeding2.27 (1.36, 3.79)0.002\xa0\xa0\xa0\xa0maternal age (≥30 y old)<30 years old1.70 (1.17, 2.48)0.0061.73 (1.15, 2.61)0.009\xa0\xa0\xa0\xa0maternal height, cm0.95 (0.92, 0.99)0.017\xa0\xa0\xa0\xa0maternal education (<high school)1.47 (1.02, 2.13)0.040\nalbw and sga models were built with low birthweight and small-for-Gestational age as primary predictor respectively.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 54, 'birthweight'), ('GO_0007596', 'blood coagulation', 385, 'birthweight'), ('GO_0007565', 'female pregnancy', 478, 'Gestational'), ('GO_0007631', 'feeding behavior', 632, 'Feeding'), ('GO_0006458', "'de novo' protein folding", 685, 'breastfeeding2'), ('GO_0007565', 'female pregnancy', 954, 'gestational'), ('GO_0007631', 'feeding behavior', 1133, 'Feeding'), ('GO_0006458', "'de novo' protein folding", 1186, 'breastfeeding2'), ('GO_0007565', 'female pregnancy', 1477, 'gestational')]
PMC4956033	7/2016	S124-PMC4956033	['gdefined as Birthweight <10thpercentile for Gestational age.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 12, 'birthweight'), ('GO_0007565', 'female pregnancy', 44, 'gestational')]
PMC4956066	7/2016	S4-PMC4956066	['large for Gestational age and small for Gestational age were defined as Birthweight > 90thpercentile or <10thpercentile, respectively, based on a national reference standard birthweight distribution.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'gestational'), ('GO_0007565', 'female pregnancy', 40, 'gestational'), ('GO_0007596', 'blood coagulation', 72, 'birthweight')]
PMC4956066	7/2016	S26-PMC4956066	['we then limited the cohort to women whose Deliveries occurred after the rpgeh health survey was completed and for whom infant Birthweight information was available (n = 9,153).']	N/A	N/A	[('GO_0007567', 'parturition', 42, 'deliveries'), ('GO_0007596', 'blood coagulation', 126, 'birthweight')]
PMC4956066	7/2016	S64-PMC4956066	['size for Gestational age was categorized as follows: large for Gestational age if Birthweight greater than the 90thpercentile, small for Gestational age if birthweight less than the 10thpercentile, and appropriate for Gestational age if Birthweight between the 10thand 90thpercentiles, inclusive.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 9, 'gestational'), ('GO_0007565', 'female pregnancy', 63, 'gestational'), ('GO_0007596', 'blood coagulation', 82, 'birthweight'), ('GO_0007565', 'female pregnancy', 137, 'gestational'), ('GO_0007565', 'female pregnancy', 218, 'gestational'), ('GO_0007596', 'blood coagulation', 237, 'birthweight')]
PMC4964025	7/2016	S110-PMC4964025	['in pakistan for example mothers will not Breastfeed till an elderly pious Person gives the baby ghutti ; believed to transfer their qualities to the baby [33].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 41, 'breastfeed'), ('NCBITaxon_10088', 'Mus <genus>', 74, 'person')]
PMC4964025	7/2016	S121-PMC4964025	['(mother from rural india) [31]\nbreastfeeding was strongly sanctioned and supported by elders, “my mother was the first one who motivated me to Breastfeed, she talked about breastfeeding before the doctor did” (young mother, vientiane) [28].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 143, 'breastfeed')]
PMC4982007	8/2016	S47-PMC4982007	['caption (table-wrap): table 1\n\nlist of mesh terms and the text word terms used for exposure and outcomeexposure: maternal nutritional status during Pregnancyoutcome: childhood and adolescent Cognitive functionmesh termstext word termsmesh termstext word terms“exp body weight/or exp body mass index/or exp anthropometry/or exp body size/or exp Skinfold thickness/or exp nutrition assessment/or exp nutritional status/or exp mothers/or exp Pregnancy/or exp malnutrition/or exp diet vegetarian/or exp haemoglobin/or Pregnancy complications/or exp anemia/or exp Folic Acid/or exp Folic Acid deficiency/or exp Vitamin B12 deficiency/or exp ferritin/or exp iron, dietary/or exp Cholecalciferol/or exp Pyridoxine/or exp Vitamin B Complex/or exp riboflavin/or exp Thiamine/or exp Vitamin D/”“maternal nutrition or maternal anthropometry or Pregnancy nutrition or Antenatal nutrition or intrauterine nutrition or Gestational nutrition or maternal undernutrition or Prenatal nutrition or maternal bmi or maternal Micronutrients or vegan mothers or vegetarian mothers or Macrobiotic mothers or maternal Folate or maternal Folic Acid or maternal Vitamin B12 or maternal cobalamin or maternal Vitamin D or 25 Hydoxy Vitamin D or maternal Cholecaliciferol or maternal haemoglobin or maternal iron or maternal b Vitamins or maternal vitamin b1 or maternal vitamin b6 or maternal Vitamin B9 or maternal b Vitamins or maternal anaemia or maternal diet”“exp child/or exp Child Development/or exp adolescent/or exp neurobehavioral manifestations/or exp child, preschool/or exp Cognition, physiology/or exp attention/or exp Memory, Long-Term/or exp Memory, short-term/or exp Memory/or exp intelligence tests/or exp psycho motor performance/or exp child psychology/or exp Decision Making/or exp psychometrics/or exp intelligence/or exp mental competence/or exp Cognition/or exp motor skills/or exp Language Development/or exp Learning/or exp Verbal Learning/or exp Problem Solving/or exp perception/or exp Thinking/or exp executive function/or exp function/or exp Human development/or exp adolescent development/or exp speech/or exp mental Processes/Cognitive function or intelligence or iq or executive function or Psychomotor Development or cognitive performance or Cognition or educational attainment or Cognitive ability or Cognitive deficits or intellectual ability or Learning or Memory or Language Development.']	N/A	N/A	[('GO_0006606', 'protein import into nucleus', 148, 'pregnancyOutcome'), ('GO_0050890', 'cognition', 191, 'cognitive'), ('UBERON_0009007', 'superficial inguinal lymph node', 344, 'skinfold'), ('GO_0007565', 'female pregnancy', 439, 'pregnancy'), ('GO_0007565', 'female pregnancy', 514, 'pregnancy'), ('CHEBI_30751', 'formic acid', 559, 'folic acid'), ('CHEBI_30751', 'formic acid', 577, 'folic acid'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 606, 'vitamin b12'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 606, 'vitamin b12'), ('CHEBI_52550', 'theopalauamide', 673, 'cholecalciferol'), ('CHEBI_16410', 'pyridoxamine', 696, 'pyridoxine'), ('CHEBI_49976', 'zinc dichloride', 714, 'vitamin b'), ('GO_0032991', 'protein-containing complex', 724, 'complex'), ('CHEBI_26948', 'vitamin B1', 757, 'thiamine'), ('CHEBI_27300', 'vitamin D', 773, 'vitamin D'), ('GO_0007565', 'female pregnancy', 833, 'pregnancy'), ('GO_0007567', 'parturition', 856, 'antenatal'), ('GO_0007565', 'female pregnancy', 905, 'gestational'), ('GO_0007565', 'female pregnancy', 957, 'prenatal'), ('CHEBI_33839', 'macromolecule', 1004, 'micronutrients'), ('CHEBI_64709', 'organic acid', 1061, 'macrobiotic'), ('CHEBI_30863', '5-azaorotic acid', 1093, 'folate'), ('CHEBI_30751', 'formic acid', 1112, 'folic acid'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 1135, 'vitamin b12'), ('PR_000004677', 'breast cancer anti-estrogen resistance protein 3', 1143, 'b12'), ('CHEBI_27300', 'vitamin D', 1181, 'vitamin D'), ('CHEBI_45557', 'sec-butyl group', 1194, '25 hydoxy'), ('CHEBI_27300', 'vitamin D', 1204, 'vitamin D'), ('CHEBI_17937', 'L-rhamnono-1,4-lactone', 1226, 'cholecaliciferol'), ('CHEBI_33277', 'gamma-tocotrienol', 1298, 'vitamins'), ('CHEBI_33229', 'vitamin (role)', 1365, 'vitamin'), ('PR_000017209', 'utrophin', 1365, 'vitamin b9'), ('CHEBI_33277', 'gamma-tocotrienol', 1390, 'vitamins'), ('GO_0001410', 'chlamydospore formation', 1454, 'child development'), ('GO_0050890', 'cognition', 1559, 'cognition'), ('GO_0007613', 'memory', 1605, 'memory'), ('GO_0007616', 'long-term memory', 1613, 'long-term'), ('GO_0007613', 'memory', 1630, 'memory'), ('GO_0007613', 'memory', 1656, 'memory'), ('GO_0016045', 'detection of bacterium', 1752, 'decision making'), ('GO_0050890', 'cognition', 1841, 'cognition'), ('GO_0060132', 'prolactin secreting cell development', 1878, 'language development'), ('GO_0007612', 'learning', 1906, 'learning'), ('GO_0008355', 'olfactory learning', 1922, 'verbal learning'), ('GO_0008283', 'cell proliferation', 1945, 'problem solving'), ('GO_0007596', 'blood coagulation', 1986, 'thinking'), ('NCBITaxon_9606', 'Homo sapiens', 2044, 'human'), ('GO_0007565', 'female pregnancy', 2120, 'processes'), ('GO_0050890', 'cognition', 2130, 'Cognitive'), ('GO_0030324', 'lung development', 2196, 'psychomotor development'), ('GO_0050890', 'cognition', 2248, 'cognition'), ('GO_0050890', 'cognition', 2287, 'cognitive'), ('GO_0050890', 'cognition', 2308, 'cognitive'), ('GO_0007612', 'learning', 2354, 'learning'), ('GO_0007613', 'memory', 2366, 'memory'), ('GO_0060132', 'prolactin secreting cell development', 2376, 'language development')]
PMC4990268	8/2016	S182-PMC4990268	['outcomes evaluated included maternal anemia at term, iron deficiency anemia at term, iron deficiency at term, Birthweight, Preterm Birth, neonatal mortality, and Placental malaria infection[76].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 110, 'birthweight'), ('GO_0007565', 'female pregnancy', 123, 'preterm'), ('GO_0007567', 'parturition', 131, 'birth'), ('UBERON_0001987', 'placenta', 162, 'placental')]
PMC4990268	8/2016	S191-PMC4990268	['in the cochrane systematic review, among infants whose mothers received Iron supplementation during Pregnancy the proportion Born low Birthweight (<2500 g) was 8.4% versus 10.3% among controls (rr = 0.84, 95% ci: 0.69–1.03)[76].']	N/A	N/A	[('CHEBI_24870', 'ion', 72, 'iron'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('GO_0007567', 'parturition', 125, 'born'), ('GO_0007596', 'blood coagulation', 134, 'birthweight')]
PMC4990268	8/2016	S396-PMC4990268	['the outcomes addressed in the review by stevens[134] included Birthweight, other newborn anthropometrics, and longer-term measures of infant growth.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 62, 'birthweight')]
PMC4990268	8/2016	S449-PMC4990268	['in haider’s cochrane review[150], overall no effect was seen on anemia rates, low Birthweight, Perinatal mortality or Preterm Birth.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 82, 'birthweight'), ('UBERON_0012101', 'perinatal stage', 95, 'perinatal'), ('GO_0007565', 'female pregnancy', 118, 'preterm birth')]
PMC4990268	8/2016	S451-PMC4990268	['incidence of very low Birthweight was reduced in the intervention arm (0 vs. 7 in the control arm).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 22, 'birthweight')]
PMC4990268	8/2016	S457-PMC4990268	['similarly, there was no effect on Birthweight.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 34, 'birthweight')]
PMC4990268	8/2016	S480-PMC4990268	['Placental malaria doubles the risk of low Birthweight[157].']	N/A	N/A	[('UBERON_0001987', 'placenta', 0, 'Placental'), ('GO_0007596', 'blood coagulation', 42, 'birthweight')]
PMC4990268	8/2016	S499-PMC4990268	['there was no reduction in low Birthweight associated with household net ownership and no mortality effect.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 30, 'birthweight')]
PMC4990268	8/2016	S902-PMC4990268	['in a community-level cluster rct in bangladesh[52], household-level Antenatal counseling for all Pregnant women encouraged continuous 24 hour per day skin-to-skin care, particularly over the first 2 days of Life, regardless of Birthweight.']	N/A	N/A	[('GO_0007567', 'parturition', 68, 'antenatal'), ('GO_0007565', 'female pregnancy', 97, 'pregnant'), ('UBERON_0000104', 'life cycle', 207, 'life'), ('GO_0007596', 'blood coagulation', 227, 'birthweight')]
PMC4993958	8/2016	S73-PMC4993958	['Prepregnancy weight and infant Birthweight were self-reported by the mothers.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prepregnancy'), ('GO_0007596', 'blood coagulation', 31, 'birthweight')]
PMC4998950	4/2016	S41-PMC4998950	['no cases of Vitamin D deficiency were recorded before the Birth Of a Child.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007596', 'blood coagulation', 58, 'birth of ... child')]
PMC5017073	7/2016	S81-PMC5017073	['other symptoms like psychomotor retardation, feeling of worthlessness, excessive or inappropriate guilt and recurrent Thoughts of suicide are primarily experienced by Pregnant women with depression.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 118, 'thoughts'), ('GO_0007565', 'female pregnancy', 167, 'pregnant')]
PMC5017073	7/2016	S122-PMC5017073	['cognitive therapy is directed at anxiety, catastrophic Thinking related to not Sleeping and having the patient develop realistic expectations about duration of Sleep.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 55, 'thinking'), ('GO_0034331', 'cell junction maintenance', 79, 'sleeping'), ('GO_0030431', 'sleep', 160, 'sleep')]
PMC5017073	7/2016	S126-PMC5017073	['cbt-i also includes Sleep hygiene and helping patient deal with maladaptive Thoughts, beliefs and behaviors like Watching tv in bed.']	N/A	N/A	[('GO_0030431', 'sleep', 20, 'sleep'), ('GO_0007596', 'blood coagulation', 76, 'thoughts'), ('GO_0007605', 'sensory perception of sound', 113, 'watching')]
PMC5017622	9/2016	S8-PMC5017622	['in all, 578 mothers who were drawing Antenatal and Postnatal Care services were interviewed using a questionnaire, which asked the mothers about their frequency of consumption of individual Foods per week since they became Pregnant or when they were Pregnant.']	N/A	N/A	[('GO_0007567', 'parturition', 37, 'antenatal'), ('GO_0007596', 'blood coagulation', 51, 'postnatal care'), ('CHEBI_33290', 'food', 190, 'foods'), ('GO_0007565', 'female pregnancy', 223, 'pregnant'), ('GO_0007565', 'female pregnancy', 250, 'pregnant')]
PMC5021204	4/2016	S40-PMC5021204	['additional outcomes were severe hypertension, Birthweight <10th percentile, and Preterm Delivery at <34 or <37 weeks.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 46, 'birthweight'), ('GO_0007565', 'female pregnancy', 80, 'preterm'), ('GO_0007567', 'parturition', 88, 'delivery')]
PMC5021204	4/2016	S68-PMC5021204	['caption (fig): figure 1\n\nrisk markers associated with (a)chipsprimary Perinatal outcome, (b) Birthweight <10th centile, (c) severe hypertension, (d) Preeclampsia, (e) Delivery at <34 weeks and (f) Delivery at <37 weeks in the final multivariable regression model.']	N/A	N/A	[('GO_0036268', 'swimming', 70, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 70, 'perinatal'), ('GO_0007596', 'blood coagulation', 93, 'birthweight'), ('GO_0007128', 'meiotic prophase I', 149, 'preeclampsia'), ('GO_0007567', 'parturition', 167, 'delivery'), ('GO_0007567', 'parturition', 197, 'delivery')]
PMC5021204	4/2016	S73-PMC5021204	['for each of the chips primary outcome and Birthweight <10th percentile, there was no statistical interaction between Antihypertensive therapy at enrolment and any variable in the model (table s4).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 42, 'birthweight'), ('CHEBI_46673', 'D-arabinosone', 117, 'antihypertensive')]
PMC5021204	4/2016	S89-PMC5021204	['using models containing all candidate predictors to start the stepwise regression, and forcing into the model, treatment group, Antihypertensive therapy type at randomization, and bp within 1 week before randomization, the point estimate for the auc was <0.70 for all outcomes (primary Perinatal, Birthweight <10th percentile, preeclampsia, and Delivery at <37 weeks) except severe hypertension (auc roc 0.70, 95% ci 0.67–0.74) and Delivery at <34 weeks (auc roc 0.71, 95% ci 0.66–0.75) for which the auc roc was borderline.']	N/A	N/A	[('CHEBI_46673', 'D-arabinosone', 128, 'antihypertensive'), ('GO_0036268', 'swimming', 286, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 286, 'perinatal'), ('GO_0007596', 'blood coagulation', 297, 'birthweight'), ('GO_0007567', 'parturition', 345, 'delivery'), ('GO_0007567', 'parturition', 432, 'delivery')]
PMC5025498	6/2016	S37-PMC5025498	['offspring Birthweight, length, circumferences and skinfold thicknesses were measured at Birth.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 10, 'birthweight'), ('GO_0007567', 'parturition', 88, 'birth')]
PMC5025498	6/2016	S38-PMC5025498	['as mentioned, the primary outcome was Birthweight, which was significantly lower in the intervention group.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 38, 'birthweight')]
PMC5025498	6/2016	S86-PMC5025498	['of 20\xa0min intervals/week)2.262.880.752\ncomparison of control and intervention groups carried out using independent sample t-tests\nbmi body mass index\nwith regard to infant feeding practices; 64.9\xa0% of women reported breastfeeding their second child while 35.1\xa0% did not Breastfeed.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 270, 'breastfeed')]
PMC5029041	9/2016	S122-PMC5029041	['in the gambia, daily dietary supplementation with high-energy groundnut biscuits (4.3\xa0mj/day) improved Gestational weight gain and increased Birthweight; effects were greatest in primigravidae and in the hunger (malaria) season [14].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 103, 'gestational'), ('GO_0007596', 'blood coagulation', 141, 'birthweight')]
PMC5042197	9/2016	S20-PMC5042197	['subjects and methods\nthe mothers were recruited after Delivery if they planned to Breastfeed for 6 months and agreed to participate in the study.']	N/A	N/A	[('GO_0007567', 'parturition', 54, 'delivery'), ('GO_0007596', 'blood coagulation', 82, 'breastfeed')]
PMC5054961	9/2015	S73-PMC5054961	['caption (table-wrap): table 2\n\ncharacteristics of women with ( n \xa0=\xa0635) and without Food cravings ( n \xa0=\xa01004)cravingsno cravings p *valueage at interview (years) (sd)29.7 (5.5)29.7 (5.5)nsgestational age at interview28.9 (1.2)28.9 (1.2)nsyears in education (years)14.7 (2.9)15.1 (2.8)0.037smoking at interview†165 (26%)218 (22%)0.05employed at interview‡453 (72%)785 (78%)0.001previous children§347 (55%)477 (48%)0.002bmi (kg/m²) <16\xa0weeks gest (mean 12.1\xa0weeks\xa0±\xa02.3)25.8 (4.9)25.5 (4.9)nsweight (kg) <16\xa0weeks gest (mean 12.1\xa0weeks\xa0±\xa02.3)68.5 (14)67.5 (13)nsweight (kg) 29\xa0weeks75.8 (14)74.9 (13)nsheight (m) 29\xa0weeks163 (6.3)163 (6.3)nsbmi (kg/m²) 29\xa0weeks28.5 (4.9)28.3 (4.8)nsweight gain <16\xa0weeks – 3rd Trimester (mean 32.8\xa0weeks\xa0±\xa04.5)9.6 (5.4)8.9 (5.5)nsrate of weight gain (kg\xa0week−1)0.5 (0.2)0.4 (0.2)nsfasting Blood Glucose 29\xa0weeks (ogtt) mmol\xa0l−15.2 (1)5.2 (1)nshba1c 29\xa0weeks4.8 (0.4)4.8 (0.3)nsneonatal Birthweight3.5 (0.6)3.5 (0.5)nsbirthweight sds−0.1 (0.9)−0.1 (0.9)nsbirth length sds0.2 (1.1)0.1 (1.2)nshead circumference sds0.3 (1)0.2 (1)nsfemale child √310 (49%)474 (48%)ns\ndata are the mean (sd) or n (%) of subjects *t‐test for independent samples or chi‐squared tests †with cravings, n = 633, and without cravings, n = 998.']	N/A	N/A	[('CHEBI_33290', 'food', 85, 'food'), ('GO_0009294', 'DNA mediated transformation', 711, 'trimester'), ('UBERON_0000178', 'blood', 823, 'blood'), ('CHEBI_17234', 'glucose', 829, 'glucose'), ('GO_0007596', 'blood coagulation', 920, 'birthweight3')]
PMC5054961	9/2015	S93-PMC5054961	['similarly no differences were observed between groups in the duration of Gestation, method of Delivery, sex of offspring, Birthweight, Head circumference or length at Delivery (table\xa02).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 73, 'gestation'), ('GO_0007567', 'parturition', 94, 'delivery'), ('GO_0007596', 'blood coagulation', 122, 'birthweight'), ('UBERON_0000033', 'head', 135, 'head'), ('GO_0007567', 'parturition', 167, 'delivery')]
PMC5073870	10/2016	S266-PMC5073870	['differences seen between arms in analysis of the second primary outcome (z-scores) will be expressed in terms of the corresponding difference in grams of Birthweight.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 154, 'birthweight')]
PMC5084028	10/2016	S34-PMC5084028	['eligibility criteria\nstudies included Human prospective cohorts, case-control, longitudinal and cross-sectional studies assessing maternal circulating zinc concentrations and Pregnancy complications including pe, eclampsia, gh, gdm, small for Gestational age (sga), Intrauterine growth restriction (iugr; ˂10th percentile), low-Birthweight (lbw; ≤2500 g) and Sptb.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 38, 'human'), ('GO_0007565', 'female pregnancy', 175, 'pregnancy'), ('GO_0007565', 'female pregnancy', 243, 'gestational'), ('UBERON_0022293', 'reproductive gland secretion', 266, 'intrauterine'), ('GO_0007596', 'blood coagulation', 328, 'birthweight'), ('PR_000015390', 'sterol O-acyltransferase 2', 359, 'sPTB')]
PMC5100620	10/2016	S21-PMC5100620	['primary outcomes were maternal haemoglobin level at 30 weeks’ Gestation, Birthweight and infant mortality.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 62, 'gestation'), ('GO_0007596', 'blood coagulation', 73, 'birthweight')]
PMC5100620	10/2016	S44-PMC5100620	['outcomes\nthe primary outcomes were maternal haemoglobin at 30 weeks of Gestation, Birthweight and infant mortality.24secondary outcomes reported in this paper are Metabolic markers (Lipid and Glucose Metabolism, inflammation, oxidative stress) at 4.5 years of age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 71, 'gestation'), ('GO_0007596', 'blood coagulation', 82, 'birthweight'), ('GO_0008152', 'metabolic process', 163, 'metabolic'), ('CHEBI_18059', 'lipid', 182, 'lipid'), ('CHEBI_17234', 'glucose', 192, 'glucose'), ('GO_0006006', 'glucose metabolic process', 192, 'glucose metabolism')]
PMC5100620	10/2016	S72-PMC5100620	['sample size\nthe original sample size calculations were based on Birthweight as one of the primary outcomes.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 64, 'birthweight')]
PMC5100627	10/2016	S32-PMC5100627	['out of 19\xa0622 eligible Individuals with Metabolic profiling data, 18\xa0649 had complete data on Birthweight, Gestational age and Adult body mass index (bmi).']	N/A	N/A	[('NCBITaxon_1', 'root', 23, 'individuals'), ('GO_0008152', 'metabolic process', 40, 'metabolic'), ('GO_0007596', 'blood coagulation', 94, 'birthweight'), ('GO_0007565', 'female pregnancy', 107, 'gestational'), ('UBERON_0007023', 'adult organism', 127, 'adult')]
PMC5100627	10/2016	S57-PMC5100627	['lipoprotein measures\nassociations of Birthweight with 43 lipoprotein measures are shown infigure 1.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 37, 'birthweight')]
PMC5100627	10/2016	S77-PMC5100627	['Fatty Acids\nassociations of Birthweight with 16 Fatty Acid measures are shown infigure 2.']	N/A	N/A	[('CHEBI_35366', 'fatty acid', 0, 'Fatty acids'), ('GO_0007596', 'blood coagulation', 28, 'birthweight'), ('CHEBI_35366', 'fatty acid', 48, 'fatty acid')]
PMC5100627	10/2016	S138-PMC5100627	['a 1 kg of difference in Birthweight is substantial, corresponding to almost 2 sds.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 24, 'birthweight')]
PMC5100627	10/2016	S154-PMC5100627	['Birthweight was obtained from Birth medical records for 88% of the study population, which minimizes bias from self-reporting, and data on Gestational age allowed accounting for lower Birthweight caused by Prematurity.']	N/A	N/A	[('GO_0007608', 'sensory perception of smell', 0, 'Birthweight'), ('GO_0007567', 'parturition', 30, 'birth'), ('GO_0007565', 'female pregnancy', 139, 'gestational'), ('GO_0007596', 'blood coagulation', 184, 'birthweight'), ('GO_0007565', 'female pregnancy', 206, 'prematurity')]
PMC5123236	11/2016	S57-PMC5123236	['for continuous variables, e.g., maternal height and Birthweight, the bivariate association with dietary pattern was first assessed by the mann-whitney u test.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 52, 'birthweight')]
PMC5126873	11/2016	S77-PMC5126873	['the specific outcomes examined included gdm defined by iadpsg criteria, lga infant ( ≥ 90thpopulation birthweight centile calculated with who centiles), small for Gestational age (sga) infant (≤10thpopulation Birthweight centile), macrosomia (Birthweight ≥4\xa0kg) and pre-eclampsia (defined as systolic Blood pressure ≥140\xa0mm hg, diastolic Blood pressure ≥90\xa0mm hg, or both, on at least two occasions 4\xa0h apart, with proteinuria ≥300\xa0mg/24\xa0h or spot Urine protein:creatinine ratio ≥30\xa0mg/mmol creatinine, or Urine dipstick protein ≥2+).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 163, 'gestational'), ('GO_0007596', 'blood coagulation', 209, 'birthweight'), ('GO_0007596', 'blood coagulation', 243, 'birthweight'), ('UBERON_0000178', 'blood', 301, 'blood'), ('UBERON_0000178', 'blood', 338, 'blood'), ('UBERON_0001088', 'urine', 448, 'urine'), ('UBERON_0001088', 'urine', 506, 'urine')]
PMC5149661	12/2016	S5-PMC5149661	['chart audit data included the following factors related to breastfeeding: age of mother, parity, Birthweight and apgar scores.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 97, 'birthweight')]
PMC5149661	12/2016	S45-PMC5149661	['using this software, standard deviation, mean and maximum and minimum scores were calculated for apgar, age, Birthweight, term Deliveries, para and gravida on the hospital record data.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 109, 'birthweight'), ('GO_0007567', 'parturition', 127, 'deliveries')]
PMC5149661	12/2016	S75-PMC5149661	['one participant stated “my friends do not Breastfeed because they have no time.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 42, 'breastfeed')]
PMC5149661	12/2016	S88-PMC5149661	['breastfeeding support\nother participants Fed their children Formula because they did not have peer or family support to Breastfeed.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 41, 'fed'), ('CHEBI_81922', 'flusilazole', 60, 'formula'), ('GO_0007596', 'blood coagulation', 120, 'breastfeed')]
PMC5215617	10/2016	S89-PMC5215617	['sample size\nthe sample size for the minimat trial had been calculated for one of the primary outcomes, that is the effect of Food and Micronutrient supplements on Birthweight.']	N/A	N/A	[('CHEBI_33290', 'food', 125, 'food'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 134, 'micronutrient'), ('GO_0007596', 'blood coagulation', 163, 'birthweight')]
PMC5215617	10/2016	S103-PMC5215617	['the mean Birthweights were 2690 and 2697 g and the Birth lengths were 47.7 and 47.6 cm in the breastfeeding counselling and usual health message groups, respectively.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 9, 'birthweights'), ('GO_0007567', 'parturition', 51, 'birth')]
PMC5226708	1/2017	S35-PMC5226708	['when a woman Lactates, she reduces her own body burden of certain Chemicals by transferring them to her nursing child via milk.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 13, 'lactates'), ('CHEBI_23089', 'chelate-forming peptide', 66, 'chemicals')]
PMC5279975	12/2016	S229-PMC5279975	['all women received structured information from the health care team; which led to less fear and more positive Thinking in diabetic mothers.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 110, 'thinking')]
PMC5282623	1/2017	S94-PMC5282623	['the group discussions take 30–40 min and focuses sequentially on education and skills-building specific to Prenatal and Postnatal Care with the help of study nurse.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 107, 'prenatal'), ('GO_0007596', 'blood coagulation', 120, 'postnatal care')]
PMC5292182	1/2017	S75-PMC5292182	['results are presented according to the three main subgroups: (1) Prenatal care (migration status, Postmigration factors, and health services factors), (2) Intrapartum Care (maternal and child health), and (3) Postnatal Care (healthcare access and individual factors).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 65, 'prenatal'), ('GO_0009856', 'pollination', 98, 'postmigration'), ('GO_0036358', 'lipoteichoic acid D-alanylation', 155, 'intrapartum care'), ('GO_0007596', 'blood coagulation', 209, 'postnatal care')]
PMC5319084	2/2017	S29-PMC5319084	['at 24\xa0weeks ga, the mother presented with generalized seizures, went into precipitous labour Delivering a male infant by Spontaneous Vaginal Delivery with a Birthweight of 590\xa0g and apgar scores of 4, 6, and 6 at 1, 5 and 10\xa0min respectively.']	N/A	N/A	[('GO_0006900', 'vesicle budding from membrane', 93, 'delivering'), ('GO_0030474', 'spindle pole body duplication', 121, 'spontaneous'), ('GO_0007601', 'visual perception', 133, 'vaginal'), ('UBERON_0001987', 'placenta', 133, 'vaginal'), ('GO_0007567', 'parturition', 141, 'delivery'), ('GO_0007596', 'blood coagulation', 157, 'birthweight')]
PMC5345907	1/2017	S225-PMC5345907	['these were excluded or controlled for in our study analysis, and our mean infant Birthweight was 3.237 kg (±0.68 kg) with no significant difference in birthweight observed when comparing infants Born Vaginally to those Delivered by cesarean ( p 0.85; table s2 and s3).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 81, 'birthweight'), ('GO_0007567', 'parturition', 195, 'born'), ('UBERON_0001844', 'cochlea', 200, 'vaginally'), ('GO_0007567', 'parturition', 219, 'delivered')]
PMC5367805	3/2017	S33-PMC5367805	['in addition to the Endocannabinoids, non-Cannabinoid acylethanolamines (oea, Pea) that shares Biosynthetic and degradation enzymatic pathways with Anandamide, also contribute to the Control of appetite, weight gain and Lipid Metabolism [28,31,32]\nthe main Endocannabinoids Anandamide (Aea) and 2-Arachidonoylglycerol (2-Ag), are synthesized from Phospholipids containing arachidonic acid (aa), which is a Linoleic Acid derivative [32] and belongs to the N-6 polyunsaturated Fatty Acid (pufa) family.']	N/A	N/A	[('CHEBI_50904', 'allergen', 19, 'endocannabinoids'), ('CHEBI_67194', 'cannabinoid', 41, 'cannabinoid'), ('CHEBI_39015', 'apolipoprotein', 77, 'PEA'), ('GO_0007596', 'blood coagulation', 94, 'biosynthetic ...'), ('CHEBI_2700', 'anandamide', 147, 'anandamide'), ('GO_0065007', 'biological regulation', 182, 'control'), ('CHEBI_18059', 'lipid', 219, 'lipid'), ('GO_0006629', 'lipid metabolic process', 219, 'lipid metabolism'), ('CHEBI_50904', 'allergen', 256, 'endocannabinoids'), ('CHEBI_2700', 'anandamide', 273, 'anandamide'), ('CHEBI_39048', 'ADA', 285, 'AEA'), ('CHEBI_52392', '2-arachidonoylglycerol', 294, '2-arachidonoylglycerol'), ('CHEBI_51383', 'hydridocarbon(3.)', 318, '2-AG'), ('CHEBI_16247', 'phospholipid', 346, 'phospholipids'), ('CHEBI_30881', 'xanthine-8-carboxylic acid', 405, 'linoleic acid'), ('31', 'ACACA (human)', 454, 'n'), ('CHEBI_35366', 'fatty acid', 474, 'fatty acid')]
PMC5369775	3/2017	S62-PMC5369775	['secondary outcomes were early-onset preeclampsia (Delivery before 34+0weeks of Gestation), late-onset preeclampsia (Delivery at or after 34+0weeks of Gestation), preterm preeclampsia (Delivery before 37+0weeks of Gestation), term preeclampsia (Delivery at or after 37+0weeks of Gestation), intermediate preeclampsia (Delivery between 34+0–36+6weeks of Gestation), severe preeclampsia (Blood pressure ≥160 mmhg systolic and/or ≥110 mmhg diastolic and/or proteinuria ≥ 5 g/24hours), small for Gestational age (sga) (Birthweight <-2sd), Gestational diabetes (diet or insulin treated), chronic hypertension (≥140/90 mmhg or Medication for hypertension before 20 weeks of Gestation), hellp syndrome (hemolysis, elevated Liver enzymes, low Platelets) and fetal demise (fetal death after 22thgestational week or over 500g weight).']	N/A	N/A	[('GO_0007567', 'parturition', 50, 'delivery'), ('GO_0007565', 'female pregnancy', 79, 'gestation'), ('GO_0007567', 'parturition', 116, 'delivery'), ('GO_0007565', 'female pregnancy', 150, 'gestation'), ('GO_0007567', 'parturition', 184, 'delivery'), ('GO_0007565', 'female pregnancy', 213, 'gestation'), ('GO_0007567', 'parturition', 244, 'delivery'), ('GO_0007565', 'female pregnancy', 278, 'gestation'), ('GO_0007567', 'parturition', 317, 'delivery'), ('GO_0007565', 'female pregnancy', 352, 'gestation'), ('UBERON_0000178', 'blood', 385, 'blood'), ('GO_0007565', 'female pregnancy', 491, 'gestational'), ('GO_0007596', 'blood coagulation', 514, 'birthweight'), ('GO_0007565', 'female pregnancy', 534, 'gestational'), ('CHEBI_60211', 'compound Z', 620, 'medication'), ('GO_0007565', 'female pregnancy', 667, 'gestation'), ('UBERON_0002107', 'liver', 715, 'liver'), ('CL_0000233', 'platelet', 734, 'platelets')]
PMC5369775	3/2017	S93-PMC5369775	['bmi >30, sga = small for Gestational age (Birthweight < 2sd), ch = chronic hypertension, pe = preeclampsia, gdmd = Gestational diabetes, diet treated.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 25, 'gestational'), ('GO_0007596', 'blood coagulation', 42, 'birthweight'), ('GO_0007565', 'female pregnancy', 115, 'gestational')]
PMC5380514	11/2016	S32-PMC5380514	['to be eligible, women needed to have a Prepregnancy bmi ≤ 40 kg/m2, be carrying a singleton fetus, have the intention to exclusively Breastfeed for at least 4 months, and be otherwise healthy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 39, 'prepregnancy'), ('GO_0007596', 'blood coagulation', 133, 'breastfeed')]
PMC5392925	4/2017	S94-PMC5392925	['infant outcomes\ninfant Birthweight and length are collected from the ehr.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 23, 'birthweight')]
PMC5392925	4/2017	S151-PMC5392925	['on average, infants were Delivered at 38.8 (sd 2.0) weeks of Gestation with a mean birthweight of 3362.9 (sd 538.3) g.\n\ncaption (table-wrap): table 2\n\ncharacteristics of participants who had Delivered as of february 29, 2016 in the petals ( n \u2009=\u20091,415)age, years, n (%)\u200318–24251 (17.7)\u200325–29377 (26.6)\u200330–34515 (36.4)\u200335–39234 (16.5)\u200340–4438 (2.7)race/ethnicity, n (%)\u2003non-hispanic white341 (24.1)\u2003hispanic582 (41.1)\u2003asian298 (21.1)\u2003african american143 (10.1)\u2003other51 (3.6)education, n (%)\u2003high school or less210 (14.8)\u2003some college568 (40.1)\u2003college graduate386 (27.3)\u2003post graduate247 (17.5)\u2003unknown4 (0.3)household income, $, n (%)\u2003\u2009<\u200950,000487 (34.4)\u200350,000-99,999467 (33.0)\u2003100,000-149,999241 (17.0)\u2003\u2009≥\u2009150,000191 (13.5)\u2003unknown29 (2.0)parity, n (%)\u20030587 (41.5)\u20031522 (36.9)\u2003\u2009≥\u20092287 (20.3)\u2003unknown19 (1.3)pre-Pregnancy bmi, kg/m2, n (%)\u2003\u2009<\u200918.537 (2.6)\u200318.5–24.9515 (36.4)\u200325.0–29.9436 (30.8)\u2003\u2009≥\u200930.0426 (30.1)\u2003unknown1 (0.1)Gestational age at study visit, weeks, mean (sd)\u2003clinic visit 113.6 (2.3)\u2003clinic visit 219.8 (2.5)Gestational diabetes, n (%)149 (10.5)Gestational age at Delivery, weeks, mean (sd)38.8 (2.0)infant Birthweight, g, mean (sd)3362.9 (538.3)\n\ndiscussion\nwe report on the rationale, objectives, and data collection of the petals prospective Pregnancy cohort and present the cohort profile among participants enrolled from october 2013 and who Delivered as of february 2016.']	N/A	N/A	[('GO_0007567', 'parturition', 25, 'delivered'), ('GO_0007565', 'female pregnancy', 61, 'gestation'), ('GO_0007567', 'parturition', 191, 'delivered'), ('GO_0007565', 'female pregnancy', 813, 'pregnancy'), ('GO_0007565', 'female pregnancy', 929, 'Gestational'), ('GO_0007565', 'female pregnancy', 1027, 'Gestational'), ('GO_0007565', 'female pregnancy', 1064, 'Gestational'), ('GO_0007567', 'parturition', 1083, 'delivery'), ('GO_0007596', 'blood coagulation', 1126, 'birthweight'), ('GO_0007565', 'female pregnancy', 1264, 'pregnancy'), ('GO_0007567', 'parturition', 1366, 'delivered')]
PMC5404142	4/2017	S10-PMC5404142	['participant-reported intention to Breastfeed increased from baseline to the end of the trial, t15=−2.76, p =.01.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 34, 'breastfeed')]
PMC5404142	4/2017	S120-PMC5404142	['caption (table-wrap): table 6\n\ntally of Preterm Birth risk symptoms reported via the mhp app by trimester.symptoms reportedtrimester 1 (n events)trimester 2 (n events)trimester 3 (n events)percent of total events (n=693), n (%)none73332205610 (88.0)cramping043236 (5.2)feeling contraction123235 (5.1)Abdominal pain0268 (1.2)Vaginal bleeding0112 (0.3)gush or Fluid leak0022 (0.3)total (n events)74341278693\n\nrisk-reduction and health-promoting behavioral intentions\n\nbreastfeeding\nagreement with the statement “i will try to Breastfeed my baby for the first 6 months” increased over the study period.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 40, 'preterm'), ('GO_0007567', 'parturition', 48, 'birth'), ('UBERON_0000916', 'abdomen', 300, 'Abdominal'), ('UBERON_0000970', 'eye', 324, 'Vaginal'), ('UBERON_0006314', 'bodily fluid', 358, 'fluid'), ('GO_0007596', 'blood coagulation', 524, 'breastfeed')]
PMC5405375	4/2017	S14-PMC5405375	['deaths in the Neonatal Period have reduced more slowly than those in the Postneonatal Period since 2000.']	N/A	N/A	[('UBERON_0007221', 'neonate stage', 14, 'neonatal period'), ('GO_0007596', 'blood coagulation', 73, 'postneonatal'), ('UBERON_2001055', 'pronephric duct opening', 86, 'period')]
PMC5410409	4/2017	S29-PMC5410409	['rationale behind panel selection\nthe panel for stakeholders meeting comprised of an allergist, a pediatric gastroenterologist, 2 general pediatricians, an Adult patient with allergic disease, a breastfeeding advocate, mother who Breastfed, a mother who did not Breastfeed, a mother with a child with allergic disease, a lay Person, a neonatologist, and an obstetrician.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 155, 'adult'), ('GO_0007567', 'parturition', 229, 'breastfed'), ('GO_0007596', 'blood coagulation', 261, 'breastfeed'), ('NCBITaxon_10088', 'Mus <genus>', 324, 'person')]
PMC5414300	5/2017	S137-PMC5414300	['data on early initiation of breastfeeding and pre-Lacteal use is collected within 24-h of Birth and on the 7th day.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 50, 'lacteal'), ('GO_0007567', 'parturition', 90, 'birth')]
PMC5434919	3/2017	S6-PMC5434919	['maternal hfd exposure did not affect offspring Birthweight but increased weaning weight, final bodyweight, adiposity, Triglyceridaemia, cholesterolaemia and insulinaemia in both female and male offspring.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 47, 'birthweight'), ('CHEBI_64720', 'L-alpha-aspartyl zwitterionic group', 118, 'triglyceridaemia')]
PMC5434919	3/2017	S70-PMC5434919	['thus, where available, we collected the mean and sd (or sem) of Birthweight, weaning weights (at ~ Postnatal day 21) and endpoint weight, adiposity, Glucose, Insulin, Triglycerides, Cholesterol and leptin for sons and daughters or grouped (i.e.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 64, 'birthweight'), ('GO_0007567', 'parturition', 99, 'postnatal'), ('CHEBI_17234', 'glucose', 149, 'glucose'), ('PR_000045358', 'insulin family protein', 158, 'insulin'), ('CHEBI_17855', 'triglyceride', 167, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 182, 'cholesterol')]
PMC5434919	3/2017	S96-PMC5434919	['maternal dietary exposure had no overall effect on Birthweight (fig.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 51, 'birthweight')]
PMC5434919	3/2017	S107-PMC5434919	['male Birth weight, b. male wean weight, c. female Birthweight, d. female wean weight.']	N/A	N/A	[('GO_0007567', 'parturition', 5, 'birth'), ('GO_0007596', 'blood coagulation', 50, 'birthweight')]
PMC5437650	5/2017	S19-PMC5437650	['infant mortality due to preterm or low Birthweight is 3.5 times higher for black women and nearly two times higher for puerto rican women, compared to non-hispanic white women [6].']	N/A	N/A	[('GO_0007596', 'blood coagulation', 39, 'birthweight')]
PMC5437650	5/2017	S108-PMC5437650	['Birth outcomes are the primary study outcomes (e.g., Preterm Birth, Birthweight, Neonatal Intensive Care Unit admission/duration).']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Birth'), ('GO_0007565', 'female pregnancy', 53, 'preterm'), ('GO_0007567', 'parturition', 61, 'birth'), ('GO_0007596', 'blood coagulation', 68, 'birthweight'), ('UBERON_0001759', 'vagus nerve', 81, 'neonatal'), ('UBERON_0011933', 'vibrissa unit', 90, 'intensive care unit')]
PMC5444625	5/2017	S178-PMC5444625	['finally, the adequacy of the intervention was assessed by asking caregivers whether they received counseling related to diet in Pregnancy, early breastfeeding, how to Breastfeed, and Exclusive breastfeeding in the health center during their last contact with a healthcare provider for Prenatal care.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 128, 'pregnancy'), ('GO_0007596', 'blood coagulation', 167, 'breastfeed'), ('GO_0007588', 'excretion', 183, 'exclusive'), ('GO_0007565', 'female pregnancy', 285, 'prenatal')]
PMC5444625	5/2017	S280-PMC5444625	['3exposure to counseling on early breastfeeding, how to Breastfeed, and counseling on exclusive breastfeeding were defined as a mother reporting she received the counseling at least once during Antenatal consultations and Postnatal consultation.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 55, 'breastfeed'), ('GO_0007567', 'parturition', 193, 'antenatal'), ('GO_0007567', 'parturition', 221, 'postnatal')]
PMC5487839	3/2016	S282-PMC5487839	['the presence of Antiphospholipid Antibodies at high titres predisposes to Arterial hypertension, pe, and to Thrombotic microangiopathy during Pregnancy.']	N/A	N/A	[('CHEBI_16240', 'hydrogen peroxide', 16, 'antiphospholipid'), ('GO_0042571', 'immunoglobulin complex, circulating', 33, 'antibodies'), ('UBERON_0001637', 'artery', 74, 'arterial'), ('GO_0007596', 'blood coagulation', 108, 'thrombotic'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy')]
PMC5489519	6/2017	S120-PMC5489519	['Human Milk was collected from the left Breast directly into a small sampling bottle at the regular Feeding time in the morning, 2\u2009h after the previous Breastfeed for consistency of results.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('UBERON_0001913', 'milk', 6, 'milk'), ('UBERON_0000310', 'breast', 39, 'breast'), ('GO_0007631', 'feeding behavior', 99, 'feeding'), ('GO_0007596', 'blood coagulation', 151, 'breastfeed')]
PMC5496067	6/2017	S177-PMC5496067	['fifty-three percent of Birthweights were measured within 72\xa0hours and 68% within 10\xa0days of Delivery.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 23, 'birthweights'), ('GO_0007567', 'parturition', 92, 'delivery')]
PMC5538262	5/2017	S143-PMC5538262	['the following variables were analyzed for associations with pmd total average methylation, hmd total average methylation, and the percent of the 20-kb windows with methylation below 60%: sequencing run, order, and coverage; child race (white non-hispanic [reference], asian, multi-racial, white hispanic, non-white hispanic); child sex (male [reference]/female); maternal pre-Pregnancy body mass index (bmi) (categorized as<25 [reference], 25 to <30 [overweight], and 30+ [obese]), home ownership (yes/no [reference]); whether the mother ever smoked in her lifetime (yes/no [reference]); maternal education (no college degree, college 4-year degree [reference], graduate or professional degree); Gestational age of child (in days); parity (one previous Live Birth is reference); maternal height; child Birthweight (grams); professionally applied Pesticides to lawn or garden 6 months before Pregnancy through the end of Pregnancy (yes, no [reference]); professionally applied Pesticides to inside of home before or during Pregnancy (yes, no [reference]; Flea/Tick Pouches applied to Pet, Flea/Tick collars, or Flea/Tick pet soaps or shampoos before or during Pregnancy (yes, no [reference]).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 376, 'pregnancy'), ('GO_0007565', 'female pregnancy', 696, 'gestational'), ('GO_0006266', 'DNA ligation', 753, 'live'), ('GO_0007567', 'parturition', 758, 'birth'), ('GO_0007596', 'blood coagulation', 802, 'birthweight'), ('CHEBI_35392', 'glucarate(1-)', 846, 'pesticides'), ('GO_0007565', 'female pregnancy', 891, 'pregnancy'), ('GO_0007565', 'female pregnancy', 920, 'pregnancy'), ('CHEBI_35392', 'glucarate(1-)', 976, 'pesticides'), ('GO_0007565', 'female pregnancy', 1022, 'pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 1054, 'flea'), ('NCBITaxon_33208', 'Metazoa', 1059, 'tick'), ('UBERON_0001443', 'chest', 1064, 'pouches'), ('NCBITaxon_10088', 'Mus <genus>', 1083, 'pet'), ('NCBITaxon_10088', 'Mus <genus>', 1088, 'flea'), ('NCBITaxon_33208', 'Metazoa', 1093, 'tick'), ('NCBITaxon_10088', 'Mus <genus>', 1110, 'flea'), ('NCBITaxon_33208', 'Metazoa', 1115, 'tick'), ('GO_0007565', 'female pregnancy', 1159, 'pregnancy')]
PMC5541627	6/2017	S71-PMC5541627	['caption (table-wrap): table 1\n\nvariables, instruments used and assessment time pointsvariablesinstrumentsassessment time pointsprimary outcomes\u2003Gestational weight gaindigital weight scale; medical recordsbaseline; hospital discharge\u2003Birth weightmedical recordshospital discharge\u2003maternal physical health problems after childbirthself-reported1, 3, 6 and 12\u2009months Postpartum\u2003infant health problemsreported by the mother1, 3, 6 and 12\u2009months Postpartumsecondary outcomes\u2003obstetric complications during Pregnancy and at Birthmedical recordshospital discharge\u2003type of deliverymedical recordshospital discharge\u2003breastfeeding: Prelacteal feeds, time to first Feed, initiation, durationbreastfeeding questionnairehospital discharge; 1, 3, 6 and 12\u2009months Postpartum\u2003infant growth at 1\u2009year of age: infant weight and length within 12\u2009monthsmedical records (infant weight and length at Birth); the local maternal and child health management system (infant weight and length between 1 and 12\u2009months)hospital discharge; 12\u2009months Postpartumexposure and confounding variables\u2003maternal weight and height at baselinedigital weight scale; stadiometerbaseline\u2003body fat compositionbioelectrical impedance analysis scalebaseline\u2003physical activity during Pregnancypregnancy physical activity questionnairebaseline\u2003dietary Intake and alcohol drinking during Pregnancyfood frequency questionnairebaseline\u2003demographic and socioeconomic characteristics: age, marital status, education level, occupation, household incomestructured questionnairebaseline\u2003health characteristics: history of diabetes and hypertension, paritystructured questionnairebaseline\u2003infant gender, Gestational age at deliverymedical recordshospital discharge\u2003cigarette smokingstructured questionnairebaseline; 6\u2009months Postpartum\u2003maternal attitudes towards infant feedingiowa infant Feeding attitude scale32–37\u2009weeks of Gestation\u2003maternal breastfeeding confidencebreastfeeding self-efficacy scalehospital discharge\u2003maternal depressive symptomsedinburgh Postnatal depression scale32–37\u2009weeks of Gestation; 1, 3 and 6\u2009months Postpartum\u2003infant dietary Intake48\u2009hours Food recall12\u2009months Postpartum\n\nmeasures\n\nanthropometric measurements\na digital scale was used to record the weight of all participants to the nearest 100 g. height was measured using a stadiometer to 0.1\u2009cm.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 144, 'Gestational'), ('GO_0007567', 'parturition', 233, 'Birth'), ('GO_0007565', 'female pregnancy', 364, 'postpartum'), ('GO_0007608', 'sensory perception of smell', 441, 'postpartumSecondary'), ('GO_0007565', 'female pregnancy', 501, 'pregnancy'), ('GO_0007596', 'blood coagulation', 518, 'birthMedical'), ('GO_0007565', 'female pregnancy', 622, 'prelacteal'), ('GO_0007631', 'feeding behavior', 654, 'feed'), ('GO_0007565', 'female pregnancy', 749, 'postpartum'), ('GO_0007567', 'parturition', 878, 'birth'), ('GO_0080184', 'response to phenylpropanoid', 1020, 'postpartumExposure'), ('GO_0007605', 'sensory perception of sound', 1237, 'pregnancyPregnancy'), ('GO_0007631', 'feeding behavior', 1304, 'intake'), ('GO_0007565', 'female pregnancy', 1339, 'pregnancyFood'), ('GO_0007565', 'female pregnancy', 1647, 'gestational'), ('GO_0007565', 'female pregnancy', 1768, 'postpartum'), ('GO_0007631', 'feeding behavior', 1832, 'Feeding'), ('GO_0007565', 'female pregnancy', 1869, 'gestation'), ('GO_0007567', 'parturition', 2002, 'Postnatal'), ('GO_0007565', 'female pregnancy', 2043, 'gestation'), ('GO_0007565', 'female pregnancy', 2072, 'postpartum'), ('GO_0060384', 'innervation', 2098, 'intake48'), ('CHEBI_33290', 'food', 2113, 'food'), ('GO_0007565', 'female pregnancy', 2134, 'postpartum')]
PMC5547508	8/2017	S84-PMC5547508	['these tasks are to take highly active Antiretroviral therapy (arv) from the moment they are diagnosed with hiv irrespective of cd4 count (and continuing for Life as per the sa guidelines); have at least one viral load (vl) tested during Pregnancy which is less than 400 copies/ ml and have vl taken at least monthly until the cessation of breastfeeding; give child Nevirapine Syrup for 6 weeks post-Birth (or Nevirapine and azt Syrup for 12 weeks if deemed high risk by a clinician); get child hiv tested with pcr at Birth and at 10 -14 weeks post Delivery; and, Breastfeed exclusively for 6 months.']	N/A	N/A	[('CHEBI_65417', '(+)-aplysinillin', 38, 'antiretroviral'), ('UBERON_0000104', 'life cycle', 157, 'life'), ('GO_0007565', 'female pregnancy', 237, 'pregnancy'), ('CHEBI_7510', 'neopinone', 365, 'Nevirapine'), ('CHEBI_46950', 'sultam', 376, 'syrup'), ('GO_0007567', 'parturition', 399, 'birth'), ('CHEBI_7510', 'neopinone', 409, 'Nevirapine'), ('CHEBI_46950', 'sultam', 428, 'syrup'), ('GO_0007567', 'parturition', 517, 'birth'), ('GO_0007567', 'parturition', 548, 'delivery'), ('GO_0007596', 'blood coagulation', 563, 'breastfeed')]
PMC5626729	10/2017	S13-PMC5626729	['Preparation Of the Endometrium for Pregnancy starts with the Postovulatory surge in circulating Progesterone levels, which in turn inhibits Estrogen-Dependent Proliferation Of the Uterine Epithelium, induces Secretory transformation of the Uterine Glands and transforms Stromal Cells into specialized Secretory Decidual Cells1.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Preparation of ... endometrium'), ('UBERON_0001852', 'endolymph', 19, 'endometrium'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0007596', 'blood coagulation', 61, 'postovulatory'), ('CHEBI_17026', 'progesterone', 96, 'progesterone'), ('CHEBI_50114', 'estrogen', 140, 'estrogen'), ('GO_0006098', 'pentose-phosphate shunt', 140, 'estrogen-dependent'), ('GO_0009825', 'multidimensional cell growth', 159, 'proliferation of ... uterine epithelium'), ('UBERON_0001782', 'pigmented layer of retina', 180, 'uterine epithelium'), ('GO_0046903', 'secretion', 208, 'secretory'), ('UBERON_0012276', 'endometrium glandular epithelium', 240, 'uterine glands'), ('CL_0000499', 'stromal cell', 270, 'stromal cells'), ('UBERON_0003891', 'stroma', 270, 'stromal'), ('CL_0000151', 'secretory cell', 301, 'secretory ... cells1'), ('UBERON_0002450', 'decidua', 311, 'decidual')]
PMC5627472	10/2017	S56-PMC5627472	['diet\nMethyl Groups for all Biological methylation reactions are primarily supplied from dietary Methyl Donors and co-factors such as Folate, Choline, methionine, Vitamin B2, Vitamin B6, and Vitamin B12.']	N/A	N/A	[('CHEBI_6822', 'Methazolamide', 5, 'Methyl groups'), ('GO_0007596', 'blood coagulation', 27, 'biological'), ('CHEBI_6842', 'methoxychlor', 96, 'methyl donors'), ('CHEBI_30863', '5-azaorotic acid', 133, 'folate'), ('CHEBI_15354', 'choline', 141, 'choline'), ('CHEBI_33279', 'vitamin D5', 162, 'vitamin B2'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 162, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 174, 'vitamin B6'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 182, 'B6'), ('CHEBI_33279', 'vitamin D5', 190, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 190, 'vitamin B12')]
PMC5634602	10/2017	S24-PMC5634602	['*all Breastfeed and partially Breastfed infants.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 5, 'breastfeed'), ('GO_0007567', 'parturition', 30, 'breastfed')]
PMC5640793	9/2017	S119-PMC5640793	['secondary outcomes included wasting and underweight at all timepoints, Birthweight, growth velocity, Feeding, hygiene, and care practices.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 71, 'birthweight'), ('GO_0007631', 'feeding behavior', 101, 'feeding')]
PMC5640793	9/2017	S183-PMC5640793	['mean Birthweight, weight-for-height z score at 18 months, mid-upper Arm circumference at 18 months, and the odds of children being stunted and wasted at 18 months were similar between intervention and control clusters.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 5, 'birthweight'), ('UBERON_0001460', 'arm', 68, 'arm')]
PMC5656136	8/2017	S42-PMC5656136	['caption (table-wrap): table 1\n\nparticipants involved in in-depth interviews (idis)\xa0and focus group discussions\xa0(fgds)method of data collectionparticipant characteristicsnumberidis33mothers of lbw babies\xa0<2\u2009years old18health workers15\u2003clinical officers\u20032\u2003medical assistants\u20034\u2003nurse–midwife technicians\u20033\u2003health surveillance assistants\u20035\u2003hospital attendant\u20031fgds36 (four groups)mothers of lbw babies\xa0<2\u2009years old17 (two groups)mothers of children\xa0<2\u2009years old9 (one group)fathers of children\xa0<2\u2009years old10 (one group)\nlbw, low Birthweight.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 526, 'birthweight')]
PMC5658906	10/2017	S90-PMC5658906	['caption (table-wrap): table 3\n\nbayesian estimates of the average of the beta coefficients, denoted μβ, within each Edc class in relation to Birth weight (g) in the home study, 2003-2006, n=272, cincinnati, ohdifference in Birthweight (grams)primary analysis (ga included)secondary analysis (ga excluded)independent variableposterior mean (sd)95% ci50% ciposterior mean (sd)95% ci50% ciphthalate class and Bpa1.18(10.3)(-19.8, 23.4)(-4.28, 6.34)2.66(10.4)(-18.4, 22.4)(-3.32, 8.85)pfas class-10.6(23.8)(-51.5, 34.0)( -20.9 , -2.26 )-18.7(28.0)(-72.6, 36.2)( -30.5 , -6.99 )pcb class0.22(4.70)(-9.31, 10.1)(-2.48, 2.91)0.47(6.21)(-11.3, 13.6)(-3.04, 3.37)pdbe class-3.93(12.5)(-30.8, 22.2)(-9.94, 2.27)-9.07(15.1)(-37.4, 22.6)( -16.6 , -2.29 )Oc Pesticide class7.26(17.9)(-25.4, 39.9)(-2.63, 16.1)13.3(22.1)(-28.5, 56.5)(1.61, 25.1)dep14.1 (33.2)(-51.4, 79.3)(-8.02, 35.9)-18.6(43.4)(-103, 64.6)(-48.1, 11.5)dmp-56.8(33.8)(-123, 10.2)( -79.3 , -34.0 )-69.4(45.2)(-156, 20.8)( -101 , -38.8 )lead-44.8(33.5)(-110, 21.7)( -67.6 , -22.2 )1.51(44.4)(-83.9, 88.2)(-27.9, 31.4)mercury5.44(31.2)(-55.9, 66.4)(-15.7, 26.6)-13.9(39.7)(-92.6, 63.7)(-40.8, 12.7)race (black/other)-98.2(90.6)(-277, 82.7) (-158 , -38.6 )-274(119)( -508 , -37.6 )( -354 , -193 )age at delivery6.04(7.71)(-8.95, 21.1)(0.83, 11.3)1.48(9.97)(-18.2, 20.8)(-5.24, 8.31)infant sex (female)-201(58.0)( -315 , -87.8 )( -240 , -162 )-163(72.9)( -307 , -21.1 )( -212 , -114 )did not finish high school-124(80.1)(-282, 34.2)( -177 , -70.4 )-98.2(104)(-302, 104)(-168, -28.1)cotinine (ng/ml >3)-76.7(38.2)(-151, 0.53)( -103 , -51.3 )-98.8(49.5)(-195, -2.45)( -133 , -65.8 )low income (<$25,000/yr)-35.7(102)(-237, 163)(-104, 34.8)86.3(131)(-173, 344)(-1.91, 173)unemployment-83.6(76.7)(-233, 65.9)( -135 , -31.0 )-5.46(101)(-205, 189)(-73.2, 64.0)public/no insurance91.4(106)(-117, 301)(19.1, 162)15.0(141)(-251, 291)(-80.1, 109)marital status (unmarried)-67.2 (99.8)(-263, 132)( -134 , -1.78 )-68.4(143)(-364, 208)(-161, 27.2)pre-Natal Vitamins (yes)139(68.2)(273, 6.99)(185, 92.2)92.9(88.1)(266, 81.1)(150, 33.4)bmi (kg/m2)19.6(4.96)(9.84, 29.2)(16.2, 23.0)23.8(6.28)(11.9, 36.3)(19.4, 28.0)\nabbreviations: sd standard deviation, ci credible interval, ses socioeconomic status, bmi body mass index\nsignificance: italicized 95%\xa0cis and 50% cis do not contain zero and therefore are considered significant at p = 0.05 or p = 0.5 respectively\n\nresults\nof 389 singleton live births, 272 (69.9%) had all covariates and were included in analysis.']	N/A	N/A	[('CHEBI_86606', 'Dehydrodiveratric acid', 115, 'EDC'), ('GO_0007567', 'parturition', 140, 'birth'), ('GO_0007596', 'blood coagulation', 222, 'birthweight'), ('PR_000004806', 'bromodomain-containing protein 2', 405, 'BPA1'), ('CHEBI_15379', 'dioxygen', 741, 'OC'), ('CHEBI_33292', 'fuel', 744, 'Pesticide'), ('GO_0007567', 'parturition', 1986, 'natal'), ('CHEBI_33277', 'gamma-tocotrienol', 1992, 'vitamins')]
PMC5659017	10/2017	S149-PMC5659017	['whole-Genome Cord Blood Methylation in offspring of active ed, past ed, and control women.']	N/A	N/A	[('SO_0001026', 'genome', 6, 'genome'), ('UBERON_0002240', 'spinal cord', 13, 'cord'), ('GO_0007596', 'blood coagulation', 18, 'blood methylation'), ('UBERON_0000178', 'blood', 18, 'blood')]
PMC5689158	11/2017	S72-PMC5689158	['it is common for women in samoa to travel to american samoa and stay with extended family during Pregnancy and for the Birth Of their Child.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('GO_0007596', 'blood coagulation', 119, 'birth of ... child')]
PMC5724074	8/2017	S9-PMC5724074	['our sample size would be 900 Pregnant women to determine 100 g differences in mean Birthweight, considering 5% type 1 error, 80% power and an intra-cluster correlation coefficient of 0.03.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 29, 'pregnant'), ('GO_0007596', 'blood coagulation', 83, 'birthweight')]
PMC5724074	8/2017	S10-PMC5724074	['the primary outcome of the trial is Birthweight of the infants and the secondary outcomes include daily caloric intake and dietary diversity score among the Pregnant women.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 36, 'birthweight'), ('GO_0007565', 'female pregnancy', 157, 'pregnant')]
PMC5724074	8/2017	S124-PMC5724074	['outcomes\n\nprimary outcome\nthe primary outcome of this study is the Birthweight of the newborn infants.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 67, 'birthweight')]
PMC5724074	8/2017	S140-PMC5724074	['all live newborn infants’ Birthweights will be assessed within 72\u2009hours of Birth with a hand-held spring balance scale (salter scale with a capacity of five\u2009kg and an accuracy of 100 g).']	N/A	N/A	[('GO_0007596', 'blood coagulation', 26, 'birthweights'), ('GO_0007567', 'parturition', 75, 'birth')]
PMC5724074	8/2017	S147-PMC5724074	['field supervisors, blinded to the outcome of interest, will also recapture 25% of the Birthweight measures for data validity.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 86, 'birthweight')]
PMC5724074	8/2017	S149-PMC5724074	['for institutional Births, the recorded Birthweights will be used.']	N/A	N/A	[('GO_0007567', 'parturition', 18, 'births'), ('GO_0007596', 'blood coagulation', 39, 'birthweights')]
PMC5732382	12/2017	S278-PMC5732382	['furthermore, rural health facilities, which are easily accessible, are not equipped with Blood Transfusion kits in case of an emergency Blood Transfusion incident [28].']	N/A	N/A	[('UBERON_0000178', 'blood', 89, 'blood'), ('GO_0009294', 'DNA mediated transformation', 95, 'transfusion'), ('GO_0007596', 'blood coagulation', 136, 'blood transfusion'), ('UBERON_0000178', 'blood', 136, 'blood')]
PMC5781192	1/2018	S106-PMC5781192	['caption (table-wrap): table 3\n\nbiological samples stored before Conception, during Pregnancy and at Birth—the recipal study, 2014–2017prepregnancypregnancy*Delivery/Birthplanned analysestotal Blood\u2003total Blood (200\u2009µl)–mother (×2)–Erythrocytic Folic Acid\u2003total Blood (500\u2009µl)–mother (×2)mother–Placenta\xa0Cordmetal level\u2003Blood spot+4°c (50\u2009µl)mother (×1)mother (×8)†mother–Placenta\xa0Cord plasmodium detection (pcr)\u2003Blood spot −20°c (100\u2009µl)mother (×1)mother (×8)†mother–Placenta\xa0Cordimmunological markers\u2003Red Cells (trizol, 100\u2009µl)mother (×1)mother (×8)mother–Placenta\xa0Cord plasmodium phenotyping\u2003Buffy Coat Pax\xa0Gene (300\u2009µl)–mother (×2)mother–Placenta\xa0Cordimmunological markersplasma/Serum\u2003Plasma–20°c‡mother (×1)mother (×2)mother–Placenta\xa0Cordmicro-rnas, cytokines and chemokines\u2003Plasma −80°c‡mother (×1)mother (×2)mother–Placenta\xa0Cordmicro-rnas, cytokines and chemokines\u2003Serum (100\u2009µl)mother (×1)– chlamydia\xa0trachomatis and neisseria\xa0gonorrhoeae detection\u2003Serum (400\u2009µl)–mother (×2)vitamin a\u2003Serum (100\u2009µl)‡mother (×1)mother (×2)–ferritin, crp, stfr, agpurine (1.8\u2009ml)mother (×2)mother (×3)–Pollutant/pesticidestool (−80°c)mother (×1)––helminthic infectionplacenta\u2003biopsy with Formalin––Placentahistopathology for malaria\u2003biopsy −20°c––Placentaimmunological markers\u2003biopsy with rna later––Placentaimmunological markers\nthe frequency of sample collection is indicated in\xa0parentheses.']	N/A	N/A	[('GO_0007620', 'copulation', 64, 'conception'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007567', 'parturition', 100, 'birth'), ('GO_0007586', 'digestion', 156, 'Delivery'), ('GO_0007596', 'blood coagulation', 165, 'birthPlanned'), ('UBERON_0000178', 'blood', 192, 'blood'), ('UBERON_0000178', 'blood', 204, 'blood'), ('CL_0000232', 'erythrocyte', 231, 'Erythrocytic'), ('CHEBI_30751', 'formic acid', 244, 'folic acid'), ('UBERON_0000178', 'blood', 261, 'blood'), ('UBERON_0001987', 'placenta', 294, 'placenta'), ('UBERON_0001983', 'crypt of Lieberkuhn', 303, 'cordMetal'), ('UBERON_0000178', 'blood', 319, 'Blood'), ('UBERON_0001956', 'cartilage of bronchus', 371, 'placenta cord'), ('UBERON_0000178', 'blood', 412, 'Blood'), ('UBERON_0008335', 'ventrolateral sulcus of medulla oblongata', 467, 'placenta cordImmunological'), ('CL_0000232', 'erythrocyte', 502, 'Red cells'), ('UBERON_0001956', 'cartilage of bronchus', 557, 'placenta cord'), ('UBERON_0010161', 'lumen of blood vessel', 594, 'Buffy coat'), ('PR_000012318', 'paired box protein Pax-6', 605, 'PAX'), ('SO_0000704', 'gene', 609, 'gene'), ('UBERON_0008335', 'ventrolateral sulcus of medulla oblongata', 641, 'placenta cordImmunological'), ('UBERON_0001977', 'blood serum', 682, 'serum'), ('UBERON_0001969', 'blood plasma', 688, 'Plasma'), ('UBERON_0001987', 'placenta', 729, 'placenta'), ('UBERON_0005432', 'aortic sac', 738, 'cordMicro'), ('UBERON_0001969', 'blood plasma', 779, 'Plasma'), ('UBERON_0001987', 'placenta', 821, 'placenta'), ('UBERON_0005432', 'aortic sac', 830, 'cordMicro'), ('UBERON_0001977', 'blood serum', 871, 'Serum'), ('UBERON_0001977', 'blood serum', 956, 'Serum'), ('UBERON_0001977', 'blood serum', 992, 'Serum'), ('CHEBI_75260', 'penicillinate salt', 1091, 'Pollutant'), ('CHEBI_16842', 'formaldehyde', 1177, 'formalin'), ('UBERON_0010005', 'placental labyrinth villous', 1187, 'PlacentaHistopathology'), ('UBERON_0003970', 'placental labyrinth vasculature', 1236, 'PlacentaImmunological'), ('UBERON_0003970', 'placental labyrinth vasculature', 1289, 'PlacentaImmunological')]
PMC5800548	2/2018	S68-PMC5800548	['these considerations follow the heuristic reasoning inspired by available economic Thinking.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 83, 'thinking')]
PMC5975263	5/2018	S73-PMC5975263	['of them, the mean maternal age was 27.3\u2009±\u20094.44\xa0years, the mean infant Birthweight was 3274.9\u2009±\u2009780.24\xa0g, the mean pre-Pregnancy bmi was 21.3\u2009±\u20093.15\xa0kg/m2, and the mean gwg was 14.4\u2009±\u20095.39\xa0kg.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 70, 'birthweight'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy')]
PMC6029118	7/2018	S113-PMC6029118	['both intervention and control treatment arms will receive the usual Antenatal and Postnatal Care services by brac.']	N/A	N/A	[('GO_0043653', 'mitochondrial fragmentation involved in apoptotic process', 68, 'antenatal ...'), ('GO_0007596', 'blood coagulation', 82, 'postnatal care')]
